### NATIONAL CANCER REGISTRY PROGRAMME

### Indian Council of Medical Research

**Prof N.K. Ganguly** Director General

Dr Usha K. Luthra

Senior Adviser, Cancer Research and Member, Steering Committee

### Division of Non-Communicable Diseases

Dr Bela Shah Dr A. Nandakumar

Chief & Sr Deputy Director General Officer-in-Charge, NCRP &

Dy Director General (Sr Gr)

**Dr Kishor Chaudhry** Dr T. Ramnath Dy Director General (Sr Gr) Dy Director General

### Steering/Monitoring Committee

Dr P. S. S. Sundar Rao, Bangalore Dr P. C. Gupta, Mumbai

Dr N.C. Misra, Lucknow Dr S. Radhakrishna, Hyderabad

Dr B.D. Gupta, Chandigarh Dr R.N. Visveswara, Bangalore

P. Gangadharan, Ernakulam Dr Kusum Joshi, Chandigarh

### Cancer Registries (With Names of Principal Investigators)

Population Based Hospital Based

Ahmedabad: Dr Pankaj Shah Bangalore : Dr Bapsy Padmanabhan

Dr P.S. Prabhakaran (till May 2005) Bangalore : Dr Bapsy Padmanabhan

Dr P.S. Prabhakaran (till May 2005) Chennai : Dr V. Shanta

Barshi : Dr K.A. Dinshaw Dibrugarh : Dr T.R. Borbora

Dr N. Choudhury (till Sept 2004) : Dr V.K. Bharadwaj Bhopal

Mumbai : Dr K.A. Dinshaw : Dr V. Shanta Chennai

Thi'puram\* : Dr B. Rajan Delhi : Dr Vinod Raina

(\*Thiruvananthapuram) Dr M. Krishnan Nair (till Nov 2003) Kolkata

: Dr Indira Chakravarty

Mumbai : Dr A.P. Kurkure

### North Eastern Regional Cancer Registry(Population Based) With Names of Principal Investigators

Monitoring Unit: Dr J. Mahanta, Director, Regional Medical Research Centre(ICMR), Dibrugarh.

Aizawl : Dr Eric Zomawia Dibrugarh: Dr T.R. Borbora

Dr N. Choudhury (till Sept 2004)

Gangtok: Dr Yogesh Verma Guwahati : Dr Jagannath D. Sharma

: Dr Sekhar Chakravarty Imphal : Dr Y. Mohen Singh Silchar

### Other Staff at Co-ordinating Unit of NCRP, Bangalore

G.C. Shivayogi, Murali Dhar, F.S. Roselind, B. Shobana, N.M. Ramesha, Kiran Prabhu, M. Rajendra

© National Cancer Registry Programme (Indian Council of Medical Research) Bangalore

August 2005

Hospital based cancer registries provided individual core data. Quality Control checks, tabulations and statistical analysis were done at the Coordinating Unit of NCRP, Bangalore.

The publications of NCRP are intended to contribute to the dissemination of authentic information on cancer patterns in the country.

### PRINTED IN INDIA

Published by the Coordinating Unit, National Cancer Registry Programme (ICMR), Bangalore 560094

### NATIONAL CANCER REGISTRY PROGRAMME

### Indian Council of Medical Research

# Two-year Report of the Hospital Based Cancer Registries 1999 - 2000

Prepared by

**Coordinating Unit of NCRP** 

**ICMR Headquarters** 

Dr A. Nandakumar

Dr Bela Shah

Dr T. Ramnath

**Dr Kishor Chaudhry** 

Murali Dhar

Kiran Prabhu

In Collaboration with the Hospital Based Cancer Registries at the following places indicated (with names of respective Principal and Co-Principal Investigators/Senior Staff)

**MUMBAI (Bombay): Tata Memorial Hospital** 

Dr K.A. Dinshaw

Mr D.N. Rao Dr B. Ganesh

**BANGALORE: Kidwai Memorial Institute of Oncology** 

Dr Bapsy Padmanabhan (from June 2005)

Dr P.S. Prabhakaran (till May 2005)

Dr K. Ramachandra Reddy

Dr C. Ramesh

CHENNAI (Madras): Cancer Institute (WIA)

Dr V. Shanta

Dr R. Swaminathan

Mrs R. Rama

**THIRUVANANTHAPURAM: Regional Cancer Centre** 

Dr B. Rajan

**Dr Aleyamma Mathew** 

Dr M. Krishnan Nair (till Nov 2003)

**DIBRUGARH: Assam Medical College** 

Dr T.R. Borbora Dr M.S. Ali
Dr N. Choudhury (till Sept 2004) Dr R. Akhtar

NCRP, Bangalore

August 2005

### **ADDRESSES**

Indian Council of Medical Research (Headquarters): V. Ramalingaswami Bhawan, Ansari Nagar, New Delhi - 110 029.

**Coordinating Unit of National Cancer Registry Programme:** No 557, 'Srinivasa Nilaya', New BEL Road, 7th Main, Dollar's Colony, Bangalore 560 094.

### Steering / Monitoring Committee - Names, Designation and Addresses

Dr P. S. S. Sundar Rao, (Former Director, Schieffelin Leprosy Research & Training Centre, S.L.R. Sanatorium, Karigiri, Tamil Nadu), No. 88, Kuvempu Layout, Gubbi Cross, Kothanur, Bangalore - 560 077.

Dr P. C. Gupta, Director, Healis - Sekhsaria Institute of Public Health, 601, Great Eastern Chambers, Plot 28, Sector 11, CBD, Belapur (East), Navi Mumbai - 400 614.

Prof N.C. Misra, Professor of Surgery (Oncology), 122, Faizabad Road, Near Indira Bridge, Lucknow - 226 007.

Dr S. Radhakrishna (Former Director, IRMS-ICMR, Chennai), D-201 High Rise Apartments, Lower Tank Bund Road, Gandhinagar, Hyderabad - 500 080.

Dr B.D. Gupta, Chairman, Professor Emeritus, Radiotherapy and Oncology, Dr Vikrant Gupta Memorial Foundation, 223, Sector 15-A, Chandigarh - 160 015.

Dr R.N. Visweswara, Prof. of Pathology, Vydehi Institute of Medical Sciences and Research Centre, No. 82, EPIP Area, White Field, Bangalore - 560 066.

Mr P. Gangadharan, Consultant - Oncology Centre, Amrita Institute of Medical Sciences, Elamakkara P.O., Kochi - 682 026

Dr Kusum Joshi, Prof. & Head of Histopathology, PGIMER, Chandigarh - 160 012.

### **Cancer Registries**

**Bangalore (PBCR & HBCR):** Kidwai Memorial Institute of Oncology, Dr M.H. Marigowda Road, Bangalore - 560 029.

Barshi (PBCR): Nargis Dutt Memorial Cancer Hospital, Barshi - 413 401 (Solapur), Maharashtra.

Bhopal (PBCR): Department of Pathology, Gandhi Medical College, Bhopal - 462 001.

Chennai (PBCR & HBCR): Cancer Institute (WIA), 18, Sardar Patel Road, Chennai - 600 020.


**Delhi (PBCR):** Institute Rotary Cancer Hospital, Department of Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi - 110 029.

Dibrugarh (HBCR): Assam Medical College, Dibrugarh - 786 002, Assam

Mumbai (PBCR): Indian Cancer Society, 74, Jerbai Wadia Road, Parel, P.O. Box No. 6033, Mumbai - 400 012.

Mumbai (HBCR): Tata Memorial Hospital, Parel, Mumbai - 400 012

**Thiruvananthapuram (HBCR):** Regional Cancer Centre, Medical College Campus, Thiruvananthapuram - 695 011.



Fore	word	xiii
Ackr	nowledgements	xiv
DAD	T I - INTRODUCTION	
PAN	TT-INTRODUCTION	
Nati	onal Cancer Registry Programme	xii
Sum	mary of report	χv
Indiv	vidual Registries' Write-up	
	Mumbai	xviii
	Bangalore	xxi
	Chennai	xxiii
	Thiruvananthapuram*	XXV
	Dibrugarh	xxvii
PAR	T II - CHAPTERS: DETAILED DESCRIPTION	
1.	Magnitude and Leading Sites of Cancer	1 - 16
2.	Chilhood Cancers	17 - 23
3.	Tobacco Related Cancers	24 - 28
4.	Basis of Diagnosis	29 - 34
5.	Broad Treatment Groups	35 - 37
6.	Clinical Extent of Disease at Presentation	38 - 39
7.	Treatment Only at Reporting Institution	40 - 48
8.	Summary of Individual Site - Mouth	49 - 61
9.	Summary of Individual Site - Tongue	62 - 68
10.	Summary of Individual Site - Oesophagus	69 - 80
11.	Summary of Individual Site - Lung (Males)	81 - 87
12.	Summary of Individual Site - Female Breast	88 - 94
13	Summary of Individual Site - Cervix	95 - 101
14.	Head and Neck Cancers	102 - 111
15.	Histologic Types of Selected Sites	112 -123
16.	Education, Marital Status, Religion and Language Spoken	124 -126
	References	127
	Other Publications of NCRP	127

<sup>\*</sup>Thiruvananthapuram is referered as Thi'puram in the tables and figures

# **LIST OF TABLES (1999-2000)**

Page	Nos
------	-----

1.1	Number and Proportion according to sex, sex ratio percent and relative proportion of cancers	1
1.2	Number, Relative Proportion and Rank of Leading Sites of Cancer	3
1.3	Number and Proportion of Cancers by Broad Age Groups	8
2.1	Number and Proportion of Cancers in childhood relative to all cancers	. 17
2.2	Number and Proportion of Childhood Cancers by 5-year Age Group	. 18
2.3	Number and Relative Proportion of Broad Types of Cancers in childhood (0-15 years)	. 19
2.4(a)	Number and Relative Proportion of Specific Types of Cancer in Childhood (0-15 years) - Males	. 22
2.4(b)	Number and Relative Proportion of Specific Types of Cancer in Childhood (0-15 years) - Females	. 23
3.1	Sites of cancer included in TRCs alongwith corresponding ICD codes	. 24
3.2	Number and Proportion of cancers associated with use of tobacco relative to all sites of cancer	. 24
3.3	Number and Relative Proportion of specific sites of cancer among Tobacco Related Cancers	. 27
3.4	Number and Relative Proportion of Tobacco Related Cancers by five-year age groups	. 28
4.1	Number and Relative Proportion of Cancers based on different methods of diagnosis	. 29
4.2	Number and Relative Proportion of Cancers based on different types of Microscopic Diagnosis	. 33
4.3	Number and Relative Proportion of Microscopic Diagnosis across different years of diagnosis	. 34
4.4	Proportion of Microscopic Diagnosis during the three periods 1984-93, 1994-98 and 1999-2000	. 34
4.5	Proportion of Cytological Diagnosis during the three periods 1984-93, 1994-98 and 1999-2000	. 34
5.1	Number and Relative Proportion of cancer patients according to Broad Groups of Treatment at	
	Reporting Institution and/or elsewhere	. 36
6.1	Number and Relative Proportion of patients according to Clinical Extent of Disease (Excludes Patients Previously Treated)	. 38
7.1	Total number of cancer patients treated, total number of treatment procedures performed and	
	procedures/patients ratio	
7.2	Number and Relative Proportion of patients according to Type of Treatment given	. 42
7.3	Number and Proportion of cancer patients according to Any Specific Treatment at Reporting Institution relative to All Treatment procedures	. 44
7.4(a)	Number and Relative Proportion of types of treatment according to Clinical Extent of Disease - Males	. 45
7.4(b)	Number and Relative Proportion of types of treatment according to Clinical Extent of Disease - Females	. 46
7.5(a)	Number and Proportion of any specific treatment relative to all treated patients according to Clinical	
	Extent of Disease - Males	. 47
7.5(b)	Number and Proportion of any specific treatment relative to all treated patients according to Clinical	
	Extent of Disease - Females	
8.1(a)	Number, Relative Proportion and Rank of cancers of the mouth	
8.1(b)	Cancers of Mouth - Number and Relative Proportion according to sub-site	
8.1(c)	Cancers of Gum - Number and Relative Proportion according to sub-site	. 50
8.1(d)	Cancers of Palate - Number and Relative Proportion according to sub-site	
8.1(e)	Cancers of Other and Uns. parts of mouth - Number and Relative Proportion according to sub-site	
8.2	Number and Relative Proportion of Mouth cancers according to five year age group	
8.3	Number and Relative Proportion of Mouth cancers based on different methods of diagnosis	. 55
8.4	Number and Relative Proportion of Mouth cancer patients according to the clinical extent of disease (Excludes Patients Previously Treated)	. 55
8.5	Number and Relative Proportion of Mouth cancer patients according to Broad Groups of Treatment	. 56
8.6	Number and Relative Proportion of Mouth cancer patients according to Type of Treatment given (Patients treated only at Reporting Institution)	57
8.7(a)	Number and Relative Proportion of types of treatment according to Clinical Extent of Disease	. 01
0.7 (a)	Mouth - Males	. 58
8.7(b)	Number and Relative Proportion of types of treatment according to Clinical Extent of Disease  Mouth - Females	50
8.8(a)	Number and Proportion of any specific treatment relative to all treated patients according to Clinical	. ၁9
0.0(a)	Extent of Disease - Mouth - Males	ൈ
8.8(b)	Number and Proportion of any specific treatment relative to all treated patients according to Clinical	. 50
(5)	Extent of Disease - Mouth - Females	. 61

9.1(a)	Number, Relative Proportion and Rank of cancers of the Tongue - Males	62
9.1(b)	Number and Relative Proportion of Tongue cancer patients according to sub-site - Males	63
9.2	Number and Relative Proportion of Tongue cancer according to five year age group - Males	64
9.3	Number and Relative Proportion of Tongue cancers based on different methods of diagnosis - Males	65
9.4	Number and Relative Proportion of Tongue cancer patients according to clinical extent of disease (Excludes Patients Previously Treated)	65
9.5	Number and Relative Proportion of Tongue cancer patients according to Broad Groups of Treatment -	
	Males	66
9.6	Number and Relative Proportion of Tongue cancer patients according to Type of Treatment given (Patients treated only at Reporting Institution) - Males	66
9.7	Number and Relative Proportion of types of treatment according to Clinical Extent of Disease - Tongue - Males	67
9.8	Number and Proportion of any specific treatment relative to all treated patients according to Clinical Extent of Disease - Tongue - Males	68
10.1(a)	Number, Relative Proportion and Rank of cancers of the Oesophagus	
10.1(a) 10.1(b)	Cancers of Oesophagus - Number and Relative Proportion according to sub-site	
10.1(b)	Number and Relative Proportion of oesophageal cancers according to five year age group	
10.3	Number and Relative Proportion of Oesophageal cancers based on different methods of diagnosis	/4
10.4	Number and Relative Proportion of oesophageal cancer patients according to the clinical extent of disease (Excludes Patients Previously Treated)	74
10.5	Number and Relative Proportion of oesophageal cancer patients according to Broad Groups of	
	Treatment	/5
10.6	Number and Relative Proportion of Oesophageal Cancer patients according to Type of Treatment given(Patients treated only at Reporting Institution)	76
10.7(a)	Number and Relative Proportion of types of treatment according to Clinical Extent of Disease - Oesophagus - Males	77
10.7(b)	Number and Relative Proportion of types of treatment according to Clinical Extent of Disease - Oesophagus - Females	78
10.8(a)	Number and Proportion of any specific treatment relative to all treated patients according to Clinical Extent of Disease - Oesophagus - Males	79
10.8(b)	Number and Proportion of any specific treatment relative to all treated patients according to Clinical	
()	Extent of Disease - Oesophagus - Females	80
11.1	Number, Relative Proportion and Rank of cancers of the Lung - Males	
11.2	Number and Relative Proportion of Lung cancers according to five year age group - Males	
11.3	Number and Relative Proportion of Lung cancers based on different methods of diagnosis - Males	
11.4	Number and Relative Proportion of Lung cancer patients according to the clinical extent of disease (Excludes Patients Previously Treated)	
11.5	Number and Relative Proportion of Lung cancer patients according to Broad Groups of Treatment -	
	Males	85
11.6	Number and Relative Proportion of Lung cancer patients according to Type of Treatment given (Patients treated only at Reporting Institution) - Males	85
11.7	Number and Relative Proportion of types of treatment according to Clinical Extent of Disease -	
	Lung - Males	86
11.8	Number and Proportion of any specific treatment relative to all treated patients according to Clinical Extent of Disease - Lung - Males	87
12.1	Number, Relative Proportion and Rank of cancers of the breast - Females	89
12.2	Number and Relative Proportion of female breast cancers according to five year age group	90
12.3	Number and Relative Proportion of female breast cancers based on different methods of diagnosis	91
12.4	Number and Relative Proportion of female breast cancer patients according to the clinical extent of disease (Excludes Patients Previously Treated)	91
12.5	Number and Relative Proportion of female breast cancer patients according to Broad Groups of	
	Treatment	92
12.6	Number and Relative Proportion of female breast cancer patients according to Type of Treatment given (Patients treated only at Reporting Institution)	
12.7	Number and Relative Proportion of types of treatment according to Clinical Extent of Disease -	UL
•	Female Breast	93

12.8	Number and Proportion of any specific treatment relative to all treated patients according to Clinical	
	Extent of Disease - Female Breast	
13.1	Number, Relative Proportion and Rank of cancers of the Cervix	
13.2	Number and Relative Proportion of cervical cancers according to five year age group	97
13.3	Number and Relative Proportion of cervical cancers based on different methods of diagnosis	98
13.4	Number and Relative Proportion of cervical cancer patients according to clinical extent of disease	
	(Excludes Patients Previously Treated)	
13.5	Number and Relative Proportion of cervical cancer patients according to Broad Groups of Treatment	99
13.6	Number and Relative Proportion of cervical cancer patients according to Type of Treatment given	
	(Patients treated only at Reporting Institution)	
13.7	Number and Relative Proportion of types of treatment according to Clinical Extent of Disease - Cervix	. 100
13.8	Number and Proportion of any specific treatment relative to all treated patients according to Clinical	
	Extent of Disease - Cervix	
14.1	Number and Proportion of Head and Neck cancers relative to all sites of cancer	
14.2	Number and Relative Proportion of specific Head and Neck sites relative to all head and neck cancers.	
14.3	Number and Relative Proportion of specific Head and Neck sites relative to all sites of cancer	
14.4	Number and Relative Proportion of Head and Neck cancers by five-year age groups	
14.5	Number and Relative Proportion of Head and Neck cancers based on different methods of diagnosis	
14.6	Number and Relative Proportion of Head and Neck cancers based on broad groups of treatment	. 109
14.7	Number and Relative Proportion of Head and Neck cancer patients according to Clinical Extent of	
	Disease (Excludes Patients Previously Treated)	. 110
14.8	Number and Relative Proportion of Head and Neck cancer patients according to Type of Treatment given	. 111
15.1	Tongue - Number and Relative Proportion of different histologic types	
15.2	Mouth - Number and Relative Proportion of different histologic types	
15.3	Pharynx - Number and Relative Proportion of different histologic types	
15.4	Oesophagus - Number and Relative Proportion of different histologic types	
15.5	Stomach - Number and Relative Proportion of different histologic types	
15.6	Lung - Number and Relative Proportion of different histologic types	
15.7	Bone - Number and Relative Proportion of different histologic types	
15.8	Soft Tissue - Number and Relative Proportion of different histologic types	
15.9	Female Breast - Number and Relative Proportion of different histologic types	
15.10	Cervix - Number and Relative Proportion of different histologic types	. 118
15.11	Ovary - Number and Relative Proportion of different histologic types	. 119
15.12	Kidney - Number and Relative Proportion of different histologic types	. 120
15.13	Brain - Number and Relative Proportion of different histologic types	. 121
15.14	Thyroid Gland - Number and Relative Proportion of different histologic types	. 122
15.15	Tumours of Lymphoid and Haematopoietic System (LHM) - Number and Relative Proportion of	
	different histologic types	. 122
15.16	Hodgkin's Disease - Number and Relative Proportion of different histologic types	. 123
15.17	Leukaemias - Number and Relative Proportion of different histologic types	. 123
16.1	Number and Relative Proportion by Educational Status (All Sites of Cancer)	. 124
16.2	Number and Relative Proportion by Marital Status (All Sites of Cancer)	. 125
16.3	Number and Relative Proportion of Cancer patients by Religion	. 125
16.4	Number and Relative Proportion by Language Spoken (All Sites of Cancer)	. 126

# **LIST OF FIGURES**

		Page Nos
1	Trends in total number of cancers registered (both sexes)	2
1.1	Ten Leading Sites of Cancer	4
1.2	Stack(100%) diagram showing Proportion of Cancers by Broad Age Groups	9
1.3	Leading Sites in Broad Age Group (15-34 Years)	11
1.4	Leading Sites in Broad Age Group (35-64 Years)	13
1.5	Leading Sites in Broad Age Group (65 Years and above)	15
2.1	Proportion of Broad Types of Childhood Cancers (0-15 years)	20
3.1	Proportion of Tobacco Related Cancers Relative to All Sites	26
3.2	Proportion of Specific Tobacco Related Sites Relative to All Tobacco Related Cancers	26
4.1	Proportion of Patients according to Method of Diagnosis	30
4.2	Proportion of Microscopically Diagnosed patients according to specific Microscopic Diagnosis	32
5.1	Stack(100%) diagram showing HBCRs, Proportion According To Broad Groups of Treatment	37
3.1	Stack(100%) diagram showing HBCRs, Proportion of Patients According To Clinical Extent of Disease	se 39
7.1	Procedure - Patient Ratio (Patients Treated only at Reporting Institution)	41
7.2	HCRs, Proportion of Different Types of Treatment (Patients Treated only at Reporting Institution)	41
7.3	Proportion of Types of Treatments (Patients Treated only at Reporting Institution)	43
3.1	Mouth - Trends in Actual Numbers	52
3.2	Mouth - Five year age group distribution	54
9.1	Tongue(Males) - Trends in Actual Numbers	63
9.2	Tongue(Males) - Five year age group distribution	64
10.1	Oesophagus - Trends in Actual Numbers	71
10.2	Oesophagus - Five year age group distribution	73
11.1	Lung(Males) - Trends in Actual Numbers	82
11.2	Lung(Males) - Five year age group distribution	83
12.1	Female Breast - Trends in Actual Numbers	89
12.2	Female Breast - Five year age group distribution	90
13.1	Cervix - Trends in Actual Numbers	96
13.2	Cervix - Five year age group distribution	97
14.1	Trends in Actual Numbers - Head and Neck Cancers	103
14.2	Proportion of Head and Neck Cancers Relative to All Sites	104
14.3	Stack(100%) diagram showing Proportion of Specific Head and Neck Cancer Sites Relative to	
	All Head and Neck Cancers	104
14.4	Relative Proportion(%) of Head and Neck Cancers by Five Year Age Group	108



This two year report of the hospital based cancer registries under the National Cancer Registry Programme (NCRP) for the years 1999 - 2000 is the result of work carried out by the five Hospital Based Cancer Registries located at the respective institutions in different parts of the country.

The broad purpose of a Hospital Based Cancer Registry (HBCR) is to assess and evaluate cancer patient care in the concerned hospital. Besides, the HBCR gives a picture of the magnitude and patterns of cancer in a given hospital and contributes to the population based cancer registry in the geographic area. Information about types of cancers and types of treatment helps in planning the facilities required in the respective hospital, thereby facilitating health services research. The HBCR is also well suited for undertaking epidemiological research.

The HBCRs under the NCRP have over the years given an assessment of the magnitude and patterns of cancer in the particular region, furnished information to the Population Based Cancer Registry and in more recent years provided data to the project on 'Development of an Atlas of Cancer in India'. In addition, they have conducted several case control studies.

The NCRP has commenced through the HBCRs, a detailed systematic study on 'Patterns of Cancer Patient Care and Survival' in three important sites of cancer, viz., cancer cervix, cancer breast and head and neck cancers. These institutions have evolved strategies for patient follow-up. In the coming years, the results of these studies is expected to give a picture of stage and treatment based survival at a national level and more importantly in the Indian context. This would pave the way for initiating multi-centric clinical trials with the HBCR as the backbone.

It is hoped that this report will encourage other cancer centres throughout the country to establish their own HBCRs and commence patterns of care studies.

Namal- fu

3 August 2005

**Prof. N. K. Ganguly,** Director General. ICMR

# 

Dr N.K. Ganguly, Director General, ICMR;

Dr Bela Shah, Chief, Division of NCD, ICMR;

Dr Usha K. Luthra, Sr Adviser, Cancer Research, ICMR;

Principal Investigators and Staff of Hospital Based Cancer Registries;

Members of Steering Committee;

Members of Monitoring Committee;

Staff of Division of NCD, ICMR;

Staff of Coordinating Unit: Mr G.C. Shivayogi, Mr N.M. Ramesha and Mr M. Rajendra;

Staff of the Project on Development of an Atlas of Cancer in India: Ms F.S. Roselind

Prof K. Ramachandra Reddy for final proof reading.

# NATIONAL CANCER REGISTRY PROGRAMME

(Indian Council of Medical Research)



### **National Cancer Registry Programme**

The Indian Council of Medical Research initiated the National Cancer Registry Programme (NCRP) in 1981 and commenced a network of cancer registries across the country that started functioning from January 1982. Three hospital based cancer registries (HBCR) were commenced at Assam Medical College, Dibrugarh; Regional Cancer Centre, Trivandrum; and Post Graduate Institute of Medical Education and Research, Chandigarh. In order to extend the assessment of cancer patient care, HBCRs were also started in 1984 at Kidwai Memorial Institute of Oncology, Bangalore; Cancer Institute (WIA), Chennai and Tata Memorial Hospital, Mumbai.

More recently, the HBCRs have embarked on 'Patterns of Cancer Patient Care and Survival Studies' in cancer cervix, cancer breast and head and neck cancers. Several other institutions not in the NCRP network are also collaborating in this multi-centric project. A common agreed patient information form has been developed for each of the sites, incorporating among other things, details of clinical stage, different aspects of types of treatment and meticulous recording of follow-up information. A manual for completing the forms has also been developed.

Data collection also commenced from 1 January 1982 in the population based cancer registries (PBCRs) at Bangalore, Chennai and Mumbai. From 1986 two more urban population based cancer registries were started in Delhi and Bhopal. For the first time a population based rural cancer registry was also started by the ICMR during the subsequent year (1987) in Barshi in the state of Maharashtra. PBCRs to cover the population of Ahmedabad rural district and Kolkata Municipal Corporation have started functioning from 1 January 2004 and 1 January 2005 respectively.

Under the auspices of the World Health Organization a project on "Development of an Atlas of Cancer in India" was commenced in 2001. The two-year report for 2001 and 2002 provided many interesting findings. As a fall out of this a North-Eastern Regional Cancer Registry (NERCR) has been commenced in six areas at Guwahati, Dibrugarh and Silchar in Assam, Aizawl in Mizoram, Imphal in Manipur and Gangtok in Sikkim. These registries have started collation of information on cancer cases from 1 January 2003. A project on developing a cancer atlas especially for the North East states (specifically to include the other four states of Arunachal Pradesh, Meghalaya, Nagaland, Tripura and other areas of Assam not included under the NERCR) has also been initiated. Role of tobacco and pesticides in the occurrence of cancer in these areas is also being investigated.

The NCRP is a long-term activity of the Indian Council of Medical Research. The programme is one of the many major activities of the Division of Non-Communicable Diseases and an Officer-in-charge coordinates it. The Programme is assisted by Steering and Monitoring Committees to help oversee and guide its functioning. A workshop followed by a review meeting is held annually. The Principal Investigators and staff of the registries present data and participate in the discussions. In recent years representatives of other functioning PBCRs that are not in the NCRP Network also participate. Over the years, the National Cancer Registry Programme (NCRP) of the ICMR has laid a strong foundation to build on for cancer research. The entire activity of the NCRP and the projects under it are directed, monitored and executed (including conduct of workshops and coordination of the Annual Review Meetings and workshops) by the Coordinating Unit of the NCRP located at Bangalore.

The NCRP is gradually fulfilling many of the objectives with which it was commenced. These include:

1. Generation of reliable data on the magnitude and patterns of cancer - this would be based on morbidity

and mortality information in different regions of the country according to sex, age and residence of the patient, anatomical site of cancer and proportion of histological type or microscopic confirmation for each site; pattern of different types of cancer according to relative proportions or ratios in various population sub-groups such as religion, language spoken, educational status; clinical stage of disease when patients come to hospital for treatment and where possible the nature of treatment received and outcome;

- 2. Undertaking epidemiologic research, such as case control or cohort studies based on observations of registry data;
- 3. Providing data base for developing appropriate strategies to aid in National Cancer Control Programme;
- 4. Developing human resource in cancer registration and epidemiology.

Cancer registration in India is active. Staff of registries visit hospitals on routine basis and scrutinise the records in various departments that include pathology, radiology, radiotherapy, in-patient wards and out-patient clinics to elicit the desired information on reported cancer cases in a "core proforma" that has been standardised for all cancer registries in India. The hospitals include the main cancer hospitals, other general hospitals in both the government and private sector. Besides pathology laboratories that routinely report cancer cases are also visited. Death certificates are also scrutinised from the municipal corporation units. Every attempt is made by registries to register all cancer patients in the registration area who are resident (at least one year) in the area in all hospitals and copy all death certificates in which cancer is mentioned.

Certain basic checks of data especially those related to duplicate verification and matching with mortality records are carried out by the individual registries. After this, the data is sent to the Coordinating Unit for subjecting the data to various range, consistency and unlikely combinations including a further round of possible duplicate listing. The list of cases with the items of patient information, that require verification are sent to the respective registries by the Coordinating Unit. Individual registries go through the records/reports of such cases and wherever necessary discuss with the concerned clinician or the pathologist. On receiving the clarifications the Coordinating Unit prepares the detailed tabulations by five-year age group, site and sex including rates. The individual registries use these tables to prepare the registry's annual report. The Coordinating Unit collates the data and tables to prepare the consolidated report of that year.

During the annual workshop, the various aspects of working of the registry, problematic cases, use of coding and discussion on medical terminology, statistical and epidemiologic methods are discussed. About 2-3 senior and junior staff from each registry, participate in the workshop.

Apart from the above the Coordinating Unit undertakes and coordinates epidemiologic and other research studies including those to ensure that the quality of data is of a high standard and that coverage of cancer cases in the registry area is as complete as possible. More recently an on-line check programme has been developed. This will enable individual registries to conduct quality checks of their data on the web-site.

Over the years, staff from registries under the NCRP, have benefited from both short and long term training fellowships in established institutions abroad. This has helped them and the registries to develop into departments of epidemiology and undertake several studies on their own and contribute to several research publications in indexed journals.

# Two-year Report of the Hospital Based Cancer Registries: 1999-2000

An Assessment of the Burden and Care of Cancer Patients

### INTRODUCTION AND SUMMARY OF THE REPORT

Objectives of Hospital Based Cancer Registries (HBCRs) (Maclennan *et al*, 1978; Young, J.L. 1991):

### 1. GENERAL:

- 1.1 Assess Patient Care;
- 1.2 Participate in Clinical Research to Evaluate Therapy;
- 1.3 Provide an idea of the patterns of cancer in the area;
- 1.4 Help plan hospital facilities.

### 2. SPECIFIC:

- 2.1 Contribute to active follow-up of the cancer patient;
- 2.2 Describe length and quality of survival in relation to anatomical site, clinical stage and aspects of types of treatment;
- 2.3 Contribute to the Population Based Cancer Registries (PBCRs) in the given area;
- 2.4 Undertake epidemiological research through short-term case control studies;
- 2.5 Show time trends in proportion of early to late stages at the time of diagnosis;
- 2.6 Help assess quality of hospital care and cancer services in covered area.

Data collection is done by the individual registries using a standardised agreed common core proforma. The information in this form mainly consists of patient identifying information, demographic facts, details of diagnosis including method of diagnosis, the clinical stage of the disease and the broad type of treatment instituted. Attempts are made to collect particulars of follow-up as well but this has been difficult and in the absence of follow-up of the majority of cases registered by the HBCR, obtaining stage and treatment based survival has not been possible.

Registries send the data to the Coordinating Unit as soft copy in MS-Excel, ASCII or other formats. These data are then converted to a uniform format at the Coordinating Unit and quality control exercises are carried out. Once data is finalized in correspondence with the individual registries, annexure tables are generated and reports prepared.

The two year (1999-2000) report of the five HBCRs is the contribution of data from the hospitals at Tata Memorial Hospital, Mumbai; Kidwai Memorial Institute of Oncology, Bangalore; Cancer Institute-Adyar, Chennai; Regional Cancer Centre, Thiruvananthapuram and Assam Medical College, Dibrugarh.

This report essentially identifies the patients who registered in these institutions and had a diagnosis

of cancer. It further distinguishes those that received cancer directed treatment (CDT) or not. Those who had received prior CDT i.e., before registration at the reporting institution were considered as 'non-analytic cases'. Those who had not received prior CDT were considered as 'analytic cases'. The rationale behind such classification is simple. The main function and objective of HBCRs is to assess and evaluate patient care of that particular hospital or reporting institution. So, if a proportion of patients received some form of cancer directed treatment elsewhere, they are not expected to be reflected in the patient care of the reporting institution, even if this group had received the additional or major course of treatment at this institution. Therefore, this report deals in detail with the analysis of analytic cases.

### **Checks on Data**

Several range, consistency and duplicate checks are carried out at the Coordinating Unit. These include all the checks based on the IARC publication (Parkin et al, 1994) on 'Comparability and Quality Control in Cancer Registration'. Some checks on certain additional items of patient information including those concerning clinical stage and treatment are also done. Detailed guidelines of each of the items in the core form and related aspects are covered in the coding manual specifically for HBCRs. Registry staff follow these guidelines while completing the core form and checks of data are entirely based on these guidelines.

The summary of checks that were carried out include:

- 1. **Range checks:** By this is meant that the numeric codes provided should be valid and be in conformity with the key to the codes (for example the code for sex should only be 1 or 2 and not any other number or character).
- 2. Consistency checks: By this is meant, that, while relating the codes of two variables there should be a meaningful or possible logical relationship. For example a patient with a code for prostate cancer can have a code only for male and cannot have the code for female. Similarly, the date of diagnosis should precede the date of commencement of treatment and cannot come after that.
- 3. **Duplicate checks** based on registration number, name, age, sex and ICD-10 are also carried out.

### ICD-9 vs ICD-10

The tabulations in this report are according to the International Classification of Disease and Related Health Problems, 10th Revision (ICD-10), whereas the previous reports were based on ICD-9. This may be kept in mind while comparing the data of individual sites with the previous reports as some minor differences could be due to this changeover.

The broad purpose of this Two Year (1999-2000) report of the HBCRs is to look into some of their functions outlined above. The HBCRs have over the years given an assessment of the magnitude and patterns of cancer in the region being catered by the centre/registry. They have also contributed to the PBCR of the area. HBCRs have also conducted several case control studies. However, in terms of assessing patient care - for various reasons, follow-up in a routine way has been difficult under Indian conditions. Therefore, the NCRP through the HBCRs has commenced a study on patterns of care and survival in cancer of the breast, cervix and head & neck cancers, so that greater focussed attention could be paid to clinical aspects and management.

The report is mainly in the form of statistical tables and graphs with the corresponding text giving only the factual description. While the report has tried to analyse, compile and consolidate the data provided by the different registries in a set format, it has in no way tried to compare and therefore comment or interpret the data between or among registries. Thus, no judgement is made of the figures in the tables. This is mainly because the individual institutions where the registries are located would have, their own

policies in patient care and management which is beyond the purview of this report. Individual registries, could however view their data, interpret its possible meaning and observe where, if at all modifications are required in administering patient care.

The report provides several pointers to policy makers. It gives an idea of the load of cancer patients in the main cancer hospitals of the country, the proportion and sites of cancers presenting at a late stage of the disease, the resources necessary for diagnosing and treatment according to different modalities, the proportion of patients who require palliative care, and so on. The report forms a base for both policy makers and institutions to plan for the future and would give a fair idea of the optimum number of patients a cancer centre/hospital would be able to effectively handle. The report could also form the basis of working out treatment costs and hospital stay. For the registries themselves the report should be a starting point in conducting follow-up and survival studies on at least selected sites of cancer and also initiating clinical trials.

A brief outline of the purpose and ways of interpreting each of the chapters and some areas where additional information should be gathered in order to get a more complete picture is indicated below.

Chapter 1 gives a picture of the overall magnitude of cancers diagnosed at the respective centres. This has to be further examined in the context of number of patients registered, and number who were diagnosed earlier. The chapter gives the relative frequencies of the leading sites of cancer in broad age groups.

Chapter 2 deals with different types of cancers in childhood.

Chapter 3 indicates the impact of the use of tobacco in the causation of cancer both in proportions and anatomical site of cancer. In planning tobacco control activity across the country this baseline is most important. Though, not in a defined population it gives a fair picture of the problem of cancer associated with the use of tobacco.

The basis of diagnosis in Chapter 4, is one index of the reliability of diagnosis. Microscopic diagnosis that includes histology, cytology and haematology constitutes the basis for establishing a diagnosis of cancer.

Chapter 5 gives an overview of the proportion of patients presenting in various conditions of diagnoses and treatment. It emphasizes the need for distinguishing patients who have been treated elsewhere and those treated only at the reporting hospital/institution.

The proportion of patients presenting in different clinical extents of disease is shown in Chapter 6. Clinical extent of disease at presentation of cancer is directly related to the type and effectiveness of treatment. This is one of the most important baseline indicators for initiating cancer control activity in the area and the success of any education and early detection programmes in the area will be reflected in changes in proportions of stage of presentation of relevant sites of cancer.

Chapter 7 gives the details of different types of treatment at the reporting institution. This is for patients who have not received treatment earlier. The types of treatment and their proportions have been tabulated. The types of treatment and their relative proportions give an idea of the forms of treatment pursued in a given institution.

Chapters 8-14 summarize important selected sites of cancer with the comprehensive tables given in the earlier Chapters. The numbers in these tables of individual sites become more meaningful.

Chapter 15 deals with the relative proportions of histological types of cancer for certain specific sites.

Chapter 16 summarises the relative proportion of cases according to educational status, religion and language spoken.

### **HOSPITAL BASED CANCER REGISTRY**

### Tata Memorial Hospital, Mumbai

Dr. K. A. Dinshaw, D.M.R.T. (Lond), F.R.C.R. (Lond),:Director & Principal Investigator

Mr. D. N. Rao, M.Sc., Co-Investigator, Head, Division of Epidemiology & Biostatistics

Dr. B. Ganesh, Epidemiologist, Division of Epidemiology & Biostatistics

### INTRODUCTION

The Tata Memorial Centre (TMC) comprises Tata Memorial Hospital (TMH) and ACTREC (Advanced Centre for Treatment Research and Education in Cancer). The Cancer Research Institute (CRI) has now become the basic research wing of ACTREC. This Centre is a grant-in-aid institution under the administrative control of the Department of Atomic Energy, Government of India. The main activities of the centre is diagnosis, treatment and research in cancer as well as training and education to provide the highest standard of patient care.

This report briefly outlines the hospital facilities available for patient care and working of the Hospital Based Cancer Registry during the period 1999-2000.

### TATA MEMORIAL HOSPITAL

The TMH is a comprehensive Cancer Centre with the state of art equipments for diagnosis and treatment and patients from different states in India and abroad attend this hospital. On an average 1000 patients attend this hospital every day. The hospital had 440 in patient beds available for patient care.

The hospital consists of Departments of Surgical Oncology, Medical Oncology, Radiation Oncology, Radio-diagnosis, Pathology, Cytology, Biochemistry and Laboratory Medicine. The Department of Radio-diagnosis is equipped with the latest equipments like CAT Scan, MRI, X-ray machines (1000 mA, 500 mA,), Mammography, Orthopantograph X-ray and Ultrasonography machines for the diagnosis of cancer. The supportive care facilities for cancer patients like Physiotherapy, Ostomy Clinic, Occupational Therapy and Transfusion Medicine are also available. Over 500 patients attend the hospital for radiation treatment on a daily basis.

The hospital initiated the Bone Marrow Transplantation (BMT) programme in 1982 and 23 patients underwent BMT in the year 2000.

The Department of Microbiology has been actively involved in setting up a dedicated system for handling the hospital's infectious waste system. A surveillance system is being set up to monitor post-operative wound infections and also control of infections in the Intensive Care Unit (ICU).

The Department of Preventive Oncology conducts lectures and audiovisual presentations educating

children on the ill effects of tobacco at 28 schools and colleges. The department also arranges poster exhibitions, lectures, workshops etc. on the ill effects of tobacco and Cancer Awareness programmes at 19 different locations for students as well as for general public.

The First Rural Outreach programme for early diagnosis and treatment started by the Centre at Barshi is continued by the Nargis Dutt Memorial Cancer Hospital (Aswini Cancer Research and Relief Society), Barshi with the support of the TMC.

The Clinical Research Secretariat (CRS) which was started in 1997 assists clinical researchers in data management, data analysis and other aspects of research projects. The CRS has offered infrastructural facilities for conducting randomised trials, and prospective clinical research studies.

A Department of Atomic Energy Clinical Trials Centre (DAE CTC) has been established at TMH to initiate clinicians in the concept of scientific and evidence based medicine and also to address burning medical and epidemiological questions essential in this part of the world.

The TMH Tissue Bank - the largest tissue bank in India supplies safe and reliable tissue for human transplantation and it is only one of its kind in processing and distributing multiple types of tissues. Over 900 allographs were produced and utilised so far.

The department of Rehabilitation Services established the Rehabilitation Research Centre (RRC), at the Dr. Earnest Borges Home, Bandra in the year 1998. It offered all types of prosthesis and orthosis and activities of daily living devices specially designed for cancer patients.

The hospital has been actively involved in implementing an "integrated & on-line" Information System for (i) Patient Administration comprising of OPD Registration, Appointments, Follow-up, Admission-Discharge-Transfer System for in-patients, Billing and Receipt system, etc (ii) Inventory Control System for Purchase, Stores, and Dispensary. This software makes use of Visual Basic as a GUI based front-end & DB2/400 on AS/400 as the bank-end database.

Specialised software such as DIS (Diagnostic Information System) RIS (Radiological Information System) were incorporated in the Hospital Information System (HIS) and most of the diagnostic reports were available for on line retrieval.

Telemedicine and telepathology have provided an opportunity for TMH to get connected with international and national centres like Guwahati in the north east and rural cancer centres in the interior of Maharashtra at Barshi and Chiplun along the west coast. This would allow exchange of thoughts, distance bearing, transfer of technology and meaningful collaboration between individual clinicians.

A Touch-Screen facility was set up in the hospital which was inaugurated by Dr. R Chidambaram. It provides information about the hospital, on cancer, on prevention and other related information etc. It was estimated that in the first 5 months about 80,000 visitors have utilized this facility.

TMH is a post-graduate teaching centre, affiliated to the University of Mumbai, National Board of Examinations, New Delhi and Maharashtra University of Health Sciences, Nasik. The Post-graduates courses (M.D.) in Pathology, Radiodiagnosis, Radiotherapy, Anaesthesia (DA), (DMRD) Radiodiagnosis, and (DMRT) Radiotherapy are available and over 50 students were registered during the year 1999-2000.

The Tata Memorial Centre is a recognised training centre by national and international organisations such as WHO, UICC and IAEA. WHO/IAEA Fellows are provided training in various fields. In an ongoing program on Continuing Education in Oncology, trainees are registered for courses such as (i) Oncology Training Program for Doctors (ii) G.I. Endoscopy (iii) Medical Oncology/Clinical Oncology (iv) Radiotherapy & Radiodiagnosis Training Course (v) Oncology Nursing Training Course (vi) Diagnostic Cytology Training Course (vii) Certificate Course in Enterostomal Therapy and (viii) Apprenticeship in Pathology Department.

Observers from all over India, SAARC countries and other parts of the world visit the institution to update their knowledge and share their experiences.

Recognition from Universithy of Mumbai was received for the conduct of MD in Immunoheamatology and Blood Transfusion.

### **CANCER REGISTRY**

Cancer Registry maintains cancer related information such as site of disease, histological classification, clinical extent of disease and primary treatment since 1941. Over 1,100 patients were diagnosed as cancer cases in 1941, since then there has been increase in patients attendance and at present over 25,000 new patients get registered and over 15,000 patients are diagnosed as cancer annually.

The Population Based Cancer Registry (PBCR) for Greater Bombay was started in the year 1964 and TMH Cancer Registry has been the important source for getting information on resident cancer cases. As TMH is a well recognized institution, patients from other states of India and abroad attend for expert medical care and opinion. Thus this HBCR has become an important source to identify resident cancer cases of PBCR's like Bhopal, Delhi, Chennai and Barshi in NCRP network.

The Cancer Registry operations were computerised in 1985. The new computer was installed and commissioned IBM AS/400 Server, which makes use of OS/400 as operating system, DB2/400 as the RDBMS. This server is based on Client Server architecture and has replaced old ND 550 system (NORSK DATA). The Software is Visual Basic front-end tool and DB2/400 as a back-end database available on AS/400 and is planned to be 'On - Line' system.

The standard international code such as International Classification of Disease for Oncology (ICD-0-ii, ICD-III, ICD-9, TNM (WHO) are used to classify the disease (topography & morphology), clinical extent of disease etc. and codes for demographic variables are also being used. The registry has started using ICD10 for 1999 & 2000 cancer cases. As cancer is not a notifiable disease, information about patient's health status is obtained through active follow-up of patients mostly by postal inquiry.

The Cancer Registry brings out comprehensive annual reports on cancer statistics covering various aspects of cancer management and care. End Results Reports on head & neck cancer and breast cancer are published periodically. Epidemiological studies and case-control studies are carried out to identify high risk and associated factors for common cancers like head & neck, oesophagus and breast cancers and the results are published in Indian and International Journals.

Staff from other hospitals are given training in cancer registry techniques and over 20 personnel have been given training so far. Cancer Registry staff also attend various workshops on cancer registry operations and are trained well in various aspect of cancer registration.

### **HOSPITAL BASED CANCER REGISTRY**

### Kidwai Memorial Institute of Oncology, Bangalore

Dr. Bapsy Padmanabhan, Principal Investigator & Director
 Dr. P.S.Prabhakaran, Former Principal Investigator & Director
 Dr. K.Ramachandra Reddy, Co-principal Investigator & Prof. & Head
 Dr. C.Ramesh, Associate Prof.

Mr. K.Mani, Lecturer

Department of Epidemiology and Biostatistics

Kidwai Memorial Institute of Oncology (KMIO) is a Comprehensive and Regional Centre for Cancer Research and Treatment in Karnataka. The Institute has all the state of art facilities for the diagnosis and treatment of cancer and in view of this, patients from all over Karnataka as well as from the adjoining areas of neighbouring states of Andhra Pradesh, Tamil Nadu, Kerala and other regions attend this hospital. The Institute which was established in 1973 with 50 inpatient beds and a radiology department has achieved a bed strength of 429 apart from the Dharmashala, a unique project of its kind in the country which provides accommodation to about 250 ambulatory patients with 250 of their attendants. These patients and attendants at the Dharmashala are provided with free food through perpetual free feeding endowment donation scheme.

As community outreach programme, the mobile cancer education and detection unit (Department of Community Oncology) organizes cancer detection and education camps in rural, semi urban areas of Karnataka and in the neighbouring areas of other states with support from voluntary organizations. KMIO as an apex body for the overall cancer control in the state has initiated several cancer control programmes / activities at different places. The Institute has been recognized as a National Centre of Excellence. Medical and paramedical personnel from all over the country come for training in various specialities / branches of oncology. KMIO is running super speciality courses in M.Ch (Surgical Oncology) and DM (Medical Oncology), Post-graduate courses in MD Radiotherapy, Nuclear Medicine and Radiation Physics apart from Undergraduate courses in B.Sc. Medical Technology (Laboratory / Radiotherapy / Radio Diagnosis). These courses are affiliated to Rajiv Gandhi University of Health Sciences.

In order to provide anti-cancer drugs at reasonably reduced prices, the Kidwai Cancer Drug Foundation Trust has been established where, the cost of Ani Cancer Drugs are available at nearly 30% cheaper rates compared to market prices. Free drugs are provided to poor and needy patients through Karnataka Chief Minister's Medical Relief Fund.

The KMIO is a well equipped Comprehensive Cancer Centre consisting of the departments of Surgical Oncology (General, Head & Neck, Oral, Gynaecologic), Radiotherapy, Medical Oncology, Paediatrics, Radiodiagnosis, Pathology, Biochemistry, Blood transfusion & Immuno Haematology, Microbiology,

Cytogenetics, Nuclear Medicine, Radiation Physics, Anaesthetics & Pain relief, Epidemiology & Biostatistics, Community Oncology, Social Welfare & Public relations, Library and information centre, Administration & supportive care facilities for cancer patients like Physiotherapy, Ostomy clinic, Occupational therapy, are also available.

KMIO being a referral cancer centre, about 70% of the patients are referred by various medical institutions and private practitioners. The Institute has established two Peripheral Cancer Centres at Mandya & Gulbarga with a main intention of reducing the distance of travel of cancer patients from far places to KMIO and to provide cancer treatment facilities at the nearest places as far as possible so that, it also reduces the load on KMIO. During the period 1999-2000 a total number of 24211 new patients were registered of which 14,498 cases were confirmed to have cancer. About 18% of the patients registered annually are from the adjacent states. On an average about 50 new cases are registered every day and 650 follow-up patients come for regular treatment. The Institute offers all modalities of cancer directed treatment - Surgery, RT, CT, Hormone therapy and Pain Relief through a multi-disciplinary team approach.

Of the total number of confirmed cancers of 14498, the proportion of cancers in females were higher and accounted for 56% (8065 cases) of the total cancers compared to 44% (6433 cases) in males.

Among males, cancer of the pharynx (ICD - CO9, C10, C12, C13 & C14) is continued to be the first predominant site of cancer (14%) followed by oral cavity (COO-CO6) (12%), oesophagus(9.4%), stomach (7%) and lung (6.9%). Among females, cancer of the cervix is the most common cancer with 32% of the total female cancer followed by breast(14.5%), oral cavity(12%), oesophagues(5.9%) and ovary (4.5%). Tobacco related cancer sites accounted for 46.5% of the total cancers in males and 22.1% in females. Together in both sexes, the tobacco related cancer sites accounted for 33% of the total cancers.

Paediatric (0-14 years) cancers formed about 4.5% of the total cancers with a slight prepondence in boys (6.02%) compared to girls (3.24%). Leukaemias and Lymphomas were the commonest sites of cancers in paediatric age-group.

### Other staff of Hospital Based Cancer Registry of the Dept. of Epidemiology & Biostatistics

Mr. D.J.Jayaram : Sr. Investigator / Scientific Assistant

Mr. C. Shivanna : Asst. Social Scientist

(On deputation to Community Oncology)

Mr. V. Bhadraiah : Asst. Social Scientist
Mr. A.V.Srinivasa Gowda : Asst. Social Scientist
Mr. R.Lingaraju : Asst. Social Scientist
Mr. M.K.M. Gowda : Asst. Social Scientist
Mrs. B.J. Kumudhini : Asst. Social Scientist
Mr. M.R. Balakrishnoji Rao : Asst. Social Scientist

(On deputation from Community Oncology)

Mr. A. Subramani : Coding Clerk
Mrs. A.K.Jyothi : Stenographer

Mr. B.M.Gangaiah : Data Entry Operator
Mr. Mahadevaiah : Literate Attender

### **HOSPITAL BASED CANCER REGISTRY**

Cancer Institute (WIA), Adyar, Chennai

Dr. V. Shanta, Principal Investigator, HBCR & Executive Chairman, Cancer Institute (WIA)

**Dr. R. Swaminathan,** Co-Investigator, HBCR & Senior Bio-Statistician, Division of Epidemiology & Cancer Registry

Mrs. R. Rama, Statistical Assistant, Division of Epidemiology & Cancer Registry

The Cancer Institute (W.I.A.), in Chennai, is the first comprehensive cancer care centre to be established in South India and the second in India. It is recognized as a Regional Cancer Centre by the Ministry of Health & Family Welfare, Government of India with state of the art facilities for cancer diagnosis, treatment and research. It is an autonomous non-profit institution with a bed strength of 423; more than 50% of the patients are boarded, lodged and treated at free of cost. The institute is primarily research oriented and is recognized by the University of Madras, Anna University and The Tamil Nadu Dr. M.G.R. Medical University for doctoral and super speciality degrees. The proportion (%) of patients attending the Institute from southern states of India: Tamil Nadu-68%, Andhra Pradesh-26% and Kerala-2%. Over 240 patients (new patients and follow-up cases) are seen at the Institute per day and these figures are increasing over the years. The three leading site of cancers among males are Oral Cavity (UICC), Oropharynx(UICC) and Oesophagus. In females Cervix, Breast and Oral Cavity (UICC) are the leading sites. In paediatric age group, all Leukemias and all Lymphomas are the predominant cancers.

The Hospital Based Cancer Registry has been functioning since the inception of the Institute in 1955. Data collection on the lines of ICMR started on 1st January 1984. All new cases attending the Institute are interviewed during registration and the required data are abstracted from the records using a standard proforma. The coded proforma are then scrutinized by the Medical Officer and Statistician. Data are then computerized. The validity and consistency checks for unlikely combinations of age, sex, site and morphology and other factors are carried out using in-house computer programs. In addition to these the IARC quality control programs are also used to validate the data. The cleaned data are then sent to the ICMR coordinating unit. Exercises on re-abstraction and coding on a random sample of cases are done regularly and presented in national level registry meetings.

Lifetime follow up of the cancer cases is generally felt difficult in India. With great efforts, we have evolved methods to overcome the problems in the follow up of cases treated at the Institute. An address

form consisting of a minimum of seven addresses of patients and their relatives / friends / referring physician is maintained to help in follow up. Reply paid cards are sent to all patients who do not report for check up on the due date. House visits / telephone enquiries are made by the field investigators to find out the vital status of the treated patients who had given a contact address in Chennai and its neighborhood. If there is no response from any of the addresses given by the patients from outside Chennai, letters are written to the Village Headman, referring doctors, President / Secretary of local service organization like the Lion, Rotary etc. for tracing the patient. The help of the cured patients from the area, who are currently on regular follow up is also sought for this purpose. We also provide concession for travel by bus, rail and air to the patient coming for treatment / follow up and an accompanying person. The completeness of follow up at three years from diagnosis is more then 80%.

Reports on the activities of hospital cancer registry are published regularly on annual / biennial basis. We have been organizing workshops on "Techniques for early detection of cancer" for the medical officers in Tamilnadu. This is one registry that has provided long-term cancer survival rates and trends for selected cancers over the period spanning four decades from 1958-1977. We had conducted cases control studies to determine the risk factors of several cancers, cohort studies on cancer patients for occurrence of second cancers and survival studies to elicit the prognostic factors. The results of these studies have been published in reports and international journals. The registry is actively involved in the Clinical trials being carried out at the institute in the form of sample size estimation, randomization of cases and rendering assistance in the analysis.

### **HOSPITAL BASED CANCER REGISTRY**

### **Regional Cancer Centre, Thiruvananthapuram**

**Dr. B.Rajan**, Principal Investigator & Director (From December 2003)

Dr. M. Krishnan Nair, Principal Investigator (Till November 2003)

Dr. Aleyamma Mathew, Associate Professor of Epidemiology & Clinical Research

### **REGIONAL CANCER CENTRE**

Regional Cancer Centre, Thiruvananthapuram, continues to keep high standards in patient management, research, teaching, training and development activities. The Centre caters to patients from all over the state of Kerala, from the neighboring states of Tamil Nadu and Karnataka and also from neighboring countries. The Centre has in-patient beds strength of 420.

Annually more than 10,000 new patients, with 95,000 follow-up visits and more than 2,00,000 non cancer patients report to the centre for various investigations and treatment. During the last five years, there has been 25% increase in the registration of both cancer and non cancer cases. The Centre conducts cancer control programmes covering the entire state by way of cancer awareness classes, screening camps and other public and professional educations programmes.

### **Hospital Based Cancer Registry**

The Hospital-Based Cancer Registry (HBCR), at the Regional Cancer Centre(RCC) Thiruvananthapuram provided the data of cancer patients reporting to the RCC, Thiruvananthapuram for the year 1999 and 2000.

The registry data entry is made online using an in-house web based software "rccintranet.org". The demographic details are collected by the social investigators and entered into the computer at the time of new patient registration and transferred to the NCRP core-proforma. The data transfer avoids the manual documentation of the first part (demographic details) of the NCRP core-proforma. The second part (diagnostic, treatment and follow-up details) is entered using the above web based software after retrieving case-sheets from the medical records division.

The HBCR maintains a follow-up system for all cancer patients. Generally all follow-up visits are through prior appointments. In-house software has been developed for appointment scheduling of patients.

Date and disease status for each follow-up visit are entered regularly.

The topography and morphology of various cancers are coded using the third edition of International Classification of Diseases for Oncology (ICD-O-3) and the International Classification of Diseases (ICD-10).

To ensure whether valid codes are entered, a series of range check as well as consistency checks and duplicates verification are done using in-house software. After necessary editing, the data are sent to the coordinating unit of national cancer registry programme in an electronic format for further checking on various range, consistency, unlikely combinations and duplicates. Necessary corrections are done based on the error list of cases sent by the coordinating unit and reports generated. The registry records around 8000 cancer cases annually.

On-line computerization of cancer registration has helped to improve the timely submission and quality of data and facilitate the access and application of data. Further, the medical documentation of case records in electronic form by the HBCR staff has helped clinicians and other researchers to obtain the necessary information. The two population based registries located in Thiruvananthapuram and Karunagappally have largely utilized the HBCR data.

The personnel of the registry are actively conducting several edidemiologic and clinical research programmes, which have helped to bring extramurally funded research programmes and publication of a number of scientific papers in peer-reviewed journals.

The official newsletter of the National Cancer Registry Programme of India, 'CRAB' has been published by the HBCR, Thiruvananthapuram.

### Other staff of Hospital Based Cancer Registry, Thiruvananthapuram

Ms. Padmakumari G. : Lecturer in Statistics

Ms. Anitha Nayar : Social Investigator Gr. I

Ms. Jalaja Kumari V : Clerk Gr. I

Ms. Asha N.M : Clerk

### **HOSPITAL BASED CANCER REGISTRY**

### **Assam Medical College, Dibrugarh**

Dr T.R. Borbora, Principal Investigator

**Dr. (Mrs) N. Choudhury, Principal Investigator (upto 30.9.2004)** 

Dr. M. S. Ali, Sr. Biostatiscian & Officer in charge

Dr. (Ms). R. Akhtar, Research Officer

Hospital Based Cancer Registry, Dibrugarh which had commenced in February, 1982 as a sequel to the recommendation of the NCRP Task Force of the ICMR has completed this year, its 22 successful years.

A systematic method for case finding, abstracting and processing are key to a successful registry programme. In a cancer hospital these can be achieved without much effort, but in a general hospital set-up achieving these objectives is a Herculean task. There are 23 OPD clinics and cancer patients may attend any clinic on any day depending on the signs and symptoms. The registry workers visit these clinics as per a prepared roster based on the patient and the information flow of certain clinics like ENT, OBG, Surgery, Medicine etc. Cancer patients attending other clinics are identified by scrutinizing the OPD cards retrieved from the central OPD counter and are noted down for subsequent matching with the admitted cases.

The central OPD counter preserves the OPD cards received from different OPD clinics at the end of the day. The Medical Records Department (MRD) of the hospital stores the records of only inpatients in a folder. The case files are not stored systematically according to MRD No. or wards. Identification and retrieval of a cancer case from a heap of files of all types of inpatients pose difficult problems. To ease the problems arrangements have been made with the MRD to transfer the case files of cancer patients to the registry office which are then indexed and arranged systematically for smooth and prompt retrieval.

During 1989-1990 the number of new cancer patients recorded at HBCR, Dibrugarh were 2397, compared to only 1533 cases registered a decade later during 1999-2000. There has been 36% reduction in cancer registration during the decade, whereas there has been around 52% increase during that decade in RCC, Thiruvananthapuram. This only signifies the difference in patient and information flow between a general hospital and an RCC or specialized cancer hospital. Qualitatively also the information on method of diagnosis, extent of disease and treatment modalities may not conform to the state of the art followed by an RCC or a specialised cancer hospital. In a general hospital each clinician usually sees and treats patients separately.

A hospital cancer registry must undertake certain essential supplementary activities like follow-up, survival and evaluation of patient care for some specific cancer sites. But because of the inherent problems

like inadequate case numbers and lack of follow-up information for the sites under review, it was not possible to undertake these activities.

Dibrugarh registry is one of the participating Centres in the WHO sponsored national programme on 'Development of an Atlas of Cancer in India'. The cancer data for the years 2001 and 2002 have already been dispatched to the coordinating unit and 2003 data are being entered in the core proformae.

The registry has also been entrusted to run a project on PBCR for Dibrugarh district comprising an area of 3381 Sq. Km with a population of 1172056 as per 2001 census. The project was initiated in March, 2003 as a part of North East Regional Cancer Registry. The cancer incidence data for the year 2003 was presented at the ARM held at Cancer Institute, Chennai. The data for the year 2004 (upto September) are being processed for presentation in the next ARM. Efforts have been made to optimize the case-finding procedures by sustained liaisoning with all the health centres and diagnostic laboratories of the district. Three camps have been conducted in 2004 in different strategic parts of the district for mobilizing the public awareness on the aims and objectives of the ongoing project and early detection of the disease.

### Other staff of Hospital Based Cancer Registry, Dibrugarh

Mrs. P. Dutta : Medical Record Officer

Mrs. S. Ahmed : Social Investigator
Mrs. S. Neog : Social Investigator

Mr. K. Saikia : Clerk
Mrs. I. Baruah : Clerk
Mr. S. R. Nath : Clerk
Mrs. R. Begum : Clerk

Mrs. J. Sonowal : Coding Clerk

Mr. P. Deuri : Typist

Mr. P.P. Saikia : Computer Operator (PBCR)

Mr. R. Dutta : Investigator (PBCR)

Sri B. Mech : Helper

# NATIONAL CANCER REGISTRY PROGRAMME

**Indian Council of Medical Research** 

# Chapter 1

### MAGNITUDE AND LEADING SITES OF CANCER

Table 1.1 gives the total number of cancers diagnosed at five different hospital based cancer registries (HBCRs), over the period of two years from 1st January 1999 to 31st December 2000. A total of 74938 cancers (38,794 males and 36,144 females) were diagnosed at the five HBCRs. Among these, the proportion of cancers diagnosed at different HBCR hospitals were: 42% at Mumbai, 18% at Bangalore and Chennai, 20% at Thiruvananthapuram and 2% at Dibrugarh. In Bangalore and Chennai for every 100 female patients 81 to 87 male patients were reported, whereas, in Mumbai (129), Thiruvananthapuram(108) and Dibrugarh(186) more male patients were reported.

Fig. 1 gives the trends in the actual total number of cancers registered from 1984 to 2000 in the different HBCRs. Mumbai, Chennai and Thiruvananthapuram have shown a significant increase in numbers over the years. Dibrugarh has shown a decline.

The number, proportion relative to all sites and rank of the ten leading sites in males and females for the year 1999-2000 have been presented in Table 1.2 and represented in Figures 1.1(a) and 1.1(b). While comparing the leading sites with that in earlier reports, it may be noted that leading sites listed here have been provided according to ICD-10.

TABLE 1.1: Number (#) and Proportion (%) according to sex, sex ratio percent and relative proportion (Rel. Prop.) of cancers (1999-2000)

Registry	Ma	ales	Fei	males	Sex*	Total	Rel.
Hegistry	#	%	#	%	Ratio%	Cases	Prop.
Mumbai	17637	56.3	13679	43.7	129	31316	41.8
Bangalore	6106	44.7	7543	55.3	81	13649	18.2
Chennai	6195	46.5	7139	53.5	87	13334	17.8
Thi'puram	7859	52.0	7247	48.0	108	15106	20.2
Dibrugarh	997	65.0	536	35.0	186	1533	2.0
	38794	51.8	36144	48.2	107	74938	100.0

<sup>\*</sup> Number of male patients per 100 female patients




Fig. 1: Trends in total number of cancers registered (both sexes) (1984-2000)

Males: (The proportion(%) of a given site relative to all sites of cancer in that sex are given in parentheses)

In *Mumbai*, mouth(11%) was the leading site of cancer, followed by lung(7%), tongue(7%), oesophagus(6%) and Non-Hodgkin's Lymphoma(NHL)(5%).

In *Bangalore*, oesophagus(10%), hypopharynx(9%), stomach(7%), lung(7%) and mouth(6%) were the five leading sites in that order.

In *Chennai*, stomach(9%) and mouth(9%) were the leading sites. These two sites were followed by oesophagus(8%), tongue(7%) and hypopharynx(7%).

In *Thiruvananthapuram*, lung(13%) was the leading site followed by mouth(9%), tongue(6%), NHL(5%) and larynx(5%).

In *Dibrugarh*, hypopharynx(16%) and oesophagus(15%) like in past years, remained the leading sites followed by mouth(9%) and tongue(7%).

### **Females**

In *Mumbai*, breast(26%) was the leading site of cancer followed by cervix(19%), ovary(6%), mouth(5%) and oesophagus(4%).

# Table 1.2: Number(#), Relative Proportion(%) and Rank(R) of Leading Sites of Cancer (1999-2000)

### **MALES**

Sites	Mumbai			Bangalore			Chennai				Thi'pura	m	Dibrugarh		
Choo	#	%	R	#	%	R	#	%	R	#	%	R	#	%	R
Mouth	1986	11.3	1	368	6.0	5	544	8.8	2	734	9.3	2	86	8.6	3
Lung	1253	7.1	2	432	7.1	3	378	6.1	6	1041	13.2	1	46	4.6	6
Tongue	1236	7.0	3	346	5.7	6	450	7.3	4	473	6.0	3	67	6.7	4
Oesophagus	998	5.7	4	587	9.6	1	478	7.7	3	412	5.2	5	147	14.7	2
NHL	950	5.4	5	250	4.1	8	269	4.3	7	408	5.2	6	10	1.0	*
Larynx	937	5.3	6	192	3.1	10	238	3.8	8	417	5.3	4	52	5.2	5
Hypopharynx	935	5.3	7	554	9.1	2	420	6.8	5	250	3.2	9	163	16.3	1
Myel. Leuk.	838	4.8	8	202	3.3	9	205	3.3	9	237	3.0	*	7	0.7	*
Lymph. Leuk.	609	3.5	9	173	2.8	*	119	1.9	*	270	3.4	8	2	0.2	*
Stomach	504	2.9	10	427	7.0	4	562	9.1	1	323	4.1	7	42	4.2	8
Brain, NS.	370	2.1	*	252	4.1	7	43	0.7	*	249	3.2	10	10	1.0	*
Rectum	483	2.7	*	128	2.1	*	174	2.8	10	213	2.7	*	14	1.4	*
Tonsil	332	1.9	*	123	2.0	*	111	1.8	*	79	1.0	*	45	4.5	7
Pharynx uns.	12	0.1	*	84	1.4	*	41	0.7	*	17	0.2	*	21	2.1	9
Oth. Oroph.	222	1.3	*	104	1.7	*	59	1.0	*	143	1.8	*	18	1.8	10
Total	11665	66.1		4222	69.1		4091	66.0		5266	67.0		730	73.2	
All Sites	17637	100.0		6106	100.0		6195	100.0		7859	100.0		997	100.0	


### **FEMALES**

Sites	Mumbai			Bangalore			Chennai				Thi'pura	m	Dibrugarh		
Onco	#	%	R	#	%	R	#	%	R	#	%	R	#	%	R
Breast	3617	26.4	1	1001	13.3	2	1412	19.8	2	1991	27.5	1	65	12.1	3
Cervix uteri	2643	19.3	2	2490	33.0	1	2499	35.0	1	951	13.1	2	82	15.3	1
Ovary	777	5.7	3	328	4.3	5	248	3.5	5	559	7.7	4	42	7.8	4
Mouth	656	4.8	4	833	11.0	3	441	6.2	3	384	5.3	5	37	6.9	5
Oesophagus	505	3.7	5	467	6.2	4	263	3.7	4	109	1.5	*	68	12.7	2
Gallbladder	381	2.8	6	23	0.3	*	19	0.3	*	17	0.2	*	29	5.4	6
Tongue	370	2.7	7	86	1.1	*	119	1.7	10	237	3.3	6	19	3.5	8
NHL	359	2.6	8	127	1.7	9	96	1.3	*	200	2.8	7	1	0.2	*
Myel. Leuk.	351	2.6	9	174	2.3	7	123	1.7	9	176	2.4	8	6	1.1	*
Lung	298	2.2	10	82	1.1	*	84	1.2	*	134	1.8	*	8	1.5	*
Thyroid	261	1.9	*	212	2.8	6	135	1.9	8	621	8.6	3	5	0.9	*
Stomach	207	1.5	*	172	2.3	8	223	3.1	6	84	1.2	*	22	4.1	7
Brain, NS.	204	1.5	*	121	1.6	10	21	0.3	*	160	2.2	9	4	0.7	*
Hypopharynx	161	1.2	*	112	1.5	*	154	2.2	7	36	0.5	*	17	3.2	9
Corpus uteri	281	2.1	*	75	1.0	*	87	1.2	*	160	2.2	10	4	0.7	*
Tonsil	41	0.3	*	15	0.2	*	14	0.2	*	9	0.1	*	13	2.4	10
Total	11112	81.2		6318	83.8		5938	83.2		5828	80.4		422	78.7	
All Sites	13679	100.0		7543	100.0		7139	100.0		7247	100.0		536	100.0	


<sup>\*</sup> Rank not within first ten

Fig. 1.1(a): Ten Leading Sites of Cancer - Males

### Mumbai



### **Bangalore**



### Chennai






Fig. 1.1(a): Ten Leading Sites of Cancer - Males (Contd..)

### Thiruvananthapuram



### Dibrugarh



In *Bangalore*, cancer of the cervix was the leading site, accounting for about 33% of cancers in females, followed by breast(13%), mouth(11%), oesophagus(6%) and ovary(4%).


In Chennai, the five leading sites were the same as that in Bangalore.

In *Thiruvananthapuram*, thyroid gland (9%) was the third leading site after breast (28%) and cervix (13%). Thyroid gland was followed by the cancers of ovary (8%) and mouth (5%).


In *Dibrugarh*, cervix was the leading site, accounting for 15% of cancers in females, followed by oesophagus(13%), breast(12%), ovary(8%) and mouth(7%).

Fig. 1.1(b): Ten Leading Sites of Cancer - Females

### Mumbai



### **Bangalore**



### Chennai






Fig. 1.1(b): Ten Leading Sites of Cancer - Females (Contd..)

### Thiruvananthapuram



### Dibrugarh



#### **LEADING SITES IN BROAD AGE GROUPS**

The numbers and relative proportions of cancers in the broad age groups 0-14, 15-34, 35-64 and 65 and above years of age, for both sexes across registries is shown in Table 1.3 and Fig. 1.2. Figures 1.3 to 1.5 give the leading sites with their relative proportions in each of these broad age groups, except, childhood cancers (which is given separately in Chapter 3).

Proportion of young adults (15-34 years) varied from 7 to 14% in all the registries and both sexes. Proportion of patients in the age group 35-64 years varied from 57% in males in Thiruvananthanpuram 75% of cancers in females in Chennai and Dibrugarh. The mean age of female patients was 48.2 while that of male patients was 50.4.


The leading sites of cancers according to broad age groups are depicted in Fig. 1.3(a) to 1.5(b).


Table 1.3: Number (#) and Proportion(%) of Cancers by Broad Age Groups (1999-2000)

Registry	00	-14	15-	-34	35-64		65+		All Ages
	#	%	#	%	#	%	#	%	#
Males									
Mumbai	1029	5.8	2342	13.3	10707	60.7	3559.0	20.2	17637
Bangalore	369	6.0	623	10.2	3603	59.0	1511.0	24.7	6106
Chennai	215	3.5	702	11.3	3892	62.8	1386.0	22.4	6195
Thi'puram	355	4.5	702	8.9	4500	57.3	2302.0	29.3	7859
Dibrugarh	28	2.8	70	7.0	668	67.0	231.0	23.2	997
Females									
Mumbai	472	3.5	1601	11.7	9716	71.0	1890.0	13.8	13679
Bangalore	254	3.4	755	10.0	5307	70.4	1227.0	16.3	7543
Chennai	130	1.8	721	10.1	5321	74.5	967.0	13.5	7139
Thi'puram	295	4.1	956	13.2	4621	63.8	1375.0	19.0	7247
Dibrugarh	6	1.1	74	13.9	400	74.9	54.0	10.1	534
Both Sexes									
Mumbai	1501	4.8	3943	12.6	20423	65.2	5449.0	17.4	31316
Bangalore	623	4.6	1378	10.1	8910	65.3	2738.0	20.1	13649
Chennai	345	2.6	1423	10.7	9213	69.1	2353.0	17.6	13334
Thi'puram	650	4.3	1658	11.0	9121	60.4	3677.0	24.3	15106
Dibrugarh	34	2.2	144	9.4	1068	69.8	285.0	18.6	1531

Fig. 1.2: Stack(100%) diagram showing Proportion of Cancers by Broad Age Groups

Males





#### Age Group (15-34 Years)

#### Males:

Myeloid leukaemia was the leading site in Mumbai and the second leading site in Bangalore, Chennai and Thiruvananthapuram. Brain was the leading site in Bangalore and within first five in Thiruvananthapuram and Dibrugarh. Bone was the leading site in Chennai and Dibrugarh and within first five at other HBCRs. NHL was an important site figuring within first five at all the registries.

#### Females:

Breast was the leading site followed by cervix and myeloid leukaemia in Mumbai and Chennai whereas in Bangalore, the leading site was cervix followed by breast and thyroid gland. Thiruvananthapuram reported thyroid gland as the leading site followed by breast and ovary. In Dibrugarh, ovary was the leading site followed by breast and cervix.

#### Age Group (35-64 Years)

#### Males:

Mouth was the leading site in Mumbai, second leading site in Chennai and Thiruvananthapuram and third in Dibrugarh. Oesophagus was the leading site in Bangalore and within first five in other registries. Stomach was first in Chennai, fourth in Bangalore and within ten in other registries. Lung was the leading site in Thiruvananthapuram and within five in other registries except Dibrugarh. Hypopharynx was the leading site in Dibrugarh.

#### Females:

Breast and cervix were the leading sites in all the registries; breast being the first in Mumbai and Thiruvananthapuram and cervix in Bangalore and Chennai. Ovary and mouth were other important sites within first five. Oesophagus was within first five leading sites in all the registries except Thiruvananthapuram. Thyroid gland was fourth leading site only in Thiruvananthapuram and within first ten in Bangalore and Chennai.

#### Age Group (65 Years and above)


#### Males:

In this age group, lung was the leading site in Mumbai and Thiruvananthapuram, oesophagus in Bangalore and Dibrugarh and mouth in Chennai. Hypopharynx was within five in Mumbai (third), Bangalore (second) and Chennai (second). Gall bladder was one of the leading sites in Dibrugarh (second) only.


#### Females:

Cervix was the leading site in this age group in all the registries except Dibrugarh. It was followed by breast except in Bangalore (mouth). In Dibrugarh, cervix was fourth leading site. Oesophagus was the leading site followed by gall bladder and mouth.


Fig. 1.3(a): Leading Sites in Broad Age Group (15-34 Years) - Males (1999-2000)




# **Bangalore**



#### Chennai



# **Thiruvananthapuram**








Fig. 1.3(b): Leading Sites in Broad Age Group (15-34 Years) - Females (1999-2000)




# **Bangalore**



#### Chennai



# Thiruvananthapuram









Fig. 1.4(a): Leading Sites in Broad Age Group (35-64 Years) - Males (1999-2000)




# **Bangalore**



#### Chennai



# **Thiruvananthapuram**









Fig. 1.4(b): Leading Sites in Broad Age Group (35-64 Years) - Females (1999-2000)




# **Bangalore**



#### Chennai



#### Thiruvananthapuram









Fig. 1.5(a): Leading Sites in Broad Age Group (65 Years and above) - Males (1999-2000)




# **Bangalore**



#### Chennai



# Thiruvananthapuram









Fig. 1.5(b): Leading Sites in Broad Age Group (65 Years and above) - Females (1999-2000)




# **Bangalore**




#### Chennai



#### Thiruvananthapuram





# **CANCERS IN CHILDHOOD**

In all registries, childhood cancer constituted approximately 1-6% (Table 2.1) of all cancers. In boys, the proportion was lowest in Dibrugarh (about 3%) and highest in Bangalore (6%). In girls, it varied from 1% at Dibrugarh to 4% at Thiruvananthapuram.

The five year age distribution of childhood cancer in different registries has been given in Table 2.2. The relative proportion in the age group 0-4 varied from 30% in boys and 32% in girls in Mumbai to a high of 43% in boys and 41% in girls in Thiruvananthapuram. The relative proportion in the age group 5-9 years varied from 28.5% in boys in Thiruvananthapuram to 35.7% in boys in Dibrugarh. This proportion was slightly less in girls in all HBCRs. Girls in all registries had a higher relative proportion of cancers in the 10-14 year age group.

Table 2.3 and Figures 2.1(a) and 2.1(b) present the proportion according to broad types of childhood cancers. Tables 2.4(a) and 2.4(b) give further details of types of childhood cancer. Leukaemia is the predominant form of childhood cancer followed by lymphomas. Tumours of the central nervous system, bone tumours, soft-tissue sarcomas and germ-cell tumours are other important types of cancer in childhood. Proportion of lymphomas was higher in boys compared to that in girls.

TABLE 2.1: Number (#) and Proportion (%) of cancers in childhood relative to all cancers (1999-2000)

Registry		Males		Females					
riegiony	All Cancers	#	%	All Cancers	#	%			
Mumbai	17637	1029	5.8	13679	472	3.5			
Bangalore	6106	369	6.0	7543	254	3.4			
Chennai	6195	215	3.5	7139	130	1.8			
Thi'puram	7859	355	4.5	7247	295	4.1			
Dibrugarh	997	28	2.8	536	6	1.1			

Table 2.2: Number (#) & Proportion (%) of Childhood Cancers by 5-year Age Group (1999-2000)


			Age Grou	ıp (Years	)		All Childhood
Registry	0-4		5-9	)	10-	14	Cancers
	#	%	#	%	#	%	
Males							
Mumbai	306	29.7	337	32.8	386	37.5	1029
Bangalore	124	33.6	125	33.9	120	32.5	369
Chennai	64	29.8	72	33.5	79	36.7	215
Thi'puram	154	43.4	101	28.5	100	28.2	355
Dibrugarh	12	42.9	10	35.7	6	21.4	28
Females							
Mumbai	151	32.0	144	30.5	177	37.5	472
Bangalore	83	32.7	77	30.3	94	37.0	254
Chennai	48	36.9	31	23.8	51	39.2	130
Thi'puram	122	41.4	67	22.7	106	35.9	295
Dibrugarh	2	33.3	2	33.3	2	33.3	6
Both Sexes							
Mumbai	389	30.3	414	32.3	480	37.4	1283
Bangalore	172	34.5	156	31.3	171	34.3	499
Chennai	112	32.5	103	29.9	130	37.7	345
Thi'puram	276	42.5	168	25.8	206	31.7	650
Dibrugarh	14	41.2	12	35.3	8	23.5	34

Table 2.3: Number (#) & Relative Proportion (%) of Broad Types of Cancers in childhood (0-14 years) (1999-2000)


Broad Types of	Mur	mbai	Bang	galore	Che	nnai	Thi'p	uram	Dibrugarh		
Cancers in Childhood	#	%	#	%	#	%	#	%	#	%	
I Leukaemias	431	41.89	140	37.94	77	35.81	157	44.23	7	25.00	
II Lymphomas	210	20.41	60	16.26	44	20.47	46	12.96	3	10.71	
III C.N.S. Tumours	80	7.77	53	14.36	8	3.72	36	10.14	2	7.14	
IV S.N.S. Tumours	26	2.53	9	2.44	7	3.26	17	4.79	0	0.00	
V Retinoblastoma	30	2.92	17	4.61	18	8.37	15	4.23	2	7.14	
VI Renal Tumours	30	2.92	14	3.79	5	2.33	14	3.94	4	14.29	
VII Hepatic Tumours	10	0.97	8	2.17	3	1.40	8	2.25	0	0.00	
VIII Bone Tumours	79	7.68	20	5.42	26	12.09	20	5.63	1	3.57	
IX Soft-tissue Sarcomas	79	7.68	10	2.71	12	5.58	26	7.32	5	17.86	
X Germ-cell Tumours	10	0.97	8	2.17	2	0.93	6	1.69	2	7.14	
XI Oth. Carcinomas	27	2.62	14	3.79	8	3.72	6	1.69	1	3.57	
XII Oth. Malignant Neop.	14	1.36	13	3.52	4	1.86	3	0.85	1	3.57	
XIII Others	3	0.29	3	0.81	1	0.47	1	0.28	0	0.00	
All Types	1029	100.00	369	100.00	215	100.00	355	100.00	28	100.00	

Broad Types of	Mui	mbai	Bang	galore	Che	nnai	Thiˈp	uram	Dibrugarh	
Cancers in Childhood	#	%	#	%	#	%	#	%	#	%
I Leukaemias	186	39.41	91	35.83	51	39.23	109	36.95	0	0.00
II Lymphomas	40	8.47	27	10.63	10	7.69	10	3.39	0	0.00
III C.N.S. Tumours	61	12.92	35	13.78	4	3.08	38	12.88	1	16.67
IV S.N.S. Tumours	4	0.85	9	3.54	4	3.08	11	3.73	0	0.00
V Retinoblastoma	22	4.66	13	5.12	14	10.77	16	5.42	0	0.00
VI Renal Tumours	14	2.97	12	4.72	3	2.31	17	5.76	1	16.67
VII Hepatic Tumours	2	0.42	0	0.00	3	2.31	3	1.02	0	0.00
VIII Bone Tumours	40	8.47	17	6.69	19	14.62	25	8.47	1	16.67
IX Soft-tissue Sarcomas	46	9.75	14	5.51	9	6.92	17	5.76	0	0.00
X Germ-cell Tumours	31	6.57	12	4.72	6	4.62	19	6.44	0	0.00
XI Oth. Carcinomas	17	3.60	11	4.33	4	3.08	28	9.49	1	16.67
XII Oth. Malignant Neop.	9	1.91	13	5.12	2	1.54	1	0.34	0	0.00
XIII Others	0	0.00	0	0.00	1	0.77	1	0.34	2	33.33
All Types	472	100.00	254	100	130	100.00	295	100.00	6	100.0


Fig. 2.1(a): Proportion of Broad Types of Childhood Cancers (0-14 years) - Males (1999-2000)




### **Bangalore**



#### Mumbai



#### **Bangalore**









Fig. 2.1(b): Proportion of Broad Types of Childhood Cancers (0-14 years) - Females (1999-2000)




### **Bangalore**




#### Mumbai



#### **Bangalore**





# Table 2.4(a): Number (#) & Relative Proportion (%) of Specific Types of Cancer in Childhood (0-14 years) - Males (1999-2000)

					-			Thi'puram D		
Specific Types of Cancers in Childhood		ımbai		galore		ennai				rugarh
L LEUKAEMIAO	#	%	#	%	#	%	#	%	#	%
I. LEUKAEMIAS (a) Lymphoid leukaemia	431 301	41.89 29.25	140 93	37.94 25.20	77 50	35.81 23.26	157 123	44.23 34.65	7 6	25.00 21.43
(b) Acute non-lymphocytic leukaemia	88	8.55	25	6.78	17	7.91	30	8.45	1	3.57
(c) Chronic myeloid leukaemia	12	1.17	5	1.36	2	0.93	2	0.43	0	0.00
(d) Other specified leukaemias	1	0.10	3	0.81	0	0.00	0	0.00	0	0.00
(e) Unspecified leukaemia	29	2.82	14	3.79	8	3.72	2	0.56	0	0.00
II. LYMPHOMAS & RETICULOENDOTHELIAL NPLMS	210	20.41	60	16.26	44	20.47	46	12.96	3	10.71
(a) Hodgkin's disease	120	11.66	35	9.49	20	9.30	26	7.32	0	0.00
(b) Non-Hodgkin lymphoma	64	6.22	10	2.71	19	8.84	13	3.66	3	10.71
(c) Burkitt's lymphoma	23	2.24	5	1.36	0	0.00	1	0.28	0	0.00
(d)Miscellaneous lymphoreticular nplms	1	0.10	4	1.08	0	0.00	0	0.00	0	0.00
(e) Unspecified lymphomas	2	0.19	6	1.63	5	2.33	6	1.69	0	0.00
III. C.N.S.& MISC.INTRACRANIAL & INTRASPINAL NEOP.	80	7.77	53	14.36	8	3.72	36	10.14	2	7.14
(a) Ependymoma	7	0.68	2	0.54	0	0.00	1	0.28	1	3.57
(b) Astrocytoma	30	2.92	14	3.79	2	0.93	11	3.10	0	0.00
(c) Primitive neuroectodermal tumours	26	2.53	24	6.50	4	1.86	12	3.38	1	3.57
(d) Other gliomas	13	1.26	6	1.63	1	0.47	3	0.85	0	0.00
(e) Other specified intracranial & intraspinal	4	0.39	1	0.27	0	0.00	0	0.00	0	0.00
(f) Unspecified intracranial & intraspinal	0	0.00	6	1.63	1	0.47	9	2.54	0	0.00
IV. SYMPATHETIC NERVOUS SYSTEM TUMOURS	26	2.53	9	2.44	7	3.26	17	4.79	0	0.00
(a) Neuroblastoma & ganglioneuroblastoma	26	2.53	9	2.44	7	3.26	17	4.79	0	0.00
(b) Other SNS tumours	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
V. RETINOBLASTOMA VI. RENAL TUMOURS	30 30	2.92 2.92	17 14	4.61 3.79	18 5	8.37 2.33	15 14	4.23	2 4	7.14
VI. RENAL TUMOURS (a) Wilms' tumour	30	2.92	11	2.98	4		13	3.94 3.66	1	14.29 3.57
(b) Renal carcinoma	0	0.00	0	0.00	0	1.86 0.00	1	0.28	0	0.00
(c) Unsp. malignant renal tumours	0	0.00	3	0.00	1	0.00	0	0.28	3	10.71
VII. HEPATIC TUMOURS	10	0.00	8	2.17	3	1.40	8	2.25	0	0.00
(a) Hepatoblastoma	9	0.97	5	1.36	3	1.40	7	1.97	0	0.00
(b) Hepatic carcinoma	0	0.00	1	0.27	0	0.00	0	0.00	0	0.00
(c) Unsp. malignant hepatic tumours	1	0.10	2	0.54	0	0.00	1	0.28	0	0.00
VIII. MALIGNANT BONE TUMOURS	79	7.68	20	5.42	26	12.09	20	5.63	1	3.57
(a) Osteosarcoma	49	4.76	9	2.44	13	6.05	16	4.51	1	3.57
(b) Chondrosarcoma	0	0.00	1	0.27	0	0.00	0	0.00	0	0.00
(c) Ewing's sarcoma	25	2.43	8	2.17	11	5.12	4	1.13	0	0.00
(d) Other specified malignant bone tumours	0	0.00	1	0.27	0	0.00	0	0.00	0	0.00
(e) Unspecified malignant bone tumours	5	0.49	1	0.27	2	0.93	0	0.00	0	0.00
IX. SOFT-TISSUE(S-T) SARCOMAS(S)	79	7.68	10	2.71	12	5.58	26	7.32	5	17.86
(a) Rhabdomyos. embryonals.	33	3.21	4	1.08	8	3.72	15	4.23	0	0.00
(b) Fibros.neurofibros.&oth.fibromatous neop.	4	0.39	0	0.00	0	0.00	0	0.00	2	7.14
(c) Kaposi's sarcoma	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
(d) Other specified soft-tissue sarcoma	28	2.72	4	1.08	0	0.00	8	2.25	2	7.14
(e) Unspecified soft-tissue sarcoma	14	1.36	2	0.54	4	1.86	3	0.85	1	3.57
X. GERM-CELL TROPHOBLASTIC & OTH GONADAL NEOP.	10	0.97	8	2.17	2	0.93	6	1.69	2	7.14
(a) Intracranial & intraspinal gc tumours	2	0.19	0	0.00	0	0.00	0	0.00	0	0.00
(b) Other & unspecified non-gonadal gc tumours	1	0.10	1 =	0.27	1	0.47	3	0.85	1	3.57
(c) Gonadal gc tumours	7	0.68	5	1.36	1	0.47	3	0.85	1	3.57
(d) Gonadal carcinomas (e) Other & unsp.malignant gonadal tumours	0	0.00	0 2	0.00 0.54	0	0.00	0	0.00	0	0.00
(e) Other & unsp.mailgnant gonadai tumours  XI. CARCINOMA & OTH MALIGNANT EPITHELIAL NEOP.	27	2.62	14	3.79	8	3.72	6	1.69	1	3.57
(a) Adrenocortical carcinoma	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
(b) Thyroid carcinoma	7	0.68	2	0.54	1	0.47	0	0.00	0	0.00
(c) Nasopharyngeal carcinoma	7	0.68	2	0.54	3	1.40	3	0.85	0	0.00
(d) Malignant melanoma	,	0.00	1	0.27	0	0.00	0	0.00	0	0.00
(e) Skin carcinoma	1	0.10	0	0.00	1	0.47	o	0.00	0	0.00
(f) Other & unspec.carcinomas	12	1.17	9	2.44	3	1.40	3	0.85	1	3.57
XII. OTHER & UNSP. MALIGNANT NEOPLASMS	14	1.36	13	3.52	4	1.86	3	0.85	1	3.57
(a) Other spec.malignant tumours	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
(b) Other unspec.malignant tumours	14	1.36	13	3.52	4	1.86	3	0.85	1	3.57
XIII. OTHERS (Not Classified)	3	0.29	3	0.81	1	0.47	1	0.28	0	0.00
All Types	1029	100.00	369	100.00	215	100.00	355	100.00	28	100.00
1,1000	1023	. 55.66	333	. 30.00	2.10	. 55.00	555	. 55.00		. 55.56

# Table 2.4(b): Number (#) & Relative Proportion (%) of Specific Types of Cancer in Childhood (0-14 years) - Females (1999-2000)

Sp	ecific Types of Cancers in Childhood	Mu	mbai	Ban	galore	Che	ennai	Thi'puram		Dibrugarh	
		#	%	#	%	#	%	#	%	#	%
I.	LEUKAEMIAS	186	39.41	91	35.83	51	39.23	109	36.95	0	0.00
	(a) Lymphoid leukaemia	114	24.15	63	24.80	29	22.31	82	27.80	0	0.00
	(b) Acute non-lymphocytic leukaemia	40	8.47	16	6.30	11	8.46	22	7.46	0	0.00
	(c) Chronic myeloid leukaemia	10	2.12	2	0.79	5	3.85	1	0.34	0	0.00
	(d) Other specified leukaemias	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
	(e) Unspecified leukaemia	22	4.66	10	3.94	6	4.62	4	1.36	0	0.00
II.	LYMPHOMAS & RETICULOENDOTHELIAL NPLMS	40	8.47	27	10.63	10 5	7.69	10	3.39	0	0.00
	(a) Hodgkin's disease (b) Non-Hodgkin lymphoma	18 19	3.81 4.03	11 4	4.33 1.57	3	3.85 2.31	3 5	1.02 1.69	0	0.00 0.00
	(c) Burkitt's lymphoma	19	0.21	4	1.57	0	0.00	1	0.34	0	0.00
	(d)Miscellaneous lymphoreticular nplms	1	0.21	3	1.18	1	0.77	0	0.00	0	0.00
	(e) Unspecified lymphomas	1	0.21	5	1.97	1	0.77	1	0.34	0	0.00
III.	C.N.S.& MISC.INTRACRANIAL & INTRASPINAL NEOP.	61	12.92	35	13.78	4	3.08	38	12.88	1	16.67
	(a) Ependymoma	3	0.64	1	0.39	0	0.00	1	0.34	0	0.00
	(b) Astrocytoma	32	6.78	12	4.72	0	0.00	12	4.07	1	16.67
	(c) Primitive neuroectodermal tumours	18	3.81	11	4.33	1	0.77	13	4.41	0	0.00
	(d) Other gliomas	7	1.48	6	2.36	1	0.77	1	0.34	0	0.00
	(e) Other specified intracranial & intraspinal	1	0.21	1	0.39	0	0.00	1	0.34	0	0.00
	(f) Unspecified intracranial & intraspinal	0	0.00	4	1.57	2	1.54	10	3.39	0	0.00
IV.	SYMPATHETIC NERVOUS SYSTEM TUMOURS	4	0.85	9	3.54	4	3.08	11	3.73	0	0.00
	(a) Neuroblastoma & ganglioneuroblastoma	4	0.85	9	3.54	4 0	3.08	11	3.73	0	0.00
V.	(b) Other SNS tumours RETINOBLASTOMA	0 22	0.00 4.66	13	0.00 5.12	14	0.00 10.77	0 16	0.00 5.42	0	0.00
V. VI.	RENAL TUMOURS	14	2.97	12	4.72	3	2.31	17	5.76	1	16.67
٧١.	(a) Wilms' tumour	14	2.97	11	4.33	2	1.54	17	5.76	1	16.67
	(b) Renal carcinoma	0	0.00	1	0.39	1	0.77	0	0.00	0	0.00
	(c) Unsp. malignant renal tumours	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
VII.	HEPATIC TUMOURS	2	0.42	0	0.00	3	2.31	3	1.02	0	0.00
	(a) Hepatoblastoma	2	0.42	0	0.00	3	2.31	3	1.02	0	0.00
	(b) Hepatic carcinoma	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
	(c) Unsp. malignant hepatic tumours	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
VIII	MALIGNANT BONE TUMOURS	40	8.47	17	6.69	19	14.62	25	8.47	1	16.67
	(a) Osteosarcoma	23	4.87	8	3.15	7	5.38	16	5.42	0	0.00
	(b) Chondrosarcoma (c) Ewing's sarcoma	0	0.00 2.75	0 6	0.00 2.36	0 7	0.00 5.38	0 9	0.00	0	0.00
	(d) Other specified malignant bone tumours	13 1	0.21	0	0.00	1	0.77	0	3.05 0.00	1	16.67 0.00
	(e) Unspecified malignant bone tumours	3	0.64	3	1.18	4	3.08	0	0.00	0	0.00
IX.	SOFT-TISSUE(S-T) SARCOMAS(S)	46	9.75	14	5.51	9	6.92	17	5.76	0	0.00
	(a) Rhabdomyos. embryonals.	18	3.81	8	3.15	4	3.08	12	4.07	0	0.00
	(b) Fibros.neurofibros.&oth.fibromatous neop.	2	0.42	0	0.00	0	0.00	0	0.00	0	0.00
	(c) Kaposi's sarcoma	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
	(d) Other specified soft-tissue sarcoma	12	2.54	4	1.57	1	0.77	4	1.36	0	0.00
	(e)_Unspecified soft-tissue sarcoma	14	2.97	2	0.79	4	3.08	1	0.34	0	0.00
Χ.	GERM-CELL TROPHOBLASTIC & OTH GONADAL NEOP.	31	6.57	12	4.72	6	4.62	19	6.44	0	0.00
	(a) Intracranial & intraspinal gc tumours	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
	(b) Other & unspecified non-gonadal gc tumours	4	0.85	1 8	0.39	1	0.77	5	1.69	0	0.00
	(c) Gonadal gc tumours (d) Gonadal carcinomas	25 1	5.30 0.21	1	3.15 0.39	4 1	3.08 0.77	13 1	4.41 0.34	0	0.00 0.00
	(e) Other & unsp.malignant gonadal tumours	1	0.21	2	0.39	0	0.00	0	0.00	0	0.00
XI.	CARCINOMA & OTH MALIGNANT EPITHELIAL NEOP.	17	3.60	11	4.33	4	3.08	28	9.49	1	16.67
,	(a) Adrenocortical carcinoma	1	0.21	0	0.00	1	0.77	0	0.00	0	0.00
	(b) Thyroid carcinoma	7	1.48	6	2.36	1	0.77	19	6.44	0	0.00
	(c) Nasopharyngeal carcinoma	1	0.21	0	0.00	0	0.00	4	1.36	0	0.00
	(d) Malignant melanoma	1	0.21	0	0.00	0	0.00	0	0.00	0	0.00
	(e) Skin carcinoma	1	0.21	0	0.00	0	0.00	0	0.00	0	0.00
	(f) Other & unspec.carcinomas	6	1.27	5	1.97	2	1.54	5	1.69	1	16.67
XII.	OTHER & UNSP. MALIGNANT NEOPLASMS	9	1.91	13	5.12	2	1.54	1	0.34	0	0.00
	(a) Other spec.malignant tumours	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
YIII	(b) Other unspec.malignant tumours . OTHERS (Not Classified)	9	1.91 0.00	13 0	5.12 0.00	2 1	1.54 0.77	1 1	0.34 0.34	0 2	0.00 33.33
VIII		_		_				•			
	All Types	472	100.00	254	100	130	100.00	295	100.00	6	100.00

# **TOBACCO RELATED CANCERS**

A list of sites of cancer (alongwith corresponding ICD-10 codes) considered to be associated with the use of tobacco [Tobacco Related Cancers (TRC)] is provided in the table below. This consideration is based on IARC monographs on overall evaluations of carcinogenicity (IARC, 1987).

Recently, International Agency for Research on Cancer Monograph (IARC 2004) states, that, there is now sufficient evidence to establish a causal association between cigarette smoking and cancers of the

Table 3.1: Sites of cancer included in TRCs alongwith corresponding ICD codes (1999-2000)

Site	ICD-10 Code
Lip	C00
Tongue	C01-C02
Mouth	C03-C06
Pharynx	C09-C10 and C12-C14
Oesophagus	C15
Larynx	C32
Lung	C33-34
Urinary Bladder	C67

Table 3.2 : Number(#) & Proportion(%) of cancers associated with use of tobacco relative to all sites of cancer (1999-2000)

		Males		Females					
Registry	All sites	#	%	All sites	#	%			
Mumbai	17637	8476	48.1	13679	2262	16.5			
Bangalore	6106	2886	47.3	7543	1731	22.9			
Chennai	6195	2815	45.4	7139	1159	16.2			
Thi'puram	7859	3701	47.1	7247	983	13.6			
Dibrugarh	997	683	68.5	536	187	34.9			
All Registries	38794	18561	47.8	36144	6322	17.5			

nasal cavities and nasal sinuses, oesophagus (Adenocarcinoma), stomach, liver, kidney (Renal Cell Carcinoma), uterine cervix and myeloid leukaemia apart from the sites in the earlier monograph (IARC, 1987).

Table 3.2 and Figure 3.1 give the number and proportion of sites of cancer associated with use of tobacco as a whole relative to all sites of cancer, in different registries. The highest percentage of TRC was observed in Dibrugarh; both in males (69%) and in females (35%). In the other registries, it varied from 45 to 48% of all cancers in males and from 14 to 23% in females.

Table 3.3 and Figure 3.2 give the number and relative precentage according to the specific sites of TRC in different registries.

Males (Relative proportion (%) of TRC given given in parentheses)

*Mumbai*: Mouth(23%), tongue(15%), and lung(15%) were the main sites that contributed to overall TRCs.

Bangalore: Oesophagus (20%) was the leading site in TRCs followed by hypopharynx (19%) and lung (15%).

Chennai: Mouth (19%) was the leading contributor to TRCs followed by oesophagus (17%) and tongue (16%).

Thiruvananthapuram: Cancer of lung accounted for 28% of TRCs followed by mouth (20%) and tongue (13%).

*Dibrugarh*: Cancer of the hypopharynx constituted 24% of TRCs followed by oesophagus (22%) and mouth (13%).

### **Females**

Mumbai: Mouth(29%), oesophagus(22%) and tongue(16%) were the leading sites among TRCs.

Bangalore: Mouth (48%) contributed almost half of the TRCs. Another important site was oesophagus (27%).

Chennai: Mouth (38%) accounted for most of TRCs followed by oesophagus (22%) and hypopharynx (13%).

*Thiruvananthapuram*: Like in Chennai, in Thiruvananthapuram also mouth (39%) accounted for most of TRCs followed by tongue (24%) and lung (14%).

Dibrugarh: Oesophagus (36%) was the leading site in TRCs followed by mouth (20%) and tongue (10%).

Table 3.4 shows the age distribution of all TRCs taken together. Among males, the mean( $\pm$ SD) age of TRCs varied between 55.1  $\pm$  12.17 in Mumbai to 59.3  $\pm$  11.11 in Thiruvananthapuram. Similarly in females, mean age varied between 51.0  $\pm$  12.18 in Dibrugarh to 58.7  $\pm$  12.68 in Thiruvananthapuram.

Fig. 3.1: Proportion(%) of Tobacco Related Cancers Relative to All Sites (1999-2000)




Fig. 3.2: Stack(100%) diagram showing Proportion of Specific Tobacco Related Sites Relative to All Tobacco Related Cancers (1999-2000)




Table 3.3 : Number(#) & Relative Proportion(%) of specific sites of cancer among Tobacco Related Cancers (TRC) (1999-2000)

Sites of Cancer	Mun	nbai	Banga	alore	Cher	ınai	Thi	puram	Dibrugarh	
	#	%	#	%	#	%	#	%	#	%
Lip	96	1.1	7	0.2	22	0.8	32	0.9	28	4.1
Tongue	1236	14.6	346	12.0	450	16.0	473	12.8	67	9.8
Mouth	1986	23.4	368	12.8	544	19.3	734	19.8	86	12.6
Oropharynx	554	6.5	227	7.9	170	6.0	222	6.0	63	9.2
Hypopharynx	935	11.0	554	19.2	420	14.9	250	6.8	163	23.9
Pharynx	12	0.1	84	2.9	41	1.5	17	0.5	21	3.1
Oesophagus	998	11.8	587	20.3	478	17.0	412	11.1	147	21.5
Larynx	937	11.1	192	6.7	238	8.5	417	11.3	51	7.5
Lung	1253	14.8	432	15.0	378	13.4	1041	28.1	46	6.7
Uri. Bladder	469	5.5	89	3.1	74	2.6	103	2.8	11	1.6
TRC	8476	100.0	2886	100.0	2815	100.0	3701	100.0	683	100.0

Sites of Cancer	Mun	nbai	Banga	alore	Cher	ınai	Thi	puram	Dibrugarh		
0.1.00 0.1 0 0.1.10 0.1	#	%	#	%	#	%	#	%	#	%	
Lip	25	1.1	30	1.7	11	0.9	27	2.7	10	5.3	
Tongue	370	16.4	86	5.0	119	10.3	237	24.1	19	10.2	
Mouth	656	29.0	833	48.1	441	38.1	384	39.1	37	19.8	
Oropharynx	83	3.7	44	2.5	22	1.9	16	1.6	17	9.1	
Hypopharynx	161	7.1	112	6.5	154	13.3	36	3.7	17	9.1	
Pharynx	0	0.0	23	1.3	18	1.6	3	0.3	5	2.7	
Oesophagus	505	22.3	467	27.0	263	22.7	109	11.1	68	36.4	
Larynx	99	4.4	20	1.2	26	2.2	19	1.9	6	3.2	
Lung	298	13.2	82	4.7	84	7.2	134	13.6	8	4.3	
Uri. Bladder	65	2.9	34	2.0	21	1.8	18	1.8	0	0.0	
TRC	2262	100.0	1731	100.0	1159	100.0	983	100.0	187	100.0	

Table 3.4: Number(#) and Relative Proportion(%) of Tobacco Related Cancers by five-year age groups with Standard Deviation (SD) (1999-2000)

Age Group	Mum	ıbai	Banga	alore	Chen	nai	Thi	'puram	Dibrugarh	
rigo di oup	#	%	#	%	#	%	#	%	#	%
00-14	6	0.1	2	0.1	1	0.0	2	0.1	6	0.9
15-19	9	0.1	3	0.1	3	0.1	2	0.1	2	0.3
20-24	34	0.4	6	0.2	15	0.5	3	0.1	6	0.9
25-29	91	1.1	26	0.9	28	1.0	8	0.2	5	0.7
30-34	224	2.6	39	1.4	50	1.8	26	0.7	18	2.6
35-39	467	5.5	93	3.2	102	3.6	92	2.5	30	4.4
40-44	758	8.9	137	4.7	174	6.2	175	4.7	43	6.3
45-49	987	11.6	311	10.8	318	11.3	393	10.6	81	11.9
50-54	1268	15.0	403	14.0	437	15.5	481	13.0	91	13.3
55-59	1262	14.9	450	15.6	486	17.3	596	16.1	94	13.8
60-64	1165	13.7	526	18.2	433	15.4	609	16.5	140	20.5
65-69	1116	13.2	405	14.0	371	13.2	622	16.8	73	10.7
70-74	635	7.5	267	9.3	221	7.9	367	9.9	52	7.6
75 <b>+</b>	454	5.4	218	7.6	176	6.3	325	8.8	42	6.1
ANS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
All Ages	8476	100.0	2886	100.0	2815	100.0	3701	100.0	683	100.0
Mean	55.1		57.3		56.4		59.3		55.5	
SD	12.17		11.55		11.71		11.11		12.14	

Age Group	Mun	nbai	Banga	alore	Cher	nai	Thi	'puram	Dib	rugarh
Age di oup	#	%	#	%	#	%	#	%	#	%
00-14	1	0.0	2	0.1	1	0.1	3	0.3	0	0.0
15-19	6	0.3	3	0.2	0	0.0	1	0.1	0	0.0
20-24	16	0.7	7	0.4	6	0.5	3	0.3	2	1.1
25-29	23	1.0	19	1.1	25	2.2	7	0.7	4	2.1
30-34	66	2.9	26	1.5	38	3.3	22	2.2	8	4.3
35-39	151	6.7	100	5.8	62	5.3	27	2.7	18	9.6
40-44	211	9.3	139	8.0	82	7.1	52	5.3	17	9.1
45-49	304	13.4	207	12.0	175	15.1	95	9.7	26	13.9
50-54	345	15.3	283	16.3	190	16.4	105	10.7	29	15.5
55-59	306	13.5	212	12.2	150	12.9	160	16.3	33	17.6
60-64	330	14.6	285	16.5	179	15.4	152	15.5	23	12.3
65-69	259	11.5	204	11.8	130	11.2	146	14.9	12	6.4
70-74	143	6.3	145	8.4	62	5.3	101	10.3	9	4.8
75+	101	4.5	99	5.7	59	5.1	109	11.1	6	3.2
ANS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
All Ages	2262	100.0	1731	100.0	1159	100.0	983	100.0	187	100.0
Mean	53.6		54.7		53.6		58.7		51.0	'
SD	12.26		12.24		12.27		12.68		12.18	

# **BASIS OF DIAGNOSIS**


The basis of diagnosis of cancers registered at the various centres is shown in Table 4.1 and depicted as  $Pie(\Pi)$  diagrams in Figure 4.1. The proportion of microscopic confirmation was about 90% and above in both sexes except in Chennai where it was 77% in males and 85% in females. Correspondingly, the proportion of diagnosis based on X-ray was higher in Chennai.


Table 4.2 and Figure 4.2 give further details of microscopically verified cancers by various types of microscopic diagnosis. Primary Histology was the predominant form of microscopic diagnosis in all registries in both sexes. In Bangalore (23% in males and 13% in females) and Thiruvananthapuram (17% in males and 9% in females), the percentage of diagnoses based on cytology was relatively higher compared to


Table 4.1 : Number(#) & Relative Proportion(%) of cancers based on different methods of diagnosis (1999-2000)


	Micros	scopic	X-r	ay	Clin	ical	Oth	ers	To	tal
Registry	#	%	#	%	#	%	#	%	#	%
Males										
Mumbai	16064	91.1	23	0.1	7	0.0	1543	8.7	17637	100.0
Bangalore	5767	94.4	140	2.3	25	2.3	174	2.8	6106	100.0
Chennai	4751	76.7	888	14.3	104	14.3	452	7.3	6195	100.0
Thi'puram	7301	92.9	117	1.5	114	1.5	327	4.2	7859	100.0
Dibrugarh	939	94.2	5	0.5	15	0.5	38	3.8	997	100.0
Females										
Mumbai	12433	90.9	21	0.2	2	0.0	1223	8.9	13679	100.0
Bangalore	7217	95.7	157	2.1	16	0.2	153	2.0	7543	100.0
Chennai	6083	85.2	821	11.5	38	0.5	197	2.8	7139	100.0
Thi'puram	6960	96.0	146	2.0	23	0.3	118	1.6	7247	100.0
Dibrugarh	477	89.0	1	0.2	8	1.5	50	9.3	536	100.0


Fig. 4.1(a): Pie(Π) diagram showing Proportion (%) of Patients according to Method of Diagnosis - Males (1999-2000)



















Fig. 4.1(b): Pie(Π) diagram showing Proportion (%) of Patients according to Method of Diagnosis - Females (1999-2000)














Fig. 4.2(a): Stack(100%) diagram showing Proportion(%) of Microscopically Diagnosed patients according to specific Microscopic Diagnosis - Males (1999-2000)




Fig. 4.2(b): Stack(100%) diagram showing Proportion(%) of Microscopically Diagnosed patients according to specific Microscopic Diagnosis - Females (1999-2000)



Table 4.2: Number (#) & Relative Proportion (%) of cancers based on different types of Microscopic Diagnosis (1999-2000)

	Primary I	Histology	Secondary Histology		Cytology		Peripheral Blood		Bone Marrow		All Microscopic*	
Registry	#	%	#	%	#	%	#	%	#	%	#	%
Mumbai	11676	72.7	6.5	3.8	2181	13.6	20	0.1	1582	9.8	16064	100.0
Bangalore	3871	67.1	110	1.9	1350	23.4	19	0.3	417	7.2	5767	100.0
Chennai	3753	79.0	247	5.2	343	7.2	6	0.1	402	8.5	4751	100.0
Thi'puram	5091	69.7	352	4.8	1202	16.5	7	0.1	649	8.9	7301	100.0
Dibrugarh	708	75.4	118	12.6	91	9.7	0	0.0	22	2.3	939	100.0

#### **Females**

	Primary	Histology	Secondary Histology		Cytology		Peripheral Blood		Bone Marrow		All Microscopic*	
Registry	#	%	#	%	#	%	#	%	#	%	#	%
Mumbai	10269	82.6	321	2.6	1212	9.7	13	0.1	618	5.0	12433	100.0
Bangalore	5880	81.5	63	0.9	964	13.4	21	0.3	289	4.0	7217	100.0
Chennai	5159	84.8	119	2.0	575	9.5	1	0.0	229	3.8	6083	100.0
Thi'puram	5819	83.6	142	2.0	590	8.5	2	0.0	407	5.8	6960	100.0
Dibrugarh	400	83.9	28	5.9	40	8.4	0	0.0	9	1.9	477	100.0

<sup>\*</sup> Excludes few cases diagnosed by autopsy.

other registries especially in males. Dibrugarh (13%) had a high proportion of cases based on secondary histology in males.

Table 4.3 presents the proportion of microscopic diagnosis from 1994-2000. The proportion has been stable in both sexes in all the registries except for a slight increase in males in Thiruvananthapuram. Table 4.4 further gives the proportion of microscopic diagnosis for the three time periods of publication of HBCR reports. The proportion seems to be stable in the three time periods except slight increase in Chennai and Thiruvananthapuram.

The relative proportion of cytological diagnosis during the three periods has been presented in Table 4.5. The proportion is stable in both sexes in Mumbai and in males in Bangalore. In other registry hospitals,

Table 4.3 : Number(#) & Relative Proportion(%) of Microscopic Diagnosis across different years of diagnosis

Year of	Mun	nbai	Bang	alore	Chen	ınai	Thi'p	uram	Dibr	ugarh
Diagnosis	#	%	#	%	#	%	#	%	#	%
MALES										
1994	7914	90.0	2913	92.9	1970	72.3	3092	88.2	710	92.8
1995	7758	88.4	3163	94.2	2041	75.8	3318	87.3	579	93.4
1996	7269	90.2	3018	94.2	2052	78.1	3563	89.7	286	92.9
1997	7945	90.9	3076	94.8	2180	78.3	3460	90.2	396	94.5
1998	7870	91.0	2838	95.1	2027	78.4	3540	91.6	513	96.2
1999	7991	90.7	2812	94.8	2270	76.4	3676	92.2	421	93.8
2000	8073	90.9	2955	93.6	2481	75	3625	93.4	518	93.4
1994-2000	54820	90.2	20775	94.3	15021	76.55	24274	89.9	3423	93.9
FEMALES										
1994	6098	89.2	3485	94.8	2521	81.4	2921	93.0	397	90.2
1995	6113	88.8	3780	96.0	2592	83.0	3069	92.8	290	90.9
1996	5673	89.4	3614	95.8	2603	84.6	3173	94.3	178	90.8
1997	6283	90.4	3558	96.1	2670	84.5	3200	94.8	240	92.3
1998	6041	90.2	3320	95.9	2609	83.5	3312	95.8	264	93.3
1999	6253	90.5	3636	96.1	2986	85.5	2472	96.2	185	86.0
2000	6180	90.7	3581	93.5	3097	80.7	4488	95.6	292	92.0
1994-2000	42641	89.8	24974	95.8	19078	83.75	22635	94.5	1846	90.6

Table 4.4: Proportion(%) of Microscopic Diagnosis during the three periods 1984-93, 1994-98 and 1999-2000

De siletos		Males		Females					
Registry	1984-93	1994-98	1999-00	1984-93	1994-98	1999-00			
Mumbai	91.3	90.1	91.1	91.5	89.6	90.9			
Bangalore	91.1	94.2	94.2	94.8	95.7	94.8			
Chennai	69.5	76.6	75.7	71.5	83.4	83.1			
Thi'puram	86.0	89.4	92.8	90.3	94.2	95.9			
Dibrugarh	88.3	93.9	94.2	88.3	91.4	89.0			

Table 4.5: Proportion(%) of Cytological Diagnosis during the three periods 1984-93, 1994-98 and 1999-2000

Deutster		Males		Females					
Registry	1984-93	1994-98	1999-00	1984-93	1994-98	1999-00			
Mumbai	13.3	13.2	13.6	8.2	9.9	9.7			
Bangalore	23.2	23.6	23.2	8.5	10.7	13.5			
Chennai	4.0	4.7	7.0	4.2	4.7	9.1			
Thi'puram	9.6	12.8	16.0	5.6	7.3	8.4			
Dibrugarh	2.6	8.1	9.7	3.6	7.6	8.4			

# **BROAD TREATMENT GROUPS**

In order to study different aspects in the management of cancer patients the data from the HBCRs are categorized into the following four groups:

#### Prior Treatment Only (Prior Tmt. Only):

Those patients who have received some or complete cancer directed treatment before registration and have not received any further treatment at the reporting institution(RI).

#### Prior Treatment & Treatment at Reporting Institution (Prior & Tmt. at RI):

These are patients who have received cancer directed treatment prior to registration and have received further treatment at the reporting institution.

#### Treatment Only at Reporting Institution (Tmt. only at RI):

Patients who have come for the first time to the reporting institution with or without a confirmed diagnosis of malignancy and have not received any cancer directed treatment earlier and received complete cancer directed treatment at the reporting institution.

#### No Cancer Directed Treatment (No CDT):

This group includes patients who have neither received nor accepted any treatment. It also includes the patients who have not completed any form of treatment and where the treatment status is unknown.

Table 5.1 and stack diagram (Fig. 5.1) shows the number and relative proportion of the patients by the above four broad treatment groups in different registries for the year 1999-2000. The proportion of patients belonging to Prior Tmt. Only varied from less than one percent in either sex in Dibrugarh to 14 -15% in both sexes at Mumbai. Similarly, the relative proportion in the second group, viz., Prior and Tmt. at RI also showed variation among the registries - from 3% in Dibrugarh to 13% in Thiruvananthapuram in males and 3% in Dibrugarh to 31% in Thiruvananthapuram in females. The relative proportion of the patients treated only at the reporting institution (Tmt. only at RI) was comparatively higher in the centres at Thiruvananthapuram and Dibrugarh with a correspondingly lower relative proportion in the 'No CDT' category as compared with the centres at Mumbai, Bangalore and Chennai.


Table 5.1 : Number(#) & Relative Proportion(%) of cancer patients according to Broad Groups of Treatment (Tmt) at Reporting Institution (RI) and/or elsewhere (1999-2000)


Treatment Group	Mur	nbai	Bangalore		Chennai		Thi'puram		Dibrugarh	
тошинот от обр	#	%	#	%	#	%	#	%	#	%
Prior Tmt. Only	2452	13.9	391	6.4	884	14.3	541	6.9	1	0.1
Prior & Tmt. at RI	1490	8.4	340	5.6	255	4.1	1052	13.4	30	3.0
Tmt. Only at RI	5667	32.1	2227	36.5	1828	29.5	4766	60.6	832	83.5
No CDT*	8028	45.5	3148	51.6	3228	52.1	1500	19.1	134	13.4
Total Patients	17637	100.0	6106	100.0	6195	100.0	7859	100.0	997	100.0

Treatment Group	Mur	nbai	Bangalore		Chennai		Thi'puram		Dibrugarh	
noumon choup	#	%	#	%	#	%	#	%	#	%
Prior Tmt. Only	2112	15.4	546	7.2	919	12.9	892	12.3	4	0.7
Prior & Tmt. at RI	2119	15.5	583	7.7	520	7.3	2212	30.5	15	2.8
Tmt. Only at RI	4470	32.7	3334	44.2	2616	36.6	3325	45.9	430	80.2
No CDT*	4978	36.4	3080	40.8	3084	43.2	818	11.3	87	16.2
Total Patients	13679	100.0	7543	100.0	7139	100.0	7247	100.0	536	100.

<sup>\*</sup> CDT - Cancer Directed Treatment

Fig. 5.1: Stack(100%) diagram showing HBCRs, Proportion(%) According To Broad Groups of Treatment(Tmt) (1999-2000)





# CLINICAL EXTENT OF DISEASE AT PRESENTATION


Table 6.1 presents number and relative proportion of cancer patients in various clinical extent of disease of presentation at the time of registering at the reporting institution for the year 1999-2000. The proportion of the patients with localised disease varied from 4.6% in males at Chennai to 34% in both sexes at Mumbai. The proportion of the patients with distant or advanced cancer was 12% in Chennai, 14% in Bangalore and 16-18% in other three registries in males. In females, the proportion was lower, 5% in Chennai to 14% in Thiruvananthapuram. The proportion under the category `Others' mainly refers to Lymphomas and Leukaemias, which are generally not staged according to the above system.


Due to a number of reasons (which are beyond the scope of this report) there have been difficulties in abstracting and standardizing this particular information (Clinical Extent of Disease) in a uniform way by all registries. Therefore, noticeable variations in relative proportions of clinical extent of disease are observed (as also in previous reports). The same problem is seen in individual site chapters as well. The patterns of care and survival studies commenced by HBCRs is expected to iron out anomalies if any. The above may be kept in mind, while observing the relative proportion of Clinical Extent of Disease.

Table 6.1: Number(#) and Relative Proportion(%) of patients according to Clinical Extent of Disease (Excludes Patients Previously Treated) (1999-2000)

Danishu	Localise	ed (L)	Regiona	ıl (R)	L+	R	Dista	nt	Othe	rs	All Sta	iges
Registry	#	%	#	%	#	%	#	%	#	%	#	%
Males												
Mumbai	4650	34.0	3685	26.9	8335	60.9	2406	17.6	786	5.7	13695	100.0
Bangalore	311	5.8	3128	58.2	3439	64.0	774	14.4	391	7.3	5375	100.0
Chennai	231	4.6	3149	62.3	3380	66.9	625	12.4	377	7.5	5056	100.0
Thi'puram	806	12.9	2945	47.0	3751	59.9	1048	16.7	556	8.9	6266	100.0
Dibrugarh	74	7.7	586	60.7	660	68.3	162	16.8	76	7.9	966	100.0
Females												
Mumbai	3264	34.5	3301	34.9	6565	69.5	969	10.3	382	4.0	9448	100.0
Bangalore	341	5.3	4624	72.1	4965	77.4	457	7.1	243	3.8	6414	100.0
Chennai	369	6.5	4318	75.8	4687	82.2	303	5.3	171	3.0	5700	100.0
Thi'puram	481	11.6	2382	57.5	2823	69.1	588	14.2	228	5.5	4143	100.0
Dibrugarh	49	9.5	310	60.0	359	69.4	65	12.6	21	4.1	517	100.0

Fig. 6.1: Stack(100%) diagram showing HBCRs, Proportion(%) of Patients According
To Clinical Extent of Disease (1999-2000)





# TREATMENT ONLY AT REPORTING INSTITUTION

This is the most important category of the broad treatment groups presented in chapter 5, since it best represents the contribution to the treatment aspect of patient care of a given institution.

Table 7.1 gives an overview of the number of patients treated during the period and the total number of treatment procedures instituted. As may be observed these ratios are indeed comparable between registries located at regional cancer centres. The ratio is slightly lower at Dibrugarh which is in a medical college setup. Table 7.1 is further diagrammatically represented in Figure 7.1.

#### TYPES OF TREATMENT

Table 7.2 and corresponding figures (Figures 7.2 and 7.3) give the numbers and relative proportions according to type of specific treatment given, whether only one type of treatment has been given (Single Modality Therapy) or more than one type of therapy (Combination Therapy) has been given. It also gives the overall number and relative proportion of any treatment with reference to the total patients treated.

Single modality of therapy ranged between 66% in Mumbai to 91% in Dibrugarh in males. In females, the lowest and highest percentages were observed in Mumbai (61%) and Dibrugarh (79%) respectively.

Table 7.1: Total number of cancer patients (Pts) treated, total number of treatment procedures (Proc) performed and procedures/patients ratio (1999-2000)

		Males			Females	
Registry	Total Pts.	Total Proc.	Ratio	Total Pts.	Total Proc.	Ratio
Mumbai	5667	7689	1.4	4470	7182	1.6
Bangalore	2227	2948	1.3	3334	4833	1.4
Chennai	1828	2353	1.3	2616	4466	1.7
Thi'puram	4766	5966	1.3	3325	4811	1.4
Dibrugarh	832	914	1.1	430	521	1.2




Fig. 7.1: Procedure - Patient Ratio (Patients Treated only at Reporting Institution) (1999-2000)

Fig. 7.2: Stack(100%) diagram showing HBCRs, Proportion of Different Types of Treatment (Patients Treated Only at Reporting Institution) (1999-2000)





Table 7.2: Number (#) & Relative Proportion (%) of patients according to Type of Treatment given (1999-2000)

Type of	Mur	nbai	Bang	alore	Che	nnai	Thi'p	uram	Dibr	ugarh
Treatment	#	%	#	%	#	%	#	%	#	%
<b>Total patients</b>	5667	100.0	2227	100.0	1828	100.0	4766	100.0	832	100.0
Specific Treatments										
Surgery(S)	1635	28.9	349	15.7	235	12.9	164	3.4	49	5.9
Radiotherapy(R)	877	15.5	820	36.8	714	39.1	2012	42.2	635	76.3
Chemotherapy(C)	1200	21.2	396	17.8	389	21.3	1035	21.7	69	8.3
S + R	788	13.9	264	11.9	174	9.5	218	4.6	37	4.4
S + C	230	4.1	88	4.0	59	3.2	64	1.3	16	1.9
R + C	695	12.3	242	10.9	166	9.1	790	16.6	20	2.4
S + R + C	142	2.5	48	2.2	34	1.9	54	1.1	3	0.4
Others	100	1.8	20	0.9	57	3.1	429	9.0	3	0.4
Modality of therapy*										
Single	3712	65.5	1565	70.3	1338	73.2	3211	67.4	753	90.5
Combination	1855	32.7	642	28.8	433	23.7	1126	23.6	76	9.1

Type of	Mumbai		Bangalore		Chennai		Thi'puram		Dibrugarh	
Treatment	#	%	#	%	#	%	#	%	#	%
Total patients	4470	100.0	3334	100.0	2616	100.0	3325	100.0	430	100.0
Specific Treatments										
Surgery(S)	1140	25.5	294	8.8	109	4.2	143	4.3	47	10.9
Radiotherapy(R)	1046	23.4	1506	45.2	1302	49.8	1247	37.5	254	59.1
Chemotherapy(C)	531	11.9	364	10.9	223	8.5	659	19.8	39	9.1
S + R	377	8.4	367	11.0	152	5.8	208	6.3	44	10.2
S + C	309	6.9	166	5.0	56	2.1	158	4.8	39	9.1
R + C	235	5.3	336	10.1	151	5.8	363	10.9	5	1.2
S + R + C	240	5.4	157	4.7	24	0.9	144	4.3	1	0.2
Others	592	13.2	144	4.3	599	22.9	403	12.1	1	0.2
Modality of therapy*										
Single	2717	60.8	2164	64.9	1634	62.5	2049	61.6	340	79.1
Combination	1161	26.0	1026	30.8	383	14.6	873	26.3	89	20.7

<sup>\*</sup> Excludes specific treatment classified as 'Others'

Fig. 7.3: Proportion of Types of Treatments (Patients Treated only at Reporting Institution)






Table 7.3: Number (#) and Proportion (%) of cancer patients according to Any Specific Treatment at Reporting Institution relative to All Treatment procedures (Proced.) (1999-2000)

Registry	Any Su	rgery	Any Radi	otherapy	Any Chen	notherapy	Any Ot	hers	Total
	#	%	#	%	#	%	#	%	Proced.
MALES									
Mumbai	2808	36.5	2509	32.6	2272	29.5	100	1.3	7689
Bangalore	765	25.9	1387	47.0	776	26.3	20	0.7	2948
Chennai	533	22.7	1099	46.7	664	28.2	57	2.4	2353
Thi'puram	504	8.4	3088	51.8	1945	32.6	429	7.2	5966
Dibrugarh	105	11.5	698	76.4	108	11.8	3	0.3	914
FEMALES									
Mumbai	2595	36.1	2236	31.1	1759	24.5	592	8.2	7182
Bangalore	1108	22.9	2473	51.2	1108	22.9	144	3.0	4833
Chennai	769	17.2	2133	47.8	965	21.6	599	13.4	4466
Thi'puram	828	17.2	2110	43.9	1470	30.6	403	8.4	4811
Dibrugarh	131	25.1	305	58.5	84	16.1	1	0.2	521

Table 7.3 and Fig. 7.3 presents the total treatment procedures according to specific treatment. Except in Mumbai, radiotherapy was the predominant form of the modalities accounting for nearly half to three fourth of treatment procedures. In Mumbai, 36% of the treatment procedures were surgery in both the sexes.

Tables 7.4(a) and 7.4(b) present number and relative proportion of various types of treatment within different categories of clinical extent of disease (viz. Localised, Regional, Distant and Others).

Tables 7.5(a) and 7.5(b) present number of proportion of specific types of treatment relative to all patients within each category of clinical extent of disease.

Table 7.4(a): Number (#) & Relative Proportion (%) of types of treatment according to Clinical Extent of Disease - Males (1999-2000)

Olivia al Fata et	Mur	nbai	Bang	alore	Che	nnai	Thi'p	ouram	Dibr	ugarh
Clinical Extent	#	%	#	%	#	%	#	%	#	%
Localised										
Surgery(S)	1133	53.7	66	39.3	27	14.0	51	8.4	13	18.1
Radiotherapy(R)	288	13.7	57	33.9	119	61.7	383	63.0	52	72.2
Chemotherapy(C)	101	4.8	3	1.8	0	0.0	24	3.9	0	0.0
S + R	195	9.3	19	11.3	42	21.8	30	4.9	6	8.3
S + C	167	7.9	7	4.2	2	1.0	15	2.5	0	0.0
R + C	120	5.7	12	7.1	1	0.5	72	11.8	1	1.4
S + R + C	73	3.5	3	1.8	0	0.0	7	1.2	0	0.0
Others	31	1.5	1	0.6	2	1.0	26	4.3	0	0.0
ALL TREATMENTS	2108	100.0	168	100.0	193	100.0	608	100.0	72	100.0
Regional										
Surgery(S)	430	24.3	248	39.3	197	17.2	99	4.3	23	4.3
Radiotherapy(R)	389	22.0	655	33.9	549	47.9	1158	50.6	461	85.8
Chemotherapy(C)	100	5.7	92	1.8	61	5.3	204	8.9	6	1.1
S + R	546	30.9	226	11.3	129	11.3	176	7.7	22	4.1
S + C	31	1.8	68	4.2	51	4.5	39	1.7	11	2.0
R + C	209	11.8	117	7.1	90	7.9	444	19.4	10	1.9
S + R + C	53	3.0	42	1.8	31	2.7	45	2.0	3	0.6
Others	11	0.6	14	0.6	38	3.3	124	5.4	1	0.2
ALL TREATMENTS	1769	100.0	1462	100.0	1146	100.0	2289	100.0	537	100.0
Distant										
Surgery(S)	48	8.1	19	12.7	9	11.0	8	1.3	8	16.7
Radiotherapy(R)	135	22.8	67	44.7	9	11.0	256	40.4	11	22.9
Chemotherapy(C)	236	39.9	27	18.0	31	37.8	126	19.9	21	43.8
S + R	4	0.7	7	4.7	0	0.0	3	0.5	2	4.2
S + C	26	4.4	6	4.0	4	4.9	8	1.3	3	6.3
R + C	76	12.8	18	12.0	10	12.2	79	12.5	3	6.3
S + R + C	12	2.0	1	0.7	2	2.4	2	0.3	0	0.0
Others	55	9.3	5	3.3	17	20.7	152	24.0	0	0.0
ALL TREATMENTS	592	100.0	150	100.0	82	100.0	634	100.0	48	100.0
Others										
Surgery(S)	24	2.0	16	3.6	2	0.5	6	0.5	5	2.9
Radiotherapy(R)	65	5.4	41	9.2	37	9.1	215	17.4	111	63.4
Chemotherapy(C)	763	63.7	274	61.3	297	73.0	681	55.1	42	24.0
S + R	43	3.6	12	2.7	3	0.7	9	0.7	7	4.0
S + C	6	0.5	7	1.6	2	0.5	2	0.2	2	1.1
R + C	290	24.2	95	21.3	65	16.0	195	15.8	6	3.4
S + R + C	4	0.3	2	0.4	1	0.2	0	0.0	0	0.0
Others	3	0.3	0	0.0	0	0.0	127	10.3	2	1.1
ALL TREATMENTS	1198	100.0	447	100.0	407	100.0	1235	100.0	175	100.0

Table 7.4(b): Number (#) & Relative Proportion (%) of types of treatment according to Clinical Extent of Disease - Females (1999-2000)

0	Mur	nbai	Bang	alore	Che	nnai	Thi'p	uram	Dibr	ugarh
Clinical Extent	#	%	#	%	#	%	#	%	#	%
Localised										
Surgery(S)	787	47.6	45	20.7	12	4.4	42	10.4	9	19.1
Radiotherapy(R)	163	9.9	67	30.9	137	50.7	172	42.6	31	66.0
Chemotherapy(C)	53	3.2	10	4.6	2	0.7	16	4.0	0	0.0
S + R	172	10.4	45	20.7	67	24.8	50	12.4	5	10.6
S + C	138	8.4	10	4.6	0	0.0	33	8.2	2	4.3
R + C	52	3.1	8	3.7	7	2.6	33	8.2	0	0.0
S + R + C	95	5.8	6	2.8	2	0.7	23	5.7	0	0.0
Others	192	11.6	26	12.0	43	15.9	35	8.7	0	0.0
ALL TREATMENTS	1652	100.0	217	100.0	270	100.0	404	100.0	47	100.0
Regional										
Surgery(S)	313	17.2	226	8.4	95	4.7	98	5.0	30	10.5
Radiotherapy(R)	745	40.9	1340	50.0	1143	56.4	936	47.7	182	63.6
Chemotherapy(C)	47	2.6	187	7.0	68	3.4	155	7.9	4	1.4
S + R	184	10.1	306	11.4	85	4.2	154	7.9	35	12.2
S + C	70	3.8	113	4.2	52	2.6	98	5.0	31	10.8
R + C	64	3.5	261	9.7	100	4.9	208	10.6	3	1.0
S + R + C	120	6.6	145	5.4	22	1.1	110	5.6	1	0.3
Others	279	15.3	103	3.8	460	22.7	202	10.3	0	0.0
ALL TREATMENTS	1822	100.0	2681	100.0	2025	100.0	1961	100.0	286	100.0
Distant										
Surgery(S)	34	5.9	14	6.4	1	0.6	0	0.0	7	16.3
Radiotherapy(R)	105	18.2	83	37.7	10	6.4	69	19.8	14	32.6
Chemotherapy(C)	147	25.5	43	19.5	34	21.8	99	28.4	15	34.9
S + R	14	2.4	11	5.0	0	0.0	4	1.1	0	0.0
S + C	92	16.0	36	16.4	3	1.9	25	7.2	6	14.0
R + C	43	7.5	14	6.4	12	7.7	42	12.1	1	2.3
S + R + C	22	3.8	5	2.3	0	0.0	9	2.6	0	0.0
Others	119	20.7	14	6.4	96	61.5	100	28.7	0	0.0
ALL TREATMENTS	576	100.0	220	100.0	156	100.0	348	100.0	43	100.0
Others										
Surgery(S)	6	1.4	9	4.2	1	0.6	3	0.5	1	1.9
Radiotherapy(R)	33	7.9	16	7.4	12	7.3	70	11.4	27	50.0
Chemotherapy(C)	284	67.6	124	57.4	119	72.1	389	63.6	20	37.0
S + R	7	1.7	5	2.3	0	0.0	0	0.0	4	7.4
S + C	9	2.1	7	3.2	1	0.6	2	0.3	0	0.0
R + C	76	18.1	53	24.5	32	19.4	80	13.1	1	1.9
S + R + C	3	0.7	1	0.5	0	0.0	2	0.3	0	0.0
Others	2	0.5	1	0.5	0	0.0	66	10.8	1	1.9
ALL TREATMENTS	420	100.0	216	100.0	165	100.0	612	100.0	54	100.0

Table 7.5(a): Number (#) and Proportion (%) of any specific treatment relative to all treated patients according to Clinical Extent of Disease - Males (1999-2000)

	Any Su	rgery	Any Radi	Any Radiotherapy		notherapy	Any Ot	hers	Total
	#	%	#	%	#	%	#	%	Patients
LOCALISED									
Mumbai	1572	74.6	678	32.2	461	21.9	31	1.5	2108
Bangalore	96	57.1	92	54.8	25	14.9	1	0.6	168
Chennai	73	37.8	164	85.0	5	2.6	2	1.0	193
Thi'puram	103	16.9	492	80.9	118	19.4	26	4.3	608
Dibrugarh	19	26.4	59	81.9	1	1.4	0	0.0	72
REGIONAL									
Mumbai	1069	60.4	1201	67.9	397	22.4	11	0.6	1769
Bangalore	595	40.7	1049	71.8	320	21.9	14	1.0	1462
Chennai	436	38.0	804	70.2	241	21.0	38	3.3	1146
Thi'puram	360	15.7	1827	79.8	733	32.0	124	5.4	2289
Dibrugarh	59	11.0	497	92.6	30	5.6	1	0.2	537
DISTANT									
Mumbai	90	15.2	228	38.5	351	59.3	55	9.3	592
Bangalore	37	24.7	96	64.0	53	35.3	5	3.3	150
Chennai	16	19.5	25	30.5	53	64.6	17	20.7	82
Thi'puram	24	3.8	350	55.2	216	34.1	152	24.0	634
Dibrugarh	13	27.1	16	33.3	27	56.3	0	0.0	48
OTHERS									
Mumbai	77	6.4	402	33.6	1063	88.7	3	0.3	1198
Bangalore	37	8.3	150	33.6	378	84.6	0	0.0	447
Chennai	8	2.0	106	26.0	365	89.7	0	0.0	407
Thi'puram	17	1.4	419	33.9	878	71.1	127	10.3	1235
Dibrugarh	14	8.0	126	72.0	50	28.6	2	1.1	175

Table 7.5(b): Number (#) and Proportion (%) of any specific treatment relative to all treated patients according to Clinical Extent of Disease - Females (1999-2000)

	Any Su	rgery	Any Radi	Any Radiotherapy		notherapy	Any Ot	hers	Total
	#	%	#	%	#	%	#	%	Patients
LOCALISED									
Mumbai	1380	83.5	576	34.9	446	27.0	192	11.6	1652
Bangalore	132	60.8	145	66.8	45	20.7	26	12.0	217
Chennai	124	45.9	251	93.0	47	17.4	43	15.9	270
Thi'puram	181	44.8	290	71.8	113	28.0	35	8.7	404
Dibrugarh	16	34.0	36	76.6	2	4.3	0	0.0	47
REGIONAL									
Mumbai	943	51.8	1285	70.5	536	29.4	279	15.3	1822
Bangalore	884	33.0	2134	79.6	770	28.7	103	3.8	2681
Chennai	631	31.2	1764	87.1	640	31.6	460	22.7	2025
Thi'puram	588	30.0	1500	76.5	668	34.1	202	10.3	1961
Dibrugarh	97	33.9	221	77.3	39	13.6	0	0.0	286
DISTANT									
Mumbai	247	42.9	256	44.4	405	70.3	119	20.7	576
Bangalore	70	31.8	119	54.1	107	48.6	14	6.4	220
Chennai	12	7.7	74	47.4	126	80.8	96	61.5	156
Thi'puram	52	14.9	158	45.4	215	61.8	100	28.7	348
Dibrugarh	13	30.2	15	34.9	22	51.2	0	0.0	43
OTHERS									
Mumbai	25	6.0	119	28.3	372	88.6	2	0.5	420
Bangalore	22	10.2	75	34.7	186	86.1	1	0.5	216
Chennai	2	1.2	44	26.7	152	92.1	0	0.0	165
Thi'puram	7	1.1	162	26.5	474	77.5	66	10.8	612
Dibrugarh	5	9.3	33	61.1	21	38.9	1	1.9	54

# Chapter 8

# MOUTH (ICD-10: C03-C06)

The total number, relative proportion and rank of the cancer of mouth in males and females for the years 1999 and 2000 is given in Table 8.1(a). Cancer of the mouth ranked as the leading site in Mumbai in males and was within the first five leading sites in all registries in both males and females.

Table 8.1(b) gives the sub-site distribution of cancers of the oral cavity. Table 8.1(c) gives the sub-site distribution of cancer of gum in all registries in both sexes. A higher proportion of cancers were seen in the lower gum. Table 8.1(d) gives the sub-site distribution of cancer of palate. The distribution of the relative proportion of hard palate and soft palate cancers show interesting variation among the registries and between the sexes. While males in Mumbai and Thiruvananthapuram registry showed almost equal proportion of hard and soft palate cancers, Bangalore, Chennai and Dibrugarh registries showed a higher proportion of cancers of the soft palate in males. In females, cancer of the hard palate was predominant in Mumbai and Thiruvananthapuram.

Table 8.1(e) shows the relative proportion of the sub-sites of cancer of other and unspecified parts of the mouth. Cheek mucosa accounted for the vast majority of cancers of this site in either sex.

Figure 8.1 gives the trends in actual number of mouth cancers from 1984 to 2000. An increasing trend in actual number was observed in Mumbai (in males & females) and in Thiruvananthapuram (in males).

Table 8.2 and Figure 8.2 give the distribution of mouth cancers by five year age group. The relatively higher distribution of mouth cancers was seen in the younger ages in Bangalore in both males and females.

The predominant form of diagnosis in all registries for mouth cancer was through microscopic examination (Table 8.3) though this proportion was slightly lower in Chennai. Table 8.4 gives the distribution of cancers according to the clinical extent of disease. Over 60% of cases have "Regional spread", at diagnosis.

Table 8.5 gives the number and relative proportion according to the broad groups of treatment and Tables 8.6, 8.7 & 8.8 give an idea of the type of treatment instituted by these registries.

Table 8.1(a): Number(#), Relative Proportion(%) and Rank(R) of cancers of the mouth (1999-2000)

Registry		Males			Females					
<u> </u>	Total	#	%	R	Total	#	%	R		
Mumbai	17637	1986	11.3	1	13679	656	4.8	4		
Bangalore	6106	368	6.0	5	7543	833	11.0	3		
Chennai	6195	544	8.8	2	7139	441	6.2	3		
Thi'puram	7859	734	9.3	2	7247	384	5.3	5		
Dibrugarh	997	86	8.6	3	536	37	6.9	5		

Table 8.1(b): Cancers of oral cavity - Number(#) and Relative Proportion(%) according to sub-site (1999-2000)

	Mur	nbai	Bang	jalore	Cher	nnai	Thi'p	ouram	Dibr	ugarh
	#	%	#	%	#	%	#	%	#	%
MALES										
Gums	487	24.5	40	10.9	125	23.0	156	21.3	12	14.0
Floor of mouth	108	5.4	50	13.6	60	11.0	93	12.7	7	8.1
Palate	180	9.1	68	18.5	78	14.3	83	11.3	15	17.4
Other & Uns.	1211	61.0	210	57.1	281	51.7	402	54.8	52	60.5
Total	1986	100.0	368	100.0	544	100.0	734	100.0	86	100.0
FEMALES										
Gums	206	31.4	118	14.2	114	25.9	99	25.8	8	21.6
Floor of mouth	13	2.0	5	0.6	5	1.1	8	2.1	2	5.4
Palate	39	5.9	33	4.0	28	6.3	25	6.5	4	10.8
Other & Uns.	398	60.7	677	81.3	294	66.7	252	65.6	23	62.2
Total	656	100.0	833	100.0	441	100.0	384	100.0	37	100.0

Table 8.1(c): Cancer of Gum - Number(#) and Relative Proportion(%) according to sub-site (1999-2000)

	Mun	nbai	Bang	jalore	Cher	nnai	Thi'p	uram	Dibr	ugarh
	#	%	#	%	#	%	#	%	#	%
Males										
Uppergum	65	13.3	7	17.5	26	20.8	24	15.4	2	16.7
Lowergum	387	79.5	14	35.0	98	78.4	128	82.1	7	58.3
Other & UNS	35	7.2	19	47.5	1	8.0	4	2.6	3	25.0
Total	487	100.0	40	100.0	125	100.0	156	100.0	12	100.0
Females										
Uppergum	30	14.6	12	10.2	19	16.7	16	16.2	0	0.0
Lowergum	166	80.6	61	51.7	95	83.3	80	80.8	7	87.5
Other & UNS	10	4.9	45	38.1	0	0.0	3	3.0	_ 1	12.5
Total	206	100.0	118	100.0	114	100.0	99	100.0	8	100.0


Table 8.1(d): Cancer of Palate - Number(#) and Relative Proportion(%) according to sub-site (1999-2000)

	Mun	nbai	Bang	jalore	Cher	nnai	Thi'p	uram	Dibr	ugarh
	#	%	#	%	#	%	#	%	#	%
Males										
Hard palate	80	44.4	13	19.1	13	16.7	38	45.8	2	13.3
Soft palate	88	48.9	46	67.6	36	46.2	31	37.3	8	53.3
Other & UNS	12	6.7	9	13.2	29	37.2	14	16.9	5	33.3
Total	180	100.0	68	100.0	78	100.0	83	100.0	15	100.0
Females										
Hard palate	29	74.4	18	54.5	14	50.0	18	72.0	1	25.0
Soft palate	6	15.4	8	24.2	9	32.1	2	8.0	2	50.0
Other & UNS	4	10.3	7	21.2	5	17.9	5	20.0	1	25.0
Total	39	100.0	33	100.0	28	100.0	25	100.0	4	100.0

Table 8.1(e): Cancer of Other and Unspecified parts of mouth - Number(#) and Relative Proportion(%) according to sub-site (1999-2000)

	Mur	nbai	Bang	jalore	Cher	nnai	Thi'p	uram	Dibr	ugarh
	#	%	#	%	#	%	#	%	#	%
MALES										
Cheek mucosa	975	80.5	128	61.0	234	83.3	358	89.1	40	76.9
Vestibule of mouth	98	8.1	22	10.5	3	1.1	2	0.5	1	1.9
Retromolar area	135	11.1	50	23.8	38	13.5	32	8.0	7	13.5
Other & UNS	3	0.2	10	4.8	6	2.1	10	2.5	4	7.7
Total	1211	100.0	210	100.0	281	100.0	402	100.0	52	100.0
FEMALES										
Cheek mucosa	338	84.9	476	70.3	280	95.2	239	94.8	16	69.6
Vestibule of mouth	19	4.8	76	11.2	2	0.7	3	1.2	0	0.0
Retromolar area	38	9.5	79	11.7	7	2.4	5	2.0	2	8.7
Other & UNS	3	0.8	46	6.8	5	1.7	5	2.0	5	21.7
Total	398	100.0	677	100.0	294	100.0	252	100.0	23	100.0

Fig. 8.1: Trends in Actual Numbers - Mouth Cancers







Table 8.2: Number(#) and Relative Proportion(%) of Mouth cancers according to five year age group (1999-2000)

Age Group	Mum	ıbai	Banga	alore	Cher	nai	Thi	'puram	Dib	rugarh
rigo aroup	#	%	#	%	#	%	#	%	#	%
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5-9	0	0.0	1	0.3	0	0.0	0	0.0	0	0.0
10-14	1	0.1	0	0.0	0	0.0	1	0.1	0	0.0
15-19	3	0.2	0	0.0	0	0.0	1	0.1	0	0.0
20-24	11	0.6	1	0.3	1	0.2	0	0.0	0	0.0
25-29	24	1.2	5	1.4	6	1.1	1	0.1	0	0.0
30-34	91	4.6	5	1.4	9	1.7	6	0.8	3	3.5
35-39	175	8.8	20	5.4	20	3.7	19	2.6	3	3.5
40-44	239	12.0	19	5.2	41	7.5	37	5.0	8	9.3
45-49	279	14.0	45	12.2	63	11.6	75	10.2	11	12.8
50-54	331	16.7	47	12.8	68	12.5	92	12.5	9	10.5
55-59	236	11.9	55	14.9	83	15.3	104	14.2	15	17.4
60-64	241	12.1	65	17.7	97	17.8	135	18.4	17	19.8
65-69	191	9.6	50	13.6	83	15.3	121	16.5	9	10.5
70-74	105	5.3	29	7.9	44	8.1	66	9.0	5	5.8
75+	59	3.0	26	7.1	29	5.3	76	10.4	6	7.0
ANS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
All Ages	1986	100.0	368	100.0	544	100.0	734	100.0	86	100.0
Mean	51.7		56.1		56.6		59.5		55.5	
SD	12.05		12.41		11.62		11.48		11.93	

Age Group	Mun	nbai	Banga	alore	Cher	nnai	Thi	'puram	Dib	rugarh
Age Group	#	%	#	%	#	%	#	%	#	%
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5- 9	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0
10-14	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0
15-19	1	0.2	1	0.1	0	0.0	1	0.3	0	0.0
20-24	4	0.6	4	0.5	1	0.2	1	0.3	0	0.0
25-29	10	1.5	6	0.7	5	1.1	0	0.0	1	1.2
30-34	16	2.4	13	1.6	6	1.4	2	0.5	3	3.5
35-39	42	6.4	49	5.9	17	3.9	5	1.3	3	3.5
40-44	70	10.7	74	8.9	29	6.6	14	3.6	6	7.0
45-49	81	12.3	94	11.3	63	14.3	43	11.2	5	5.8
50-54	99	15.1	142	17.0	74	16.8	33	8.6	8	9.3
55-59	90	13.7	112	13.4	57	12.9	71	18.5	1	1.2
60-64	95	14.5	136	16.3	80	18.1	64	16.7	5	5.8
65-69	73	11.1	88	10.6	60	13.6	53	13.8	4	4.7
70-74	47	7.2	61	7.3	24	5.4	46	12.0	0	0.0
75+	27	4.1	52	6.2	25	5.7	51	13.3	1	1.2
ANS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
All Ages	656	100.0	833	100.0	441	100.0	384	100.0	37	43.0
Mean	53.5		54.4		55.2	•	60.7	,	48.7	
SD	12.28		12.22		11.42		11.53		12.61	

Fig. 8.2: Five year age group distribution - Mouth Cancers (1999-2000)






Table 8.3: Number(#) and Relative Proportion(%) of Mouth cancers based on different methods of diagnosis (1999-2000)

	Micros	scopic	Clin	ical	X-r	ay	Oth	ers	Tot	tal
Registry	#	%	#	%	#	%	#	%	#	%
Males										
Mumbai	1877	94.5	2	0.1	0	0.0	107	5.4	1986	100.0
Bangalore	351	95.4	11	3.0	0	0.0	6	1.6	368	100.0
Chennai	316	58.1	227	41.7	0	0.0	1	0.2	544	100.0
Thi'puram	683	93.1	47	6.4	0	0.0	4	0.5	734	100.0
Dibrugarh	86	100.0	0	0.0	0	0.0	0	0.0	86	100.0
Females										
Mumbai	634	96.6	1	0.2	0	0.0	21	3.2	656	100.0
Bangalore	809	97.1	19	2.3	1	0.1	4	0.5	833	100.0
Chennai	269	61.0	172	39.0	0	0.0	0	0.0	441	100.0
Thi'puram	353	91.9	30	7.8	0	0.0	1	0.3	384	100.0
Dibrugarh	37	100.0	0	0.0	0	0.0	0	0.0	37	100.0

Table 8.4: Number(#) and Relative Proportion(%) of Mouth cancer patients according to the clinical extent of disease (Excludes Patients Previously Treated) (1999-2000)

Destates	Localise	ed (L)	Regiona	ıl (R)	L+	R	Dista	nt	Other	rs	All St	ages
Registry	#	%	#	%	#	%	#	%	#	%	#	%
Males												
Mumbai	512	30.8	1038	62.4	1550	93.1	114	6.9	0	0.0	1664	100.0
Bangalore	28	8.1	295	85.0	323	93.1	20	5.8	4	1.2	347	100.0
Chennai	52	11.3	408	88.3	460	99.6	2	0.4	0	0.0	462	100.0
Thi'puram	90	13.5	566	85.0	656	98.5	10	1.5	0	0.0	666	100.0
Dibrugarh	14	17.5	62	77.5	76	95.0	3	3.8	1	1.3	80	100.0
Females												
Mumbai	191	31.7	373	62.0	564	93.7	38	6.3	0	0.0	602	100.0
Bangalore	46	5.7	692	85.2	738	90.9	60	7.4	14	1.7	812	100.0
Chennai	32	8.2	359	91.6	391	99.7	1	0.3	0	0.0	392	100.0
Thi'puram	49	13.8	299	84.0	348	97.8	8	2.2	0	0.0	356	100.0
Dibrugarh	10	27.0	26	70.3	36	97.3	1	2.7	0	0.0	37	100.0

Table 8.5: Number(#) and Relative Proportion(%) of Mouth cancer patients according to Broad Groups of Treatment(Tmt) (1999-2000)

Treatment Group	Mur	nbai	Ban	galore	Che	nnai	Thi'ı	ouram	Dibr	ugarh
	#	%	#	%	#	%	#	%	#	%
MALES										
Prior Tmt. Only	214	10.8	18	4.9	76	14.0	22	3.0	0	0.0
Prior & Tmt. at RI	108	5.4	3	0.8	6	1.1	46	6.3	6	7.0
Tmt. Only at RI	820	41.3	175	47.6	219	40.3	555	75.6	73	84.9
No Treatment	844	42.5	172	46.7	243	44.7	111	15.1	7	8.1
Total Patients	1986	100.0	368	100.0	544	100.0	734	100.0	86	100.0
FEMALES										
Prior Tmt. Only	33	5.0	16	1.9	45	10.2	9	2.3	0	0.0
Prior & Tmt. at RI	21	3.2	5	0.6	4	0.9	19	4.9	0	0.0
Tmt. Only at RI	328	50.0	410	49.2	201	45.6	304	79.2	35	94.6
No Treatment	274	41.8	402	48.3	191	43.3	52	13.5	2	5.4
Total Patients	656	100.0	833	100.0	441	100.0	384	100.0	37	100.0

Table 8.6: Number(#) and Relative Proportion(%) of Mouth cancer patients according to Type of Treatment given (Patients treated only at Reporting Institution) (1999-2000)

Type of	Mur	nbai	Bangalore		Chennai		Thi'p	ouram	Dibrugarh	
Treatment	#	%	#	%	#	%	#	%	#	%
Total patients	820	100.0	175	100.0	219	100.0	555	100.0	73	100.0
Specific Treatments										
Surgery(S)	327	39.9	19	10.9	3	1.4	19	3.4	5	6.8
Radiotherapy(R)	63	7.7	76	43.4	171	78.1	336	60.5	59	80.8
Chemotherapy(C)	45	5.5	29	16.6	0	0.0	11	2.0	1	1.4
S+R	335	40.9	32	18.3	34	15.5	82	14.8	6	8.2
S + C	9	1.1	1	0.6	0	0.0	3	0.5	0	0.0
R + C	23	2.8	11	6.3	11	5.0	79	14.2	2	2.7
S + R + C	18	2.2	6	3.4	0	0.0	12	2.2	0	0.0
Others	0.0	0	1.0	0.6	0.0	0	13.0	2.3	0.0	0.0
Modality of therapy										
Single	435	53.0	124	70.9	174	79.5	366	65.9	65	89.0
Combination	385	47.0	50	28.6	45	20.5	176	31.7	8	11.0
Type of Any Treatment										
Any Surgery	689	84.0	58	33.1	37	16.9	116	20.9	11	15.1
Any R	439	53.5	125	71.4	216	98.6	509	91.7	67	91.8
Any C	95	11.6	47	26.9	11	5.0	105	18.9	3	4.1

Type of	Mur	nbai	Bang	alore	Che	nnai	Thi'p	ouram	Dibr	ugarh
Treatment	#	%	#	%	#	%	#	%	#	%
Total patients	328	100.0	410	100.0	201	100.0	304	100.0	35	100.0
Specific Treatments										
Surgery(S)	178	54.3	44	10.7	4	2.0	17	5.6	2	5.7
Radiotherapy(R)	7	2.1	108	26.3	170	84.6	193	63.5	27	77.1
Chemotherapy(C)	17	5.2	108	26.3	0	0.0	5	1.6	0	0.0
S+R	118	36.0	108	26.3	24	11.9	46	15.1	6	17.1
S + C	3	0.9	5	1.2	0	0.0	2	0.7	0	0.0
R + C	3	0.9	23	5.6	3	1.5	26	8.6	0	0.0
S + R + C	2	0.6	13	3.2	0	0.0	5	1.6	0	0.0
Others	0	0.0	1	0.2	0	0.0	10	3.3	0	0.0
Modality of therapy										
Single	202	61.6	260	63.4	174	86.6	215	70.7	29	82.9
Combination	126	38.4	149	36.3	27	13.4	79	26.0	6	17.1
Type of Any Treatment										
Any Surgery	301	91.8	170	41.5	28	13.9	70	23.0	8	22.9
Any R	130	39.6	252	61.5	197	98.0	270	88.8	33	94.3
Any C	25	7.6	149	36.3	3	1.5	38	12.5	0	0.0

Table 8.7(a): Number (#) & Relative Proportion (%) of types of treatment according to Clinical Extent of Disease - Mouth - Males (1999-2000)

Clinical Extent	Mur	nbai	Bang	alore	Che	nnai	Thi'p	uram	Dibr	ugarh
Clinical Extent	#	%	#	%	#	%	#	%	#	%
Localised										
Surgery(S)	145	64.4	8	40.0	3	6.7	5	7.0	1	7.7
Radiotherapy(R)	21	9.3	5	25.0	34	75.6	53	74.6	11	84.6
Chemotherapy(C)	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0
S + R	52	23.1	4	20.0	8	17.8	7	9.9	1	7.7
S + C	2	0.9	0	0.0	0	0.0	0	0.0	0	0.0
R + C	2	0.9	2	10.0	0	0.0	5	7.0	0	0.0
S + R + C	2	0.9	1	5.0	0	0.0	0	0.0	0	0.0
Others	0	0.0	0	0.0	0	0.0	1	1.4	0	0.0
ALL TREATMENTS	225	100.0	20	100.0	45	100.0	71	100.0	13	100.0
Regional										
Surgery(S)	180	31.3	10	6.7	0	0.0	14	2.9	3	5.4
Radiotherapy(R)	40	7.0	69	46.3	136	78.6	281	58.9	47	83.9
Chemotherapy(C)	35	6.1	26	17.4	0	0.0	10	2.1	0	0.0
S + R	281	48.9	28	18.8	26	15.0	75	15.7	4	7.1
S + C	6	1.0	1	0.7	0	0.0	2	0.4	0	0.0
R + C	17	3.0	9	6.0	11	6.4	73	15.3	2	3.6
S + R + C	16	2.8	5	3.4	0	0.0	11	2.3	0	0.0
Others	0	0.0	1	0.7	0	0.0	11	2.3	0	0.0
ALL TREATMENTS	575	100.0	149	100.0	173	100.0	477	100.0	56	100.0
Distant										
Surgery(S)	2	10.0	1	16.7	0	0.0	0	0.0	1	33.3
Radiotherapy(R)	2	10.0	2	33.3	1	100.0	2	28.6	1	33.3
Chemotherapy(C)	9	45.0	3	50.0	0	0.0	1	14.3	0	0.0
S + R	2	10.0	0	0.0	0	0.0	0	0.0	1	33.3
S + C	1	5.0	0	0.0	0	0.0	1	14.3	0	0.0
R + C	4	20.0	0	0.0	0	0.0	1	14.3	0	0.0
S + R + C	0	0.0	0	0.0	0	0.0	1	14.3	0	0.0
Others	0	0.0	0	0.0	0	0.0	1	14.3	0	0.0
ALL TREATMENTS	20	100.0	6	100.0	1	100.0	7	100.0	3	100.0

Table 8.7(b): Number (#) & Relative Proportion (%) of types of treatment according to Clinical Extent of Disease - Mouth - Females (1999-2000)

Clinical Extent	Mur	nbai	Bang	alore	Che	nnai	Thi'p	uram	Dibr	ugarh
Clinical Extent	#	%	#	%	#	%	#	%	#	%
Localised										
Surgery(S)	77	76.2	8	21.1	1	4.0	5	10.9	1	10.0
Radiotherapy(R)	2	2.0	13	34.2	18	72.0	34	73.9	8	80.0
Chemotherapy(C)	1	1.0	2	5.3	0	0.0	1	2.2	0	0.0
S + R	20	19.8	15	39.5	6	24.0	4	8.7	1	10.0
S + C	1	1.0	0	0.0	0	0.0	0	0.0	0	0.0
R + C	0	0.0	0	0.0	0	0.0	2	4.3	0	0.0
S + R + C	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Others	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
ALL TREATMENTS	101	100.0	38	100.0	25	100.0	46	100.0	10	100.0
Regional										
Surgery(S)	99	45.4	34	9.7	3	1.7	12	4.8	1	4.2
Radiotherapy(R)	3	1.4	91	26.1	152	86.4	156	62.2	18	75.0
Chemotherapy(C)	13	6.0	95	27.2	0	0.0	3	1.2	0	0.0
S + R	97	44.5	91	26.1	18	10.2	42	16.7	5	20.8
S + C	2	0.9	4	1.1	0	0.0	2	0.8	0	0.0
R + C	3	1.4	22	6.3	3	1.7	24	9.6	0	0.0
S + R + C	1	0.5	12	3.4	0	0.0	5	2.0	0	0.0
Others	0	0.0	0	0.0	0	0.0	7	2.8	0	0.0
ALL TREATMENTS	218	100.0	349	100.0	176	100.0	251	100.0	24	100.0
Distant										
Surgery(S)	2	22.2	2	9.5	0	0.0	0	0.0	0	0.0
Radiotherapy(R)	2	22.2	4	19.0	0	0.0	3	42.9	1	100.0
Chemotherapy(C)	3	33.3	11	52.4	0	0.0	1	14.3	0	0.0
S + R	1	11.1	1	4.8	0	0.0	0	0.0	0	0.0
S + C	0	0.0	1	4.8	0	0.0	0	0.0	0	0.0
R + C	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
S + R + C	1	11.1	1	4.8	0	0.0	0	0.0	0	0.0
Others	0	0.0	1	4.8	0	0.0	3	42.9	0	0.0
ALL TREATMENTS	9	100.0	21	100.0	0.001	0.0	7	100.0	1	100.0

Table 8.8a): Number (#) and Proportion (%) of any specific treatment relative to all treated patients according to Clinical Extent of Disease - Mouth - Males (1999-2000)

	Any Surgery		Any Rad	Any Radiotherapy		notherapy	Any Ot	hers	Total
	#	%	#	%	#	%	#	%	Patients
LOCALISED									
Mumbai	201	89.3	77	34.2	7	3.1	0	0.0	225
Bangalore	13	65.0	12	60.0	3	15.0	0	0.0	20
Chennai	11	24.4	42	93.3	0	0.0	0	0.0	45
Thi'puram	12	16.9	65	91.5	5	7.0	1	1.4	71
Dibrugarh	2	15.4	12	92.3	0	0.0	0	0.0	13
REGIONAL									
Mumbai	483	84.0	354	61.6	74	12.9	0	0.0	575
Bangalore	44	29.5	111	74.5	41	27.5	1	0.7	149
Chennai	26	15.0	173	100.0	11	6.4	0	0.0	173
Thi'puram	102	21.4	440	92.2	96	20.1	11	2.3	477
Dibrugarh	7	12.5	53	94.6	2	3.6	0	0.0	56
DISTANT									
Mumbai	5	25.0	8	40.0	14	70.0	0	0.0	20
Bangalore	1	16.7	2	33.3	3	50.0	0	0.0	6
Chennai	0	0.0	1	100.0	0	0.0	0	0.0	1
Thi'puram	2	28.6	4	57.1	4	57.1	1	14.3	7
Dibrugarh	2	66.7	2	66.7	0	0.0	0	0.0	3

Table 8.8(b): Number (#) and Proportion (%) of any specific treatment relative to all treated patients according to Clinical Extent of Disease - Mouth - Females (1999-2000)

	Any Su	ırgery	Any Radi	iotherapy	Any Cher	notherapy	Any Ot	hers	Total
	#	%	#	%	#	%	#	%	Patients
LOCALISED									
Mumbai	98	97.0	22	21.8	2	2.0	0	0.0	101
Bangalore	23	60.5	28	73.7	2	5.3	0	0.0	38
Chennai	7	28.0	24	96.0	0	0.0	0	0.0	25
Thi'puram	9	19.6	40	87.0	3	6.5	0	0.0	46
Dibrugarh	2	20.0	9	90.0	0	0.0	0	0.0	10
REGIONAL									
Mumbai	199	91.3	104	47.7	19	8.7	0	0.0	218
Bangalore	141	40.4	216	61.9	133	38.1	0	0.0	349
Chennai	21	11.9	173	98.3	3	1.7	0	0.0	176
Thi'puram	61	24.3	227	90.4	34	13.5	7	2.8	251
Dibrugarh	6	25.0	23	95.8	0	0.0	0	0.0	24
DISTANT									
Mumbai	4	44.4	4	44.4	4	44.4	0	0.0	9
Bangalore	5	23.8	6	28.6	13	61.9	1	4.8	21
Chennai	0	0.0	0	0.0	0	0.0	0	0.0	0
Thi'puram	0	0.0	3	42.9	1	14.3	3	42.9	7
Dibrugarh	0	0.0	1	100.0	0	0.0	0	0.0	1

# Chapter 9

# **TONGUE (ICD-10: C01-C02)**

The total number, relative proportion and rank of cancer of tongue in males and females for the years 1999 and 2000 is given in Table 9.1(a). Cancer of the tongue was among the five leading sites in all registries except Bangalore where it was the sixth leading site.

Table 9.1(b) gives the number and relative proportion of tongue cancer according to sub-site. Mumbai and Chennai show almost equal distribution of base tongue and rest of tongue cancers. Bangalore and Dibrugarh had a higher proportion of base tongue cancer, whereas Thiruvananthapuram had relatively lower proportion of base tongue cancer.

Figure 9.1 gives the trends in actual number of tongue cancers from 1984 to 2000. A significant increase in the numbers was seen in Chennai and Thiruvananthapuram and a decrease was seen in Dibrugarh.

Figure 9.2 and Table 9.2 show the distribution of tongue cancers by five year age group. The predominant form of diagnosis of tongue cancer was through microscopic examination (Table 9.3).

Tale 9.4 gives the distribution of tongue cancer according to the clinical extent of disease. The regional spread of the disease varied from 59.6% in Mumbai to 87.2% in Chennai.

Table 9.5 gives the relative proportion of tongue cancer according to the broad groups of treatment.

Tables 9.6, 9.7 and 9.8 give the picture of the different types of treatment given to these patients.

Table 9.1(a): Number(#), Relative Proportion(%) and Rank(R) of cancers of the Tongue - Males (1999-2000)

Registry	Total	#	%	R
Mumbai	17637	1236	7.0	3
Bangalore	6106	346	5.7	6
Chennai	6195	450	7.3	4
Thi'puram	7859	473	6.0	3
Dibrugarh	997	67	6.7	4

Table 9.1(b): Number(#) and Relative Proportion(%) of Tongue Cancer patients according to sub-site - Males (1999-2000)

	Mun	Mumbai		Bangalore		Chennai		Thi'puram		Dibrugarh	
	#	%	#	%	#	%	#	%	#	%	
Base of tongue	509	41.2	238	68.8	201	44.7	89	18.8	53	79.1	
Rest of tongue	604	48.9	31	9.0	227	50.4	233	49.3	8	11.9	
NOS	123	10.0	77	22.3	22	4.9	151	31.9	6	9.0	
Total tongue	1236	100.0	346	100.0	450	100.0	473	100.0	67	100.0	

Fig. 9.1: Trends in Actual Numbers - Tongue Cancer - Males




Fig. 9.2: Five year age group distribution - Tongue Cancer - Males (1999-2000)




Table 9.2: Number(#) and Relative Proportion(%) of Tongue cancer according to five year age group - Males (1999-2000)

					•	•				
Age Group	Mum	nbai	Banga	alore	Cher	ınai	Thi	'puram	Dib	rugarh
rigo ai oup	#	%	#	%	#	%	#	%	#	%
0-4	0	0.0	0	0.0	0	0.0	0	0.0	1.0	1.5
5- 9	0	0.0	0	0.0	1	0.2	0	0.0	0.0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0.0
15-19	2	0.2	1	0.3	1	0.2	0	0.0	0.0	0.0
20-24	7	0.6	1	0.3	1	0.2	3	0.6	0.0	0.0
25-29	30	2.4	1	0.3	8	1.8	4	0.8	1.0	1.5
30-34	44	3.6	6	1.7	7	1.6	4	0.8	1.0	1.5
35-39	94	7.6	11	3.2	24	5.3	19	4.0	7.0	10.4
40-44	142	11.5	20	5.8	27	6.0	34	7.2	2.0	3.0
45-49	177	14.3	38	11.0	47	10.4	67	14.2	8.0	11.9
50-54	178	14.4	47	13.6	86	19.1	73	15.4	9.0	13.4
55-59	186	15.0	47	13.6	67	14.9	65	13.7	8.0	11.9
60-64	138	11.2	68	19.7	72	16.0	69	14.6	13.0	19.4
65-69	123	10.0	44	12.7	53	11.8	56	11.8	8.0	11.9
70-74	72	5.8	27	7.8	27	6.0	35	7.4	8.0	11.9
75+	43	3.5	35	10.1	29	6.4	44	9.3	1.0	1.5
ANS	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0.0
All Ages	1236	100.0	346	100.0	450	100.0	473	100.0	67	100.0
Mean	52.3		57.4		55.3		57.0		54.1	
SD	12.27		11.88		12.05		12.14		13.44	

Table 9.3: Number(#) and Relative Proportion(%) of Tongue cancers based on different methods of diagnosis - Males (1999-2000)

Registry	Micros	copic	Clir	nical	<b>X</b> -	ray	Oth	ers	To	tal
,	#	%	#	%	#	%	#	%	#	%
Mumbai	1155	93.4	1	0.1	0	0.0	80	6.5	1236	100.0
Bangalore	327	94.5	10	2.9	0	0.0	9	2.6	346	100.0
Chennai	290	64.4	160	35.6	0	0.0	0	0.0	450	100.0
Thi'puram	455	96.2	17	3.6	0	0.0	1	0.2	473	100.0
Dibrugarh	66	98.5	0	0.0	0	0.0	1	1.5	67	100.0

Table 9.4: Number(#) and Relative Proportion(%) of Tongue cancer patients according to the clinical extent of disease (Excludes Patients Previously Treated) (1999-2000)

	Localis	ed (L)	Region	al (R)	L+	- R	Distant Others		All St	tages		
Registry	#	%	#	%	#	%	#	%	#	%	#	%
Mumbai	365	35.0	621	59.6	986	94.6	56	5.4	0	0.0	1042	100.0
Bangalore	29	8.8	268	81.5	297	90.3	29	8.8	3	0.9	329	100.0
Chennai	47	12.3	334	87.2	381	99.5	2	0.5	0	0.0	383	100.0
Thi'puram	74	17.4	332	78.1	406	95.5	19	4.5	0	0.0	425	100.0
Dibrugarh	8	12.1	57	86.4	65	98.5	0	0.0	1	1.5	66	100.0

Table 9.5: Number(#) and Relative Proportion(%) of Tongue cancer patients according to Broad Groups of Treatment(Tmt) - Males (1999-2000)

Treatment Group	Mun	nbai	Bang	jalore	Che	nnai	Thi	'puram	Dibrugarh	
ireatinent droup	#	%	#	%	#	%	#	%	#	%
Prior Tmt. Only	133	10.8	14	4.0	62	13.8	15	3.2	0	0.0
Prior & Tmt. at RI	61	4.9	3	0.9	5	1.1	33	7.0	1	1.5
Tmt. Only at RI	491	39.7	155	44.8	179	39.8	345	72.9	63	94.0
No Treatment	551	44.6	174	50.3	204	45.3	80	16.9	3	4.5
<b>Total Patients</b>	1236	100.0	346	100.0	450	100.0	473	100.0	67	100.0

Table 9.6: Number(#) and Relative Proportion(%) of Tongue cancer patients according to Type of Treatment given (Patients treated only at Reporting Institution) - Males (1999-2000)

Type of	Mur	nbai	Bang	alore	Che	nnai	Thi'p	ouram	Dibr	ugarh
Treatment	#	%	#	%	#	%	#	%	#	%
<b>Total patients</b>	491	100.0	155	100.0	179	100.0	345	100.0	63	100.0
Specific Treatments										
Surgery(S)	176	35.8	14	9.0	0	0.0	36	10.4	0	0.0
Radiotherapy(R)	136	27.7	102	65.8	142	79.3	115	33.3	58	92.1
Chemotherapy(C)	19	3.9	5	3.2	0	0.0	38	11.0	1	1.6
S + R	110	22.4	18	11.6	32	17.9	58	16.8	1	1.6
S + C	1	0.2	1	0.6	0	0.0	4	1.2	0	0.0
R + C	40	8.1	13	8.4	4	2.2	71	20.6	3	4.8
S + R + C	9	1.8	1	0.6	1	0.6	18	5.2	0	0.0
Others	0	0.0	1	0.6	0	0.0	5	1.4	0	0.0
Modality of therapy										
Single	331	67.4	121	78.1	142	79.3	189	54.8	59	93.7
Combination	160	32.6	33	21.3	37	20.7	151	43.8	4	6.3
Type of Any Treatment										
Any Surgery	296	60.3	34	21.9	33	18.4	116	33.6	1	1.6
Any R	295	60.1	134	86.5	179	100.0	262	75.9	62	98.4
Any C	69	14.1	20	12.9	5	2.8	131	38.0	4	6.3

Table 9.7: Number (#) & Relative Proportion (%) of types of treatment according to Clinical Extent of Disease - Tongue - Males (1999-2000)

Olivia al Fata et	Mur	nbai	Bang	alore	Che	nnai	Thi'p	uram	Dibr	ugarh
Clinical Extent	#	%	#	%	#	%	#	%	#	%
Localised										
Surgery(S)	116	64.1	7	50.0	0	0.0	18	25.7	0	0.0
Radiotherapy(R)	29	16.0	5	35.7	26	66.7	27	38.6	5	71.4
Chemotherapy(C)	0	0.0	0	0.0	0	0.0	2	2.9	0	0.0
S + R	29	16.0	2	14.3	13	33.3	12	17.1	1	14.3
S + C	1	0.6	0	0.0	0	0.0	1	1.4	0	0.0
R + C	4	2.2	0	0.0	0	0.0	10	14.3	1	14.3
S + R + C	2	1.1	0	0.0	0	0.0	0	0.0	0	0.0
Others	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
ALL TREATMENTS	181	100.0	14	100.0	39	100.0	70	100.0	7	100.0
Regional										
Surgery(S)	60	20.1	6	4.5	0	0.0	18	6.8	0	0.0
Radiotherapy(R)	102	34.2	93	69.4	116	82.9	86	32.6	53	96.4
Chemotherapy(C)	15	5.0	4	3.0	0	0.0	32	12.1	0	0.0
S + R	81	27.2	16	11.9	19	13.6	46	17.4	0	0.0
S + C	0	0.0	1	0.7	0	0.0	3	1.1	0	0.0
R + C	33	11.1	12	9.0	4	2.9	58	22.0	2	3.6
S + R + C	7	2.3	1	0.7	1	0.7	18	6.8	0	0.0
Others	0	0.0	1	0.7	0	0.0	3	1.1	0	0.0
ALL TREATMENTS	298	100.0	134	100.0	140	100.0	264	100.0	55	100.0
Distant										
Surgery(S)	0	0.0	1	16.7	0	0.0	0	0.0	0	0.0
Radiotherapy(R)	5	41.7	3	50.0	0	0.0	2	18.2	0	0.0
Chemotherapy(C)	4	33.3	1	16.7	0	0.0	4	36.4	0	0.0
S + R	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
S + C	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
R + C	3	25.0	1	16.7	0	0.0	3	27.3	0	0.0
S + R + C	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Others	0	0.0	0	0.0	0	0.0	2	18.2	0	0.0
ALL TREATMENTS	12	100.0	6	100.0	0.001	0.0	11	100.0	0.001	0.0

Table 9.8: Number (#) and Proportion (%) of any specific treatment relative to all treated patients according to Clinical Extent of Disease - Tongue - Males (1999-2000)

	Any Su	ırgery	Any Rad	iotherapy	Any Cher	notherapy	Any Ot	hers	Total
	#	%	#	%	#	%	#	%	Patients
LOCALISED									
Mumbai	148	81.8	64	35.4	7	3.9	0	0.0	181
Bangalore	9	64.3	7	50.0	0	0.0	0	0.0	14
Chennai	13	33.3	39	100.0	0	0.0	0	0.0	39
Thi <sup>'</sup> puram	31	44.3	49	70.0	13	18.6	0	0.0	70
Dibrugarh	1	14.3	7	100.0	1	14.3	0	0.0	7
REGIONAL									
Mumbai	148	49.7	223	74.8	55	18.5	0	0.0	298
Bangalore	24	17.9	122	91.0	18	13.4	1	0.7	134
Chennai	20	14.3	140	100.0	5	3.6	0	0.0	140
Thi'puram	85	32.2	209	79.2	111	42.0	3	1.1	264
Dibrugarh	0	0.0	55	100.0	2	3.6	0	0.0	55
DISTANT									
Mumbai	0	0.0	8	66.7	7	58.3	0	0.0	12
Bangalore	1	16.7	4	66.7	2	33.3	0	0.0	6
Chennai	0	0.0	0	0.0	0	0.0	0	0.0	0
Thi'puram	0	0.0	5	45.5	7	63.6	2	18.2	11
Dibrugarh	0	0.0	0	0.0	0	0.0	0	0.0	0

# Chapter 10

# **OESOPHAGUS (ICD-10: C15)**

The total number, relative proportion and rank of cancer of oesophagus in males and females for the years 1999 and 2000 is given in Table 10.1(a). Cancer of the oesophagus ranked as the leading site in Bangalore and was among the first five leading sites in all registries in both sexes, except in females in Thiruvananthapuram.

The sub-site distribution of oesophageal cancer is depicted in Table 10.1(b). All registries in both sexes had a lower proportion of cancers of the oesophagus in the upper third. In females the highest relative proportion was the middle third of the oesophagus, in all registries.

Figure 10.1 gives the trends in the actual number of oesophageal cancers in both males and females from 1984 to 2000. A significant increase in the numbers was observed in males and females in Thiruvananthapuram and in females in Chennai. A decline was seen in males and females in Dibrugarh.

Table 10.2 and Figure 10.2 give the distribution of cancer of oesophagus according to five year age group. In both males & females the mean age was higher in Thiruvananthapuram.

The predominant form of diagnosis was through microscopic examination (Table 10.3) though the category "others" which represents endoscopic diagnosis also showed a suggestive proportion.

Table 10.4 gives the distribution of cancers according to the clinical extent of disease.

Table 10.5 gives the number and relative proportion according to the broad groups of treatment. Tables 10.6 to 10.8 give the number and relative proportion according to the different types of treatment.

Table 10.1(a): Number(#), Relative Proportion(%) and Rank (R) of cancer of the Oesophagus (1999-2000)


Registry		Males				Females		
	Total	#	%	R	Total	#	%	R
Mumbai	17637	998	5.7	4	13679	505	3.7	5
Bangalore	6106	587	9.6	1	7543	467	6.2	4
Chennai	6195	478	7.7	3	7139	263	3.7	4
Thi'puram	7859	412	5.2	5	7247	109	1.5	>10
Dibrugarh	997	147	14.7	2	536	68	12.7	2

Table 10.1(b): Cancer of Oesophagus - Number(#) and Relative Proportion(%) according to sub-site (1999-2000)

	Mun	nbai	Bang	jalore	Cher	nnai	Thi'p	ouram	Dibr	ugarh
	#	%	#	%	#	%	#	%	#	%
MALES										
Cervical-upper 3rd	134	13.4	48	8.2	67	14.0	50	12.2	14	9.5
Thoracic-middle 3rd	388	38.9	224	38.4	155	32.4	143	34.8	61	41.5
Abdominal-lower 3rd	303	30.4	129	22.1	158	33.1	134	32.6	42	28.6
Overlap of subsite	0	0.0	15	2.6	38	7.9	4	1.0	2	1.4
NOS	173	17.3	167	28.6	60	12.6	80	19.5	28	19.0
Total Oesophagus	998	100.0	583	100.0	478	100.0	411	100.0	147	100.0
FEMALES										
Cervical-upper 3rd	67	13.3	46	9.9	26	9.9	11	10.1	7	10.3
Thoracic-middle 3rd	206	40.8	209	44.8	98	37.3	44	40.4	38	55.9
Abdominal-lower 3rd	144	28.5	75	16.1	91	34.6	26	23.9	20	29.4
Overlap of subsite	0	0.0	15	3.2	26	9.9	5	4.6	0	0.0
NOS*	88	17.4	122	26.1	22	8.4	23	21.1	3	4.4
Total Oesophagus	505	100.0	467	100.0	263	100.0	109	100.0	68	100.0

<sup>\*</sup> NOS - Not otherwise specified

Fig. 10.1: Trends in Actual Numbers - Oesophageal Cancer







Table 10.2: Number(#) and Relative Proportion(%) of oesophageal cancers according to five year age group (1999-2000)

Age Group	Mum	ıbai	Banga	alore	Cher	nai	Thi	puram	Dib	rugarh
rigo aroup	#	%	#	%	#	%	#	%	#	%
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5- 9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0
20-24	1	0.1	1	0.2	2	0.4	0	0.0	0	0.0
25-29	6	0.6	1	0.2	2	0.4	1	0.2	0	0.0
30-34	18	1.8	9	1.5	11	2.3	2	0.5	5	3.4
35-39	36	3.6	15	2.6	18	3.8	9	2.2	7	4.8
40-44	63	6.3	32	5.5	36	7.5	16	3.9	12	8.2
45-49	97	9.7	63	10.7	44	9.2	35	8.5	20	13.6
50-54	156	15.6	84	14.3	80	16.7	54	13.1	19	12.9
55-59	153	15.3	93	15.8	88	18.4	68	16.5	19	12.9
60-64	151	15.1	105	17.9	66	13.8	68	16.5	31	21.1
65-69	154	15.4	79	13.5	66	13.8	81	19.7	13	8.8
70-74	87	8.7	64	10.9	35	7.3	48	11.7	13	8.8
75 <b>+</b>	76	7.6	40	6.8	30	6.3	30	7.3	8	5.4
ANS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
All Ages	998	100.0	587	100.0	478	100.0	412	100.0	147	100.0
Mean	57.6		57.6		56.5		60.0		55.3	
SD	11.45		11.06		11.48		10.34		11.94	

Age Group	Mun	nbai	Banga	alore	Cher	ınai	Thi	'puram	Dib	rugarh
Age Group	#	%	#	%	#	%	#	%	#	%
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5- 9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	3	0.6	1	0.2	2	0.8	0	0.0	0	0.0
25-29	0	0.0	2	0.4	2	0.8	1	0.9	1	1.5
30-34	8	1.6	2	0.4	5	1.9	2	1.8	1	1.5
35-39	25	5.0	23	4.9	12	4.6	2	1.8	8	11.8
40-44	31	6.1	31	6.6	15	5.7	5	4.6	5	7.4
45-49	73	14.5	63	13.5	44	16.7	9	8.3	9	13.2
50-54	78	15.4	77	16.5	36	13.7	10	9.2	10	14.7
55-59	70	13.9	50	10.7	38	14.4	19	17.4	18	26.5
60-64	93	18.4	80	17.1	42	16.0	16	14.7	5	7.4
65-69	64	12.7	63	13.5	30	11.4	28	25.7	4	5.9
70-74	31	6.1	48	10.3	21	8.0	6	5.5	4	5.9
75 <b>+</b>	29	5.7	27	5.8	16	6.1	11	10.1	3	4.4
ANS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
All Ages	505	100.0	467	100.0	263	100.0	109	100.0	68	100.0
Mean	55.7		56.1		55.4		59.3		52.4	•
SD	11.27		11.40		11.86		11.33		11.45	

Fig. 10.2: Five year age group distribution - Oesophageal Cancer (1999-2000)






Table 10.3: Number(#) and Relative Proportion(%) of Oesophageal cancers based on different methods of diagnosis (1999-2000)

	Micros	scopic	Clin	ical	X-r	ay	Oth	ers	Tot	tal
Registry	#	%	#	%	#	%	#	%	#	%
Males										
Mumbai	911	91.3	2	0.2	1	0.1	84	8.4	998	100.0
Bangalore	565	96.3	6	1.0	0	0.0	16	2.7	587	100.0
Chennai	387	81.0	30	6.3	2	0.4	59	12.3	478	100.0
Thi'puram	389	94.4	4	1.0	6	1.5	13	3.2	412	100.0
Dibrugarh	133	90.5	2	1.4	10	6.8	2	1.4	147	100.0
Females										
Mumbai	469	92.9	0	0.0	0	0.0	36	7.1	505	100.0
Bangalore	454	97.2	3	0.6	1	0.2	9	1.9	467	100.0
Chennai	223	84.8	13	4.9	1	0.4	26	9.9	263	100.0
Thi'puram	103	94.5	0	0.0	1	0.9	5	4.6	109	100.0
Dibrugarh	59	86.8	0	0.0	7	10.3	2	2.9	68	100.0

Table 10.4: Number(#) and Relative Proportion(%) of oesophageal cancer patients according to the clinical extent of disease (Excludes Patients Previously Treated) (1999-2000)

Destates	Localise	ed (L)	Regiona	al (R)	L+	R	Dista	nt	Othe	rs	All St	ages
Registry	#	%	#	%	#	%	#	%	#	%	#	%
Males												
Mumbai	630	67.7	114	12.2	744	79.9	187	20.1	0	0.0	931	100.0
Bangalore	54	9.4	433	75.6	487	85.0	66	11.5	20	3.5	573	100.0
Chennai	0	0.0	319	72.0	319	72.0	124	28.0	0	0.0	443	100.0
Thi'puram	104	26.7	242	62.2	346	88.9	43	11.1	0	0.0	389	100.0
Dibrugarh	20	14.1	95	66.9	115	81.0	7	4.9	20	14.1	142	100.0
Females												
Mumbai	349	74.3	51	10.9	400	85.1	70	14.9	0	0.0	470	100.0
Bangalore	61	13.4	333	73.2	394	86.6	42	9.2	19	4.2	455	100.0
Chennai	1	0.4	181	77.0	182	77.4	53	22.6	0	0.0	235	100.0
Thi'puram	30	29.1	63	61.2	93	90.3	10	9.7	0	0.0	103	100.0
Dibrugarh	11	16.2	41	60.3	52	76.5	6	8.8	10	14.7	68	100.0

Table 10.5: Number(#) and Relative Proportion(%) of oesophageal cancer patients according to Broad Groups of Treatment(Tmt) (1999-2000)

Treatment Group	Mur	Mumbai		Bangalore		Chennai		uram	Dibrugarh	
·	#	%	#	%	#	%	#	%	#	%
MALES										
Prior Tmt. Only	47	4.7	12	2.0	35	7.3	11	2.7	0	0.0
Prior & Tmt. at RI	20	2.0	2	0.3	0	0.0	12	2.9	5	3.4
Tmt. Only at RI	384	38.5	217	37.0	93	19.5	292	70.9	126	85.7
No Treatment	547	54.8	356	60.6	350	73.2	97	23.5	16	10.9
Total Patients	998	100.0	587	100.0	478	100.0	412	100.0	147	100.0
FEMALES										
Prior Tmt. Only	21	4.2	10	2.1	27	10.3	2	1.8	0	0.0
Prior & Tmt. at RI	14	2.8	2	0.4	1	0.4	4	3.7	0	0.0
Tmt. Only at RI	192	38.0	227	48.6	60	22.8	86	78.9	57	83.8
No Treatment	278	55.0	228	48.8	175	66.5	17	15.6	11	16.2
Total Patients	505	100.0	467	100.0	263	100.0	109	100.0	68	100.0

Table 10.6: Number(#) and Relative Proportion(%) of Oesophageal Cancer patients according to Type of Treatment given(Patients treated only at Reporting Institution) (1999-2000)

Type of	Mumbai		Bangalore		Chennai		Thi'puram		Dibrugarh	
Treatment	#	%	#	%	#	%	#	%	#	%
Total patients	384	100.0	217	100.0	93	100.0	292	100.0	126	100.0
Specific Treatments										
Surgery(S)	149	38.8	47	21.7	25	26.9	2	0.7	1	0.8
Radiotherapy(R)	68	17.7	123	56.7	55	59.1	205	70.2	121	96.0
Chemotherapy(C)	56	14.6	5	2.3	0	0.0	19	6.5	4	3.2
S + R	3	0.8	17	7.8	1	1.1	1	0.3	0	0.0
S + C	35	9.1	7	3.2	0	0.0	3	1.0	0	0.0
R + C	66	17.2	15	6.9	12	12.9	50	17.1	0	0.0
S + R + C	7	1.8	3	1.4	0	0.0	1	0.3	0	0.0
Others	0.0	0	0.0	0.0	0.0	0	11.0	3.8	0.0	0.0
Modality of therapy										
Single	273	71.1	175	80.6	80	86.0	226	77.4	126	100.0
Combination	111	28.9	42	19.4	13	14.0	55	18.8	0	0.0
Type of Any Treatment										
Any Surgery	194	50.5	74	34.1	26	28.0	7	2.4	1	0.8
Any R	144	37.5	158	72.8	68	73.1	257	88.0	121	96.0
Any C	164	42.7	30	13.8	12	12.9	73	25.0	4	3.2

Type of	Mumbai		Bangalore		Chennai		Thi'puram		Dibrugarh	
Treatment	#	%	#	%	#	%	#	%	#	%
Total patients	192	100.0	227	100.0	60	100.0	86	100.0	57	100.0
Specific Treatments										
Surgery(S)	85	44.3	28	12.3	11	18.3	0	0.0	0	0.0
Radiotherapy(R)	31	16.1	156	68.7	42	70.0	60	69.8	55	96.5
Chemotherapy(C)	29	15.1	3	1.3	0	0.0	5	5.8	2	3.5
S + R	3	1.6	9	4.0	0	0.0	0	0.0	0	0.0
S + C	9	4.7	8	3.5	0	0.0	0	0.0	0	0.0
R + C	31	16.1	20	8.8	7	11.7	19	22.1	0	0.0
S + R + C	4	2.1	2	0.9	0	0.0	1	1.2	0	0.0
Others	0	0.0	1	0.4	0	0.0	1	1.2	0	0.0
Modality of therapy										
Single	145	75.5	187	82.4	53	88.3	65	75.6	57	100.0
Combination	47	24.5	39	17.2	7	11.7	20	23.3	0	0.0
Type of Any Treatment										
Any Surgery	101	52.6	47	20.7	11	18.3	1	1.2	0	0.0
Any R	69	35.9	187	82.4	49	81.7	80	93.0	55	96.5
Any C	73	38.0	33	14.5	7	11.7	25	29.1	2	3.5

Table 10.7(a): Number (#) & Relative Proportion (%) of types of treatment according to Clinical Extent of Disease - Oesophagus - Males (1999-2000)

Clinical Extent	Mur	nbai	Bangalore		Chennai		Thi'puram		Dibrugarh	
	#	%	#	%	#	%	#	%	#	%
Localised										
Surgery(S)	127	46.2	4	18.2	0	0.0	1	1.3	0	0.0
Radiotherapy(R)	49	17.8	14	63.6	0	0.0	54	69.2	20	100.0
Chemotherapy(C)	25	9.1	0	0.0	0	0.0	1	1.3	0	0.0
S + R	3	1.1	1	4.5	0	0.0	0	0.0	0	0.0
S + C	23	8.4	0	0.0	0	0.0	2	2.6	0	0.0
R + C	45	16.4	3	13.6	0	0.0	19	24.4	0	0.0
S + R + C	3	1.1	0	0.0	0	0.0	0	0.0	0	0.0
Others	0	0.0	0	0.0	0	0.0	1	1.3	0	0.0
ALL TREATMENTS	275	100.0	22	100.0	0.001	0.0	78	100.0	20	100.0
Regional										
Surgery(S)	15	27.3	39	21.5	25	27.8	1	0.5	0	0.0
Radiotherapy(R)	6	10.9	99	54.7	52	57.8	135	73.4	84	100.0
Chemotherapy(C)	10	18.2	5	2.8	0	0.0	16	8.7	0	0.0
S + R	0	0.0	16	8.8	1	1.1	1	0.5	0	0.0
S + C	9	16.4	7	3.9	0	0.0	1	0.5	0	0.0
R + C	12	21.8	12	6.6	12	13.3	24	13.0	0	0.0
S + R + C	3	5.5	3	1.7	0	0.0	0	0.0	0	0.0
Others	0	0.0	0	0.0	0	0.0	6	3.3	0	0.0
ALL TREATMENTS	55	100.0	181	100.0	90	100.0	184	100.0	84	100.0
Distant										
Surgery(S)	149	38.8	47	21.8	25	26.9	2	0.7	1	0.9
Radiotherapy(R)	68	17.7	122	56.5	55	59.1	205	70.2	106	96.4
Chemotherapy(C)	56	14.6	5	2.3	0	0.0	19	6.5	3	2.7
S + R	3	0.8	17	7.9	1	1.1	1	0.3	0	0.0
S + C	35	9.1	7	3.2	0	0.0	3	1.0	0	0.0
R + C	66	17.2	15	6.9	12	12.9	50	17.1	0	0.0
S + R + C	7	1.8	3	1.4	0	0.0	1	0.3	0	0.0
Others	0	0.0	0	0.0	0	0.0	11	3.8	0	0.0
ALL TREATMENTS	384	100.0	216	100.0	93	100.0	292	100.0	110	100.0

Table 10.7(b): Number (#) & Relative Proportion (%) of types of treatment according to Clinical Extent of Disease - Oesophagus - Females (1999-2000)

Oliminal Francis	Mur	nbai	Bangalore		Chennai		Thi'puram		Dibrugarh	
Clinical Extent	#	%	#	%	#	%	#	%	#	%
Localised										
Surgery(S)	71	46.1	2	7.1	0	0.0	0	0.0	0	0.0
Radiotherapy(R)	26	16.9	23	82.1	0	0.0	17	65.4	10	100.0
Chemotherapy(C)	20	13.0	0	0.0	0	0.0	0	0.0	0	0.0
S + R	2	1.3	1	3.6	0	0.0	0	0.0	0	0.0
S + C	8	5.2	1	3.6	0	0.0	0	0.0	0	0.0
R + C	23	14.9	1	3.6	0	0.0	8	30.8	0	0.0
S + R + C	4	2.6	0	0.0	0	0.0	1	3.8	0	0.0
Others	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
ALL TREATMENTS	154	100.0	28	100.0	0.001	0.0	26	100.0	10	100.0
Regional										
Surgery(S)	13	59.1	24	13.3	11	19.3	0	0.0	0	0.0
Radiotherapy(R)	2	9.1	122	67.8	39	68.4	38	73.1	40	100.0
Chemotherapy(C)	2	9.1	2	1.1	0	0.0	4	7.7	0	0.0
S + R	0	0.0	7	3.9	0	0.0	0	0.0	0	0.0
S + C	1	4.5	6	3.3	0	0.0	0	0.0	0	0.0
R + C	4	18.2	16	8.9	7	12.3	9	17.3	0	0.0
S + R + C	0	0.0	2	1.1	0	0.0	0	0.0	0	0.0
Others	0	0.0	1	0.6	0	0.0	1	1.9	0	0.0
ALL TREATMENTS	22	100.0	180	100.0	57	100.0	52	100.0	40	100.0
Distant										
Surgery(S)	1	6.3	2	11.8	0	0.0	0	0.0	0	0.0
Radiotherapy(R)	3	18.8	11	64.7	3	100.0	5	62.5	1	50.0
Chemotherapy(C)	7	43.8	1	5.9	0	0.0	1	12.5	1	50.0
S + R	1	6.3	1	5.9	0	0.0	0	0.0	0	0.0
S + C	0	0.0	1	5.9	0	0.0	0	0.0	0	0.0
R + C	4	25.0	1	5.9	0	0.0	2	25.0	0	0.0
S + R + C	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Others	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
ALL TREATMENTS	16	100.0	17	100.0	3	100.0	8	100.0	2	100.0

Table 10.8(a): Number (#) and Proportion (%) of any specific treatment relative to all treated patients according to Clinical Extent of Disease - Oesophagus - Males (1999-2000)

	Any Surgery		Any Radi	iotherapy	Any Chen	notherapy	Any Ot	hers	Total
	#	%	#	%	#	%	#	%	Patients
LOCALISED									
Mumbai	156	56.7	100	36.4	96	34.9	0	0.0	275
Bangalore	5	22.7	18	81.8	3	13.6	0	0.0	22
Chennai	0	0.0	0	0.0	0	0.0	0	0.0	0
Thi'puram	3	3.8	73	93.6	22	28.2	1	1.3	78
Dibrugarh	0	0.0	20	100.0	0	0.0	0	0.0	20
REGIONAL									
Mumbai	27	49.1	21	38.2	34	61.8	0	0.0	55
Bangalore	65	35.9	130	71.8	27	14.9	0	0.0	181
Chennai	26	28.9	65	72.2	12	13.3	0	0.0	90
Thi'puram	3	1.6	160	87.0	41	22.3	6	3.3	184
Dibrugarh	0	0.0	84	100.0	0	0.0	0	0.0	84
DISTANT									
Mumbai	11	20.4	23	42.6	34	63.0	0	0.0	54
Bangalore	4	30.8	9	69.2	0	0.0	0	0.0	13
Chennai	0	0.0	3	100.0	0	0.0	0	0.0	3
Thi'puram	1	3.3	24	80.0	10	33.3	4	13.3	30
Dibrugarh	1	16.7	2	33.3	3	50.0	0	0.0	6

Table 10.8(b): Number (#) and Proportion (%) of any specific treatment relative to all treated patients according to Clinical Extent of Disease - Oesophagus - Females (1999-2000)

	Any Su	ırgery	Any Radi	iotherapy	Any Chen	notherapy	Any Ot	hers	Total
	#	%	#	%	#	%	#	%	Patients
LOCALISED									
Mumbai	85	55.2	55	35.7	55	35.7	0	0.0	154
Bangalore	4	14.3	25	89.3	2	7.1	0	0.0	28
Chennai	0	0.0	0	0.0	0	0.0	0	0.0	0
Thi'puram	1	3.8	26	100.0	9	34.6	0	0.0	26
Dibrugarh	0	0.0	10	100.0	0	0.0	0	0.0	10
REGIONAL									
Mumbai	14	63.6	6	27.3	7	31.8	0	0.0	22
Bangalore	39	21.7	147	81.7	27	15.0	1	0.6	180
Chennai	11	19.3	46	80.7	7	12.3	0	0.0	57
Thi'puram	0	0.0	47	90.4	13	25.0	1	1.9	52
Dibrugarh	0	0.0	40	100.0	0	0.0	0	0.0	40
DISTANT									
Mumbai	2	12.5	8	50.0	11	68.8	0	0.0	16
Bangalore	4	23.5	13	76.5	3	17.6	0	0.0	17
Chennai	0	0.0	3	100.0	0	0.0	0	0.0	3
Thi'puram	0	0.0	7	87.5	3	37.5	0	0.0	8
Dibrugarh	0	0.0	1	50.0	1	50.0	0	0.0	2

# **LUNG (ICD-10: C33-C34)**

Cancer of the lung in males was the leading site of cancer in Thiruvananthapuram accounting for 13.2% of all cancers in males (Table 11.1).

Figure 11.1 gives the trends in actual numbers of lung cancers from 1984 to 2000. A significant increase was seen in Mumbai, Chennai and Thiruvananthapuram, whereas a decline was seen in Bangalore and Dibrugarh.

Table 11.2 and Figure 11.2 give the five year age distribution of lung cancers. The mean age varied from 56.6 in Chennai to 59.7 in Thiruvananthapuram.

Table 11.3 gives the number and relative proportion according to the different methods of diagnosis.

The number and relative proportion of lung cancers according to the clinical extent of disease is given in Table 11.4.

Table 11.5 gives the number and relative proportion according to the broad groups of treatment.

Tables 11.6 to 11.8 give the number and relative proportion according to different types of treatment.

Table 11.1: Number(#), Relative Proportion(%) and Rank(R) of cancers of the Lung - Males (1999-2000)

Registry	Total	#	%	R
Mumbai	17637	1253	7.1	2
Bangalore	6106	432	7.1	3
Chennai	6195	378	6.1	6
Thi'puram	7859	1041	13.2	1
Dibrugarh	997	46	4.6	6

Fig. 11.1: Trends in Actual Numbers - Lung Cancer - Males




Table 11.2: Number(#) and Relative Proportion(%) of Lung cancers according to five year age group - Males (1999-2000)

Age Group	Mum	ıbai	Banga	alore	Cher	ınai	Thi	puram	Dibı	rugarh
Age Group	#	%	#	%	#	%	#	%	#	%
0-4	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0
5- 9	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	2	0.2	1	0.2	0	0.0	0	0.0	0	0.0
20-24	3	0.2	1	0.2	0	0.0	0	0.0	1	2.2
25-29	10	0.8	4	0.9	1	0.3	1	0.1	0	0.0
30-34	21	1.7	5	1.2	4	1.1	8	0.8	0	0.0
35-39	48	3.8	10	2.3	11	2.9	19	1.8	0	0.0
40-44	92	7.3	21	4.9	16	4.2	42	4.0	4	8.7
45-49	110	8.8	45	10.4	52	13.8	103	9.9	2	4.3
50-54	171	13.6	58	13.4	61	16.1	123	11.8	8	17.4
55-59	225	18.0	78	18.1	77	20.4	191	18.3	9	19.6
60-64	190	15.2	81	18.8	65	17.2	183	17.6	7	15.2
65-69	207	16.5	57	13.2	59	15.6	188	18.1	6	13.0
70-74	109	8.7	38	8.8	20	5.3	107	10.3	6	13.0
75+	64	5.1	32	7.4	12	3.2	76	7.3	3	6.5
ANS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
All Ages	1253	100.0	432	100.0	378	100.0	1041	100.0	46	100.0
Mean	57.1		57.4		56.6		59.7		57.5	
SD	11.46		11.39		9.61		10.25		11.21	

Fig. 11.2: Five year age group distribution - Lung Cancer - Males (1999-2000)




Table 11.3: Number(#) and Relative Proportion(%) of Lung cancers based on different methods of diagnosis - Males (1999-2000)

Registry	Micros	scopic	Clir	ical	X-	ray	Oth	iers	Total	
Ticgioti y	#	%	#	%	#	%	#	%	#	%
Mumbai	1141	91.1	4	0.3	3	0.2	105	8.4	1253	100.0
Bangalore	385	89.1	15	3.5	9	2.1	23	5.3	432	100.0
Chennai	253	66.9	16	4.2	75	19.8	34	9.0	378	100.0
Thi'puram	855	82.1	1	0.1	79	7.6	106	10.2	1041	100.0
Dibrugarh	41	89.1	0	0.0	3	6.5	2	4.3	46	100.0

Table 11.4: Number(#) and Relative Proportion(%) of Lung cancer patients according to the clinical extent of disease (Excludes Patients Previously Treated) (1999-2000)

Davistor	Localise	ed (L)	Regional (R)		L + R		Distant		Others		All Stages	
Registry	#	%	#	%	#	%	#	%	#	%	#	%
Mumbai	466	40.0	49	4.2	515	44.2	649	55.7	1	0.1	1165	100.0
Bangalore	17	4.3	214	53.9	231	58.2	154	38.8	12	3.0	397	100.0
Chennai	0	0.0	249	73.0	249	73.0	92	27.0	0	0.0	341	100.0
Thi <sup>'</sup> puram	120	12.3	361	36.9	481	49.1	498	50.9	0	0.0	979	100.0
Dibrugarh	0	0.0	3	6.7	3	6.7	12	26.7	30	66.7	45	100.0

Table 11.5: Number(#) and Relative Proportion(%) of Lung cancer patients according to Broad Groups of Treatment(Tmt) - Males (1999-2000)

Treatment Group	Mumbai		Bangalore		Che	ennai	Thi'p	uram	Dibrugarh	
п синпон споир	#	%	#	%	#	%	#	%	#	%
Prior Tmt. Only	68	5.4	23	5.3	33	8.7	25	2.4	0	0.0
Prior & Tmt. at RI	20	1.6	12	2.8	4	1.1	37	3.6	1	2.2
Tmt. Only at RI	400	31.9	133	30.8	76	20.1	697	67.0	28	60.9
No Treatment	765	61.1	264	61.1	265	70.1	282	27.1	17	37.0
<b>Total Patients</b>	1253	100.0	432	100.0	378	100.0	1041	100.0	46	100.0

Table 11.6: Number(#) and Relative Proportion(%) of Lung cancer patients according to Type of Treatment given (Patients treated only at Reporting Institution) - Males (1999-2000)

Type of	Mur	nbai	Bang	alore	Che	nnai	Thi'p	ouram	Dibr	ugarh
Treatment	#	%	#	%	#	%	#	%	#	%
Total patients	400	100.0	133	100.0	76	100.0	697	100.0	28	100.0
Specific Treatments										
Surgery(S)	69	17.3	3	2.3	3	3.9	5	0.7	0	0.0
Radiotherapy(R)	120	30.0	75	56.4	10	13.2	375	53.8	10	35.7
Chemotherapy(C)	128	32.0	28	21.1	58	76.3	122	17.5	13	46.4
S + R	8	2.0	1	0.8	0	0.0	4	0.6	1	3.6
S + C	12	3.0	4	3.0	0	0.0	1	0.1	0	0.0
R + C	49	12.3	22	16.5	5	6.6	101	14.5	4	14.3
S + R + C	14	3.5	0	0.0	0	0.0	1	0.1	0	0.0
Others	0	0.0	0	0.0	0	0.0	88	12.6	0	0.0
Modality of therapy										
Single	317	79.3	106	79.7	71	93.4	502	72.0	23	82.1
Combination	83	20.8	27	20.3	5	6.6	107	15.4	5	17.9
Type of Any Treatment										
Any Surgery	103	25.8	8	6.0	3	3.9	11	1.6	1	3.6
Any R	191	47.8	98	73.7	15	19.7	481	69.0	15	53.6
Any C	203	50.8	54	40.6	63	82.9	225	32.3	17	60.7

Table 11.7: Number (#) & Relative Proportion (%) of types of treatment according to Clinical Extent of Disease - Lung - Males (1999-2000)

O	Mur	nbai	Bang	alore	Che	nnai	Thi'p	uram	Dibr	ugarh
Clinical Extent	#	%	#	%	#	%	#	%	#	%
Localised										
Surgery(S)	63	38.9	1	11.1	0	0.0	3	3.3	0	0.0
Radiotherapy(R)	36	22.2	2	22.2	0	0.0	55	61.1	0	0.0
Chemotherapy(C)	28	17.3	2	22.2	0	0.0	7	7.8	0	0.0
S + R	8	4.9	0	0.0	0	0.0	3	3.3	0	0.0
S + C	8	4.9	2	22.2	0	0.0	1	1.1	0	0.0
R + C	13	8.0	2	22.2	0	0.0	11	12.2	0	0.0
S + R + C	6	3.7	0	0.0	0	0.0	0	0.0	0	0.0
Others	0	0.0	0	0.0	0	0.0	10	11.1	0	0.0
ALL TREATMENTS	162	100.0	9	100.0	0.001	0.0	90	100.0	0.001	0.0
Regional										
Surgery(S)	3	13.6	2	2.6	3	5.4	1	0.4	0	0.0
Radiotherapy(R)	5	22.7	43	55.1	8	14.3	128	49.8	1	33.3
Chemotherapy(C)	3	13.6	19	24.4	42	75.0	52	20.2	1	33.3
S + R	0	0.0	1	1.3	0	0.0	0	0.0	1	33.3
S + C	2	9.1	2	2.6	0	0.0	0	0.0	0	0.0
R + C	5	22.7	11	14.1	3	5.4	42	16.3	0	0.0
S + R + C	4	18.2	0	0.0	0	0.0	1	0.4	0	0.0
Others	0	0.0	0	0.0	0	0.0	33	12.8	0	0.0
ALL TREATMENTS	22	100.0	78	100.0	56	100.0	257	100.0	3	100.0
Distant										
Surgery(S)	3	1.4	0	0.0	0	0.0	1	0.3	0	0.0
Radiotherapy(R)	79	36.6	29	67.4	2	10.0	192	54.9	3	37.5
Chemotherapy(C)	97	44.9	6	14.0	16	80.0	63	18.0	3	37.5
S + R	0	0.0	0	0.0	0	0.0	1	0.3	0	0.0
S + C	2	0.9	0	0.0	0	0.0	0	0.0	0	0.0
R + C	31	14.4	8	18.6	2	10.0	48	13.7	2	25.0
S + R + C	4	1.9	0	0.0	0	0.0	0	0.0	0	0.0
Others	0	0.0	0	0.0	0	0.0	45	12.9	0	0.0
ALL TREATMENTS	216	100.0	43	100.0	20	100.0	350	100.0	8	100.0

Table 11.8: Number (#) and Proportion (%) of any specific treatment relative to all treated patients according to Clinical Extent of Disease - Lung - Males (1999-2000)

	Any Su	ırgery	Any Radi	iotherapy	Any Cher	notherapy	Any Ot	hers	Total
	#	%	#	%	#	%	#	%	Patients
LOCALISED									
Mumbai	85	52.5	63	38.9	55	34.0	0	0.0	162
Bangalore	3	33.3	4	44.4	6	66.7	0	0.0	9
Chennai	0	0.0	0	0.0	0	0.0	0	0.0	0
Thi'puram	7	7.8	69	76.7	19	21.1	10	11.1	90
Dibrugarh	0	0.0	0	0.0	0	0.0	0	0.0	0
REGIONAL									
Mumbai	9	40.9	14	63.6	14	63.6	0	0.0	22
Bangalore	5	6.4	55	70.5	32	41.0	0	0.0	78
Chennai	3	5.4	11	19.6	45	80.4	0	0.0	56
Thi'puram	2	0.8	171	66.5	95	37.0	33	12.8	257
Dibrugarh	1	33.3	2	66.7	1	33.3	0	0.0	3
DISTANT									
Mumbai	9	4.2	114	52.8	134	62.0	0	0.0	216
Bangalore	0	0.0	37	86.0	14	32.6	0	0.0	43
Chennai	0	0.0	4	20.0	18	90.0	0	0.0	20
Thi'puram	2	0.6	241	68.9	111	31.7	45	12.9	350
Dibrugarh	0	0.0	5	62.5	5	62.5	0	0.0	8

## **FEMALE BREAST (ICD-10: C50)**

Cancer of the female breast was the leading site of cancer in Mumbai and Thiruvananthapuram, the second leading site in Bangalore and Chennai and the third leading site in Dibrugarh (Table 12.1).

Figure 12.1 gives the trends in actual numbers of breast cancer in females from 1984 to 2000. A significant increase in numbers was seen in all registries except Dibrugarh.

Table 12.2 and Figure 12.2 give the five year age distribution of breast cancer in females. The mean age was slightly lower in Dibrugarh at 42, compared to over 47 in other HBCRs.

Table 12.3 gives the number and relative proportion according to the different methods of diagnosis. The proportion of microscopic diagnosis varied from 87.8% in Mumbai to 98.9% in Thiruvananthapuram.

Table 12.4 gives the number and relative proportion according to the clinical extent of disease. The proportion with "Regional" spread varied from 37.5% in Mumbai to 79.3% in Dibrugarh.

Table 12.5 gives the number and relative proportion according to the broad groups of treatment.

Tables 12.6 to 12.8 gives the number and relative proportion according to the different types of treatment.

Table 12.1: Number(#), Relative Proportion(%) and Rank(R) of cancers of the breast - Females (1999-2000)

Registry	Total	#	%	R
Mumbai	13679	3617	26.4	1
Bangalore	7543	1001	13.3	2
Chennai	7139	1412	19.8	2
Thi <sup>'</sup> puram	7247	1991	27.5	1
Dibrugarh	536	65	12.1	3

Fig. 12.1: Trends in Actual Numbers - Female Breast Cancer




Table 12.2: Number(#) and Relative Proportion(%) of female breast cancers according to five year age group (1999-2000)

Age Group	Mun	nbai	Banga	alore	Cher	ınai	Thi	'puram	Dib	rugarh
Ago di oup	#	%	#	%	#	%	#	%	#	%
0-4	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0
5- 9	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	1.0	1.5
15-19	2	0.1	0	0.0	2	0.1	0	0.0	0.0	0.0
20-24	24	0.7	6	0.6	7	0.5	6	0.3	1.0	1.5
25-29	106	2.9	32	3.2	25	1.8	39	2.0	2.0	3.1
30-34	229	6.3	57	5.7	101	7.2	111	5.6	9.0	13.8
35-39	489	13.5	130	13.0	151	10.7	224	11.3	14.0	21.5
40-44	608	16.8	146	14.6	216	15.3	298	15.0	10.0	15.4
45-49	636	17.6	189	18.9	241	17.1	410	20.6	10.0	15.4
50-54	524	14.5	158	15.8	206	14.6	275	13.8	7.0	10.8
55-59	362	10.0	88	8.8	164	11.6	224	11.3	4.0	6.2
60-64	276	7.6	84	8.4	120	8.5	183	9.2	6.0	9.2
65-69	205	5.7	59	5.9	93	6.6	119	6.0	1.0	1.5
70-74	91	2.5	29	2.9	50	3.5	56	2.8	0.0	0.0
75+	65	1.8	23	2.3	36	2.5	46	2.3	0.0	0.0
ANS	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0.0
All Ages	3617	100.0	1001	100.0	1412	100.0	1991	100.0	65	100.0
Mean	47.8		47.9		49.1		49.4		42.1	
SD	11.44		11.78		11.90		11.31		10.78	

Fig. 12.2: Five year age group distribution - Female Breast Cancer (1999-2000)




Table 12.3: Number(#) and Relative Proportion(%) of female breast cancers based on different methods of diagnosis (1999-2000)

Registry	Micros	scopic	Clir	nical	X-	ray	Oth	iers	Total	
ricgiotiy	#	%	#	%	#	%	#	%	#	%
Mumbai	3175	87.8	5	0.1	0	0.0	437	12.1	3617	100.0
Bangalore	944	94.3	29	2.9	1	0.1	27	2.7	1001	100.0
Chennai	1293	91.6	113	8.0	0	0.0	6	0.4	1412	100.0
Thi'puram	1970	98.9	19	1.0	0	0.0	2	0.1	1991	100.0
Dibrugarh	64	98.5	0	0.0	0	0.0	1	1.5	65	100.0

Table 12.4: Number(#) and Relative Proportion(%) of female breast cancer patients according to the clinical extent of disease (Excludes Patients Previously Treated) (1999-2000)

Davistor	Localise	ed (L)	Regional (R)		L + R		Distant		Others		All Stages	
Registry	#	%	#	%	#	%	#	%	#	%	#	%
Mumbai	825	44.0	703	37.5	1528	81.4	348	18.6	0	0.0	1876	100.0
Bangalore	48	8.3	405	69.9	453	78.2	112	19.3	14	2.4	579	100.0
Chennai	61	6.9	642	72.1	703	79.0	187	21.0	0	0.0	890	100.0
Thi'puram	80	12.3	425	65.5	505	77.8	144	22.2	0	0.0	649	100.0
Dibrugarh	3	5.2	46	79.3	49	84.5	7	12.1	2	3.4	58	100.0

Table 12.5: Number(#) and Relative Proportion(%) of female breast cancer patients according to Broad Groups of Treatment(Tmt) (1999-2000)

Treatment Group	Mumbai		Bangalore		Chennai		Thi'puram		Dibrugarh	
	#	%	#	%	#	%	#	%	#	%
Prior Tmt. Only	671	18.6	187	18.7	213	15.1	184	9.2	0	0.0
Prior & Tmt. at RI	1070	29.6	235	23.5	309	21.9	1158	58.2	7	10.8
Tmt. Only at RI	1267	35.0	318	31.8	650	46.0	533	26.8	51	78.5
No Treatment	609	16.8	261	26.1	240	17.0	116	5.8	7	10.8
<b>Total Patients</b>	3617	100.0	1001	100.0	1412	100.0	1991	100.0	65	100.0

Table 12.6: Number(#) and Relative Proportion(%) of female breast cancer patients according to Type of Treatment given (Patients treated only at Reporting Institution) (1999-2000)

Type of	Mur	nbai	Bang	alore	Che	nnai	Thi'p	uram	Dibr	ugarh
Treatment	#	%	#	%	#	%	#	%	#	%
Total patients	1267	100.0	318	100.0	650	100.0	533	100.0	51	100.0
Specific Treatments										
Surgery(S)	247	19.5	27	8.5	1	0.2	18	3.4	13	25.5
Radiotherapy(R)	20	1.6	9	2.8	1	0.2	10	1.9	12	23.5
Chemotherapy(C)	51	4.0	24	7.5	23	3.5	46	8.6	1	2.0
S + R	51	4.0	26	8.2	2	0.3	19	3.6	20	39.2
S + C	108	8.5	29	9.1	0	0.0	53	9.9	4	7.8
R + C	14	1.1	9	2.8	52	8.0	27	5.1	1	2.0
S + R + C	189	14.9	82	25.8	4	0.6	106	19.9	0	0.0
Others	587	46.3	112	35.2	567	87.2	254	47.7	0	0.0
Modality of therapy										
Single	318	25.1	60	18.9	25	3.8	74	13.9	26	51.0
Combination	362	28.6	146	45.9	58	8.9	205	38.5	25	49.0
Type of Any Treatment										
Any Surgery	595	47.0	164	51.6	7	1.1	196	36.8	37	72.5
Any R	274	21.6	126	39.6	59	9.1	162	30.4	33	64.7
Any C	362	28.6	144	45.3	79	12.2	232	43.5	6	11.8

Table 12.7: Number (#) & Relative Proportion (%) of types of treatment according to Clinical Extent of Disease - Female Breast (1999-2000)

Clinical Extent	Mur	nbai	Bang	alore	Che	nnai	Thi'p	uram	Dibr	ugarh
Clinical Extent	#	%	#	%	#	%	#	%	#	%
Localised										
Surgery(S)	151	30.8	5	14.3	0	0.0	3	4.5	2	66.7
Radiotherapy(R)	11	2.2	0	0.0	0	0.0	0	0.0	0	0.0
Chemotherapy(C)	2	0.4	0	0.0	1	2.0	2	3.0	0	0.0
S + R	30	6.1	5	14.3	1	2.0	3	4.5	1	33.3
S + C	39	8.0	4	11.4	0	0.0	8	12.1	0	0.0
R + C	1	0.2	0	0.0	5	10.0	0	0.0	0	0.0
S + R + C	65	13.3	2	5.7	1	2.0	17	25.8	0	0.0
Others	191	39.0	19	54.3	42	84.0	33	50.0	0	0.0
ALL TREATMENTS	490	100.0	35	100.0	50	100.0	66	100.0	3	100.0
Regional										
Surgery(S)	93	16.4	19	7.7	1	0.2	15	4.3	11	26.2
Radiotherapy(R)	2	0.4	6	2.4	1	0.2	9	2.6	7	16.7
Chemotherapy(C)	14	2.5	12	4.8	5	1.0	19	5.5	1	2.4
S + R	21	3.7	19	7.7	1	0.2	16	4.6	19	45.2
S + C	52	9.2	21	8.5	0	0.0	39	11.3	4	9.5
R + C	1	0.2	9	3.6	41	8.5	9	2.6	0	0.0
S + R + C	106	18.7	79	31.9	3	0.6	82	23.7	0	0.0
Others	278	49.0	83	33.5	431	89.2	157	45.4	0	0.0
ALL TREATMENTS	567	100.0	248	100.0	483	100.0	346	100.0	42	100.0
Distant										
Surgery(S)	3	1.4	3	8.6	0	0.0	0	0.0	0	0.0
Radiotherapy(R)	7	3.3	3	8.6	0	0.0	1	0.8	4	80.0
Chemotherapy(C)	35	16.7	12	34.3	17	14.5	25	20.7	0	0.0
S + R	0	0.0	2	5.7	0	0.0	0	0.0	0	0.0
S + C	17	8.1	4	11.4	0	0.0	6	5.0	0	0.0
R + C	12	5.7	0	0.0	6	5.1	18	14.9	1	20.0
S + R + C	18	8.6	1	2.9	0	0.0	7	5.8	0	0.0
Others	118	56.2	10	28.6	94	80.3	64	52.9	0	0.0
ALL TREATMENTS	210	100.0	35	100.0	117	100.0	121	100.0	5	100.0

Table 12.8: Number (#) and Proportion (%) of any specific treatment relative to all treated patients according to Clinical Extent of Disease - Female Breast (1999-2000)

	Any Su	ırgery	Any Radi	iotherapy	Any Chen	notherapy	Any Ot	hers	Total
	#	%	#	%	#	%	#	%	Patients
LOCALISED									
Mumbai	472	96.3	201	41.0	215	43.9	191	39.0	490
Bangalore	35	100.0	22	62.9	17	48.6	19	54.3	35
Chennai	44	88.0	44	88.0	43	86.0	42	84.0	50
Thi'puram	63	95.5	32	48.5	35	53.0	33	50.0	66
Dibrugarh	3	100.0	1	33.3	0	0.0	0	0.0	3
REGIONAL									
Mumbai	527	92.9	302	53.3	408	72.0	278	49.0	567
Bangalore	213	85.9	181	73.0	180	72.6	83	33.5	248
Chennai	354	73.3	459	95.0	447	92.5	431	89.2	483
Thi'puram	279	80.6	207	59.8	244	70.5	157	45.4	346
Dibrugarh	34	81.0	26	61.9	5	11.9	0	0.0	42
DISTANT									
Mumbai	123	58.6	109	51.9	183	87.1	118	56.2	210
Bangalore	13	37.1	12	34.3	23	65.7	10	28.6	35
Chennai	7	6.0	57	48.7	100	85.5	94	80.3	117
Thi'puram	27	22.3	60	49.6	96	79.3	64	52.9	121
Dibrugarh	0	0.0	5	100.0	1	20.0	0	0.0	5

# **CERVIX (ICD-10: C53)**

Cancer of the cervix continued to be the leading site in Bangalore, Chennai & Dibrugarh and was the second leading site in Mumbai & Thiruvananthapuram (Table 13.1).

Figure 13.1 gives the trends in actual numbers of cancer cervix. A statistically significant decline was seen in Mumbai and Dibrugarh.

Table 13.2 and Figure 13.2 give the five year age distribution of cancer cervix in different registries. The mean age varied from a low of 46.3 in Dibrugarh to 55.9 in Thiruvananthapuram.

The predominant form of diagnosis of cancer cervix was through microscopic examination (Table 13.3).

Table 13.4 gives the number and relative proportion according to the clinical extent of disease. Over 75% of patients had regional disease at the time of diagnosis.

Table 13.5 gives the number and relative proportion according to the broad groups of treatment.

Tables 13.6 to 13.8 give the number and relative proportion according to the different types of treatment.

Table 13.1: Number(#), Relative Proportion(%) and Rank(R) of cancers of the Cervix (1999-2000)

Registry	Total	#	%	R
Mumbai	13679	2643	19.3	2
Bangalore	7543	2490	33.0	1
Chennai	7139	2499	35.0	1
Thi <sup>'</sup> puram	7247	951	13.1	2
Dibrugarh	536	82	15.3	1

Fig. 13.1: Trends in Actual Numbers - Cancer Cervix




Table 13.2: Number(#) and Relative Proportion(%) of cervical cancers according to five year age group (1999-2000)

Age Group	Mum	ıbai	Banga	alore	Cher	nai	Thi	puram	Dib	ugarh
rigo di oup	#	%	#	%	#	%	#	%	#	%
0- 4	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0.0
5- 9	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0.0
10-14	1	0.0	0	0.0	0	0.0	0	0.0	0.0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0.0
20-24	6	0.2	8	0.3	8	0.3	1	0.1	0.0	0.0
25-29	33	1.2	35	1.4	36	1.4	4	0.4	1.0	1.2
30-34	101	3.8	121	4.9	88	3.5	19	2.0	6.0	7.3
35-39	248	9.4	282	11.3	268	10.7	58	6.1	11.0	13.4
40-44	372	14.1	358	14.4	328	13.1	69	7.3	16.0	19.5
45-49	460	17.4	466	18.7	441	17.6	149	15.7	21.0	25.6
50-54	421	15.9	381	15.3	439	17.6	115	12.1	10.0	12.2
55-59	295	11.2	273	11.0	322	12.9	150	15.8	5.0	6.1
60-64	324	12.3	257	10.3	288	11.5	137	14.4	8.0	9.8
65-69	211	8.0	171	6.9	143	5.7	123	12.9	1.0	1.2
70-74	113	4.3	90	3.6	84	3.4	70	7.4	1.0	1.2
75+	58	2.2	48	1.9	54	2.2	56	5.9	2.0	2.4
ANS	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0.0
All Ages	2643	100.0	2490	100.0	2499	100.0	951	100.0	82	100.
Mean	50.4		49.0		49.8		55.9		46.3	
SD	11.32		11.31		10.94		11.62		10.15	

Fig. 13.2: Five year age group distribution - Cancer Cervix (1999-2000)




Table 13.3: Number(#) and Relative Proportion(%) of cervical cancers based on different methods of diagnosis (1999-2000)

Registry	Micros	copic	Clinical		X-	ray	Others		Total	
riogioti y	#	%	#	%	#	%	#	%	#	%
Mumbai	2477	93.7	2	0.1	0	0.0	164	6.2	2643	100.0
Bangalore	2389	95.9	66	2.7	0	0.0	35	1.4	2490	100.0
Chennai	2169	86.8	328	13.1	0	0.0	2	0.1	2499	100.0
Thi'puram	886	93.2	60	6.3	0	0.0	5	0.5	951	100.0
Dibrugarh	80	97.6	0	0.0	0	0.0	2	2.4	82	100.0

Table 13.4: Number(#) and Relative Proportion(%) of cervical cancer patients according to the clinical extent of disease (Excludes Patients Previously Treated) (1999-2000)

Davistos	Localise	ed (L)	Regional (R)		L + R		Distant		Others		All Stages	
Registry	#	%	#	%	#	%	#	%	#	%	#	%
Mumbai	395	18.5	1596	74.9	1991	93.5	138	6.5	1	0.0	2130	100.0
Bangalore	60	2.6	2018	88.2	2078	90.9	185	8.1	24	1.0	2287	100.0
Chennai	214	9.5	1988	88.4	2202	97.9	48	2.1	0	0.0	2250	100.0
Thi'puram	57	6.6	772	89.0	829	95.6	38	4.4	0	0.0	867	100.0
Dibrugarh	5	6.1	64	78.0	69	84.1	12	14.6	1	1.2	82	100.0

Table 13.5: Number(#) and Relative Proportion(%) of cervical cancer patients according to Broad Groups of Treatment(Tmt) (1999-2000)

Treatment Group	Mumbai		Bangalore		Chennai		Thi'p	uram	Dibrugarh	
	#	%	#	%	#	%	#	%	#	%
Prior Tmt. Only	318	12.0	96	3.9	226	9.0	19	2.0	0	0.0
Prior & Tmt. at RI	195	7.4	107	4.3	23	0.9	65	6.8	0	0.0
Tmt. Only at RI	948	35.9	1365	54.8	1000	40.0	757	79.6	70	85.4
No Treatment	1182	44.7	922	37.0	1250	50.0	110	11.6	12	14.6
Total Patients	2643	100.0	2490	100.0	2499	100.0	951	100.0	82	100.0

Table 13.6: Number(#) and Relative Proportion(%) of cervical cancer patients according to Type of Treatment given (Patients treated only at Reporting Institution) (1999-2000)

Type of	Mur	nbai	Bang	alore	Che	nnai	Thi'p	uram	Dibr	ugarh
Treatment	#	%	#	%	#	%	#	%	#	%
Total patients	948	100.0	1365	100.0	1000	100.0	757	100.0	70	100.0
Specific Treatments										
Surgery(S)	62	6.5	16	1.2	7	0.7	4	0.5	2	2.9
Radiotherapy(R)	780	82.3	1036	75.9	901	90.1	615	81.2	62	88.6
Chemotherapy(C)	2	0.2	11	0.8	1	0.1	3	0.4	0	0.0
S+R	61	6.4	94	6.9	76	7.6	37	4.9	4	5.7
S + C	2	0.2	7	0.5	1	0.1	0	0.0	0	0.0
R + C	36	3.8	164	12.0	14	1.4	90	11.9	1	1.4
S + R + C	4	0.4	37	2.7	0	0.0	4	0.5	1	1.4
Others	1	0.1	0	0.0	0	0.0	4	0.5	0	0.0
Modality of therapy										
Single	844	89.0	1063	77.9	909	90.9	622	82.2	64	91.4
Combination	103	10.9	302	22.1	91	9.1	131	17.3	6	8.6
Type of Any Treatment										
Any Surgery	129	13.6	154	11.3	84	8.4	45	5.9	7	10.0
Any R	881	92.9	1331	97.5	991	99.1	746	98.5	68	97.1
Any C	44	4.6	219	16.0	16	1.6	97	12.8	2	2.9

Table 13.7: Number (#) & Relative Proportion (%) of types of treatment according to Clinical Extent of Disease - Cervix (1999-2000)

Olivia al Fata est	Mur	nbai	Bang	alore	Che	nnai	Thi'p	uram	Dibr	ugarh
Clinical Extent	#	%	#	%	#	%	#	%	#	%
Localised										
Surgery(S)	52	33.8	3	7.9	6	4.1	1	1.9	1	20.0
Radiotherapy(R)	57	37.0	18	47.4	93	63.7	33	63.5	4	80.0
Chemotherapy(C)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
S + R	41	26.6	9	23.7	47	32.2	13	25.0	0	0.0
S + C	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0
R + C	3	1.9	4	10.5	0	0.0	5	9.6	0	0.0
S + R + C	0	0.0	4	10.5	0	0.0	0	0.0	0	0.0
Others	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
ALL TREATMENTS	154	100.0	38	100.0	146	100.0	52	100.0	5	100.0
Regional										
Surgery(S)	10	1.4	13	1.0	1	0.1	3	0.4	1	1.7
Radiotherapy(R)	668	91.8	970	76.3	802	94.8	561	82.7	51	87.9
Chemotherapy(C)	1	0.1	10	0.8	0	0.0	2	0.3	0	0.0
S + R	14	1.9	85	6.7	29	3.4	24	3.5	4	6.9
S + C	0	0.0	6	0.5	1	0.1	0	0.0	0	0.0
R + C	30	4.1	156	12.3	13	1.5	82	12.1	1	1.7
S + R + C	4	0.5	32	2.5	0	0.0	4	0.6	1	1.7
Others	1	0.1	0	0.0	0	0.0	2	0.3	0	0.0
ALL TREATMENTS	728	100.0	1272	100.0	846	100.0	678	100.0	58	100.0
Distant										
Surgery(S)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Radiotherapy(R)	54	83.1	48	87.3	6	75.0	21	77.8	6	100.0
Chemotherapy(C)	1	1.5	1	1.8	1	12.5	1	3.7	0	0.0
S + R	6	9.2	0	0.0	0	0.0	0	0.0	0	0.0
S + C	1	1.5	1	1.8	0	0.0	0	0.0	0	0.0
R + C	3	4.6	4	7.3	1	12.5	3	11.1	0	0.0
S + R + C	0	0.0	1	1.8	0	0.0	0	0.0	0	0.0
Others	0	0.0	0	0.0	0	0.0	2	7.4	0	0.0
ALL TREATMENTS	65	100.0	55	100.0	8	100.0	27	100.0	6	100.0

Table 13.8: Number (#) and Proportion (%) of any specific treatment relative to all treated patients according to Clinical Extent of Disease - Cervix (1999-2000)

	Any Su	ırgery	Any Radi	iotherapy	Any Cher	notherapy	Any Ot	hers	Total
	#	%	#	%	#	%	#	%	Patients
LOCALISED									
Mumbai	94	61.0	101	65.6	4	2.6	0	0.0	154
Bangalore	16	42.1	35	92.1	8	21.1	0	0.0	38
Chennai	53	36.3	140	95.9	0	0.0	0	0.0	146
Thi'puram	14	26.9	51	98.1	5	9.6	0	0.0	52
Dibrugarh	1	20.0	4	80.0	0	0.0	0	0.0	5
REGIONAL									
Mumbai	29	4.0	716	98.4	35	4.8	1	0.1	728
Bangalore	136	10.7	1243	97.7	204	16.0	0	0.0	1272
Chennai	31	3.7	844	99.8	14	1.7	0	0.0	846
Thi'puram	31	4.6	671	99.0	88	13.0	2	0.3	678
Dibrugarh	6	10.3	57	98.3	2	3.4	0	0.0	58
DISTANT									
Mumbai	7	10.8	63	96.9	5	7.7	0	0.0	65
Bangalore	2	3.6	53	96.4	7	12.7	0	0.0	55
Chennai	0	0.0	7	87.5	2	25.0	0	0.0	8
Thi'puram	0	0.0	24	88.9	4	14.8	2	7.4	27
Dibrugarh	0	0.0	6	100.0	0	0.0	0	0.0	6

# HEAD AND NECK CANCERS (ICD-10: C00-14, C30-31, C32, C33)

Chapter 14 gives a comprehensive picture of Head and Neck cancers. These include cancer of the Lip, Tongue, Mouth, Salivary glands, Oropharynx, Nasopharynx, Hypopharynx, Pharynx, Nose and Sinus, Larynx and Trachea.

Table 14.1 gives the number and relative proportion of Head and Neck cancers relative to all sites of cancers. Overall, Head and Neck cancers accounted for one-third of all cancers in males and one-eighth of all cancers in females.

Figure 14.2 and Table 14.2 depicts the relative proportion of specific sites that constitute Head & Neck cancer. Table 14.3 gives the number and relative proportion of specific sites of Head and Neck cancers relative to all sites of cancer.

Table 14.4 and Figure 14.3 give the five year age distribution of this group of cancers.

Table 14.5 gives the number and relative proportion based on different methods of diagnosis.


Table 14.6 gives the idea of the broad treatment groups. Over 60% of cancers in males had regional spread of the disease at the time of diagnosis.

Table 14.8 gives the number and relative proportion according to the type of treatment.

Table 14.1 : Number(#) & Proportion(%) of Head and Neck Cancers relative to all sites of cancer (1999-2000)

		Males			Females	
Registry	All sites	#	%	All sites	#	%
Mumbai	17637	6123	34.7	13679	1564	11.4
Bangalore	6106	1901	31.1	7543	1242	16.5
Chennai	6195	2043	33.0	7139	884	12.4
Thi'puram	7850	2342	29.8	7247	829	11.4
Dibrugarh	997	502	50.4	536	116	21.6
All Registries	38785	12911	33.3	36144	4635	12.8

Fig. 14.1: Trends in Actual Numbers - Head and Neck Cancers (1999-2000)






Fig. 14.2: Proportion(%) of Head and Neck Cancers Relative to All Sites (1999-2000)




Fig. 14.3: Stack(100%) diagram showing Proportion of Specific Head and Neck Cancer Sites
Relative to All Head and Neck Cancers (1999-2000)




Table 14.2: Number(#) & Relative Proportion(%) of specific Head and Neck sites relative to all sites of cancer (1999-2000)

Sites of Cancer	Mun	nbai	Banga	alore	Cher	nai	Thi	puram	Dib	rugarh
	#	%	#	%	#	%	#	%	#	%
Lip	96	0.5	7	0.1	22	0.4	32	0.4	16	1.6
Tongue	1236	7.0	346	5.7	450	7.3	473	6.0	67	6.7
Mouth	1986	11.3	368	6.0	544	8.8	734	9.3	86	8.6
Salivary Gl.	84	0.5	38	0.6	31	0.5	54	0.7	13	1.3
Oropharynx	554	3.1	227	3.7	170	2.7	222	2.8	63	6.3
Nasopharynx	115	0.7	33	0.5	62	1.0	61	0.8	16	1.6
Hypopharynx	935	5.3	554	9.1	420	6.8	250	3.2	163	16.3
Pharynx etc.	12	0.1	84	1.4	41	0.7	17	0.2	21	2.1
Nose & sinus	163	0.9	52	0.9	65	1.0	78	1.0	5	0.5
Larynx	937	5.3	192	3.1	238	3.8	417	5.3	52	5.2
Trachea	5	0.0	0	0.0	0	0.0	4	0.1	0	0.0
Head & Neck	6123	34.7	1901	31.1	2043	33.0	2342	29.8	502	50.4
All Sites	17637	100.0	6106	100.0	6195	100.0	7859	100.0	997	100.0

Sites of Cancer	Mun	nbai	Banga	alore	Cher	nai	Thi	puram	Dib	rugarh
	#	%	#	%	#	%	#	%	#	%
Lip	25	0.2	30	0.4	11	0.2	27	0.4	6	1.1
Tongue	370	2.7	86	1.1	119	1.7	237	3.3	19	3.5
Mouth	656	4.8	833	11.0	441	6.2	384	5.3	37	6.9
Salivary Gl.	49	0.4	19	0.3	30	0.4	36	0.5	5	0.9
Oropharynx	83	0.6	44	0.6	22	0.3	16	0.2	17	3.2
Nasopharynx	33	0.2	17	0.2	31	0.4	33	0.5	3	0.6
Hypopharynx	161	1.2	112	1.5	154	2.2	36	0.5	17	3.2
Pharynx etc.	0	0.0	23	0.3	18	0.3	3	0.0	5	0.9
Nose & sinus	88	0.6	58	0.8	32	0.4	38	0.5	1	0.2
Larynx	99	0.7	20	0.3	26	0.4	19	0.3	6	1.1
Trachea	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Head & Neck	1564	11.4	1242	16.5	884	12.4	829	11.4	116	21.6
All Sites	13679	100.0	7543	100.0	7139	100.0	7247	100.0	536	100.0

Table 14.3 : Number(#) & Relative Proportion(%) of specific Head and Neck sites relative to all head and neck cancers (1999-2000)

Sites of Cancer	Mun	nbai	Banga	alore	Cher	nnai	Thi	puram	Dib	rugarh
	#	%	#	%	#	%	#	%	#	%
Lip	96	1.6	7	0.4	22	1.1	32	1.4	16	3.2
Tongue	1236	20.2	346	18.2	450	22.0	473	20.2	67	13.3
Mouth	1986	32.4	368	19.4	544	26.6	734	31.3	86	17.1
Salivary Gl.	84	1.4	38	2.0	31	1.5	54	2.3	13	2.6
Oropharynx	554	9.0	227	11.9	170	8.3	222	9.5	63	12.5
Nasopharynx	115	1.9	33	1.7	62	3.0	61	2.6	16	3.2
Hypopharynx	935	15.3	554	29.1	420	20.6	250	10.7	163	32.5
Pharynx etc.	12	0.2	84	4.4	41	2.0	17	0.7	21	4.2
Nose & sinus	163	2.7	52	2.7	65	3.2	78	3.3	5	1.0
Larynx	937	15.3	192	10.1	238	11.6	417	17.8	52	10.4
Trachea	5	0.1	0	0.0	0	0.0	4	0.2	0	0.0
Head & Neck	6123	100.0	1901	100.0	2043	100.0	2342	100.0	502	100.0


Sites of Cancer	Mun	nbai	Banga	alore	Cher	nai	Thi	'puram	Dib	rugarh
	#	%	#	%	#	%	#	%	#	%
Lip	25	1.6	30	2.4	11	1.2	27	3.3	6	5.2
Tongue	370	23.7	86	6.9	119	13.5	237	28.6	19	16.4
Mouth	656	41.9	833	67.1	441	49.9	384	46.3	37	31.9
Salivary Gl.	49	3.1	19	1.5	30	3.4	36	4.3	5	4.3
Oropharynx	83	5.3	44	3.5	22	2.5	16	1.9	17	14.7
Nasopharynx	33	2.1	17	1.4	31	3.5	33	4.0	3	2.6
Hypopharynx	161	10.3	112	9.0	154	17.4	36	4.3	17	14.7
Pharynx etc.	0	0.0	23	1.9	18	2.0	3	0.4	5	4.3
Nose & sinus	88	5.6	58	4.7	32	3.6	38	4.6	1	0.9
Larynx	99	6.3	20	1.6	26	2.9	19	2.3	6	5.2
Trachea	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Head & Neck	1564	100.0	1242	100.0	884	100.0	829	100.0	116	100.0

Table 14.4: Number(#) and Relative Proportion(%) of Head and Neck Cancers by five-year age groups (1999-2000)

Age Group	Mum	ıbai	Banga	alore	Cher	nai	Thi	puram	Dib	rugarh
rigo aroup	#	%	#	%	#	%	#	%	#	%
00-14	23	0.4	8	0.4	6	0.3	8	0.3	3	0.6
15-19	35	0.6	7	0.4	10	0.5	7	0.3	1	0.2
20-24	51	0.8	11	0.6	18	0.9	9	0.4	4	0.8
25-29	78	1.3	21	1.1	28	1.4	11	0.5	7	1.4
30-34	197	3.2	21	1.1	37	1.8	23	1.0	13	2.6
35-39	395	6.5	74	3.9	91	4.5	66	2.8	25	5.0
40-44	611	10.0	91	4.8	136	6.7	131	5.6	29	5.8
45-49	752	12.3	207	10.9	228	11.2	267	11.4	60	12.0
50-54	937	15.3	262	13.8	306	15.0	315	13.5	69	13.7
55-59	850	13.9	278	14.6	331	16.2	344	14.7	67	13.3
60-64	788	12.9	338	17.8	310	15.2	378	16.1	105	20.9
65-69	709	11.6	267	14.0	246	12.0	354	15.1	54	10.8
70-74	407	6.6	174	9.2	163	8.0	214	9.1	34	6.8
75+	290	4.7	142	7.5	133	6.5	215	9.2	31	6.2
All ages	6123	100.0	1901	100.0	2043	100.0	2342	100.0	502	100.0
Mean	53.5		56.7		55.6		58.4		54.9	
SD	12.90		12.41		12.68		12.21		12.99	

Age Group	Mun	ıbai	Banga	alore	Cher	ınai	Thi	'puram	Dib	rugarh
Age Group	#	%	#	%	#	%	#	%	#	%
00-14	9	0.6	6	0.5	3	0.3	10	1.2	0	0.0
15-19	14	0.9	9	0.7	6	0.7	6	0.7	0	0.0
20-24	17	1.1	8	0.6	10	1.1	9	1.1	2	1.7
25-29	35	2.2	12	1.0	28	3.2	10	1.2	1	0.9
30-34	61	3.9	26	2.1	37	4.2	22	2.7	6	5.2
35-39	112	7.2	81	6.5	52	5.9	33	4.0	11	9.5
40-44	158	10.1	108	8.7	67	7.6	48	5.8	13	11.2
45-49	200	12.8	140	11.3	127	14.4	73	8.8	18	15.5
50-54	229	14.6	202	16.3	143	16.2	83	10.0	18	15.5
55-59	199	12.7	155	12.5	105	11.9	127	15.3	13	11.2
60-64	207	13.2	194	15.6	127	14.4	122	14.7	17	14.7
65-69	159	10.2	133	10.7	96	10.9	104	12.5	9	7.8
70-74	99	6.3	94	7.6	41	4.6	86	10.4	5	4.3
75+	65	4.2	74	6.0	42	4.8	96	11.6	3	2.6
All ages	1564	100.0	1242	100.0	884	100.0	829	100.0	116	100.0
Mean	52.0		53.7		52.1		57.3		50.2	
SD	13.48		13.08		13.30		14.69		12.45	

Fig. 14.4: Relative Proportion(%) of Head and Neck Cancers by Five Year Age Group (1999-2000)






Table 14.5: Number(#) & Relative Proportion(%) of head and neck cancers based on different methods of diagnosis (1999-2000)

	Micros	scopic	Clin	ical	X-r	ay	Oth	ers	To	tal
Registry	#	%	#	%	#	%	#	%	#	%
Males										
Mumbai	5752	93.9	1	0.0	5	0.1	365	6.0	6123	100.0
Bangalore	1798	94.6	2	0.1	99	5.2	2	0.1	1901	100.0
Chennai	1386	67.8	3	0.1	650	31.8	4	0.2	2043	100.0
Thiˈpuram	2247	95.9	0	0.0	92	3.9	3	0.1	2342	100.0
Dibrugarh	499	99.4	0	0.0	1	0.2	2	0.4	502	100.0
Females										
Mumbai	1489	95.2	0	0.0	3	0.2	72	4.6	1564	100.0
Bangalore	1204	96.9	2	0.2	34	2.7	2	0.2	1242	100.0
Chennai	622	70.4	0	0.0	262	29.6	0	0.0	884	100.0
Thiˈpuram	774	93.4	0	0.0	52	6.3	3	0.4	829	100.0
Dibrugarh	116	100.0	0	0.0	0	0.0	0	0.0	116	100.0

Table 14.6: Number(#) & Relative Proportion(%) of head and neck cancers based on broad groups of treatment (1999-2000)

Treatment Group	Mun	nbai	Bang	jalore	Che	nnai	Thi'p	uram	Dibru	ıgarh
	#	%	#	%	#	%	#	%	#	%
Males										
Prior Tmt. Only	580	9.5	80	4.2	287	14.0	69	2.9	0	0.0
Prior & Tmt. at RI	313	5.1	21	1.1	30	1.5	167	7.1	12	2.4
Tmt. Only at RI	2342	38.2	826	43.5	783	38.3	1739	74.3	455	90.6
No CDT*	2888	47.2	974	51.2	943	46.2	367	15.7	35	7.0
Total Patients	6123	100.0	1901	100.0	2043	100.0	2342	100.0	502	100.0
Females										
Prior Tmt. Only	117	7.5	29	2.3	100	11.3	27	3.3	0	0.0
Prior & Tmt. at RI	69	4.4	17	1.4	18	2.0	75	9.0	0	0.0
Tmt. Only at RI	693	44.3	586	47.2	378	42.8	593	71.5	111	95.7
No CDT*	685	43.8	610	49.1	388	43.9	134	16.2	5	4.3
Total Patients	1564	100.0	1242	100.0	884	100.0	829	100.0	116	100.0

Table 14.7: Number(#) and Relative Proportion(%) of Head and Neck cancer patients according to Clinical Extent of Disease (Excludes Patients Previously Treated) (1999-2000)

Registry	Localise	Localised (L)		Regional (R)		R	Dista	nt	Othe	rs	All Sta	ges
ricgisti y	#	%	#	%	#	%	#	%	#	%	#	%
Mumbai	1616	30.9	3273	62.6	4889	93.5	341	6.5	0	0.0	5230	100.0
Bangalore	126	7.0	1543	85.7	1669	92.7	109	6.1	22	1.2	1800	100.0
Chennai	193	11.2	1514	87.7	1707	98.9	19	1.1	0	0.0	1726	100.0
Thi'puram	332	15.8	1715	81.4	2047	97.2	59	2.8	0	0.0	2106	100.0
Dibrugarh	39	8.0	419	85.5	458	93.5	11	2.2	21	4.3	490	100.0

Registry	Localise	ed (L)	Regional (R)		L+	R	Dista	nt	Other	rs	All Sta	ges
ricgisti y		%	#	%	#	%	#	%	#	%	#	%
Mumbai	495	35.9	805	58.4	1300	94.3	77	5.6	1	0.1	1378	100.0
Bangalore	78	6.5	1008	84.3	1086	90.8	87	7.3	23	1.9	1196	100.0
Chennai	70	9.1	693	90.5	763	99.6	3	0.1	0	0.0	766	100.0
Thi'puram	127	17.5	580	79.8	707	97.3	20	2.8	0	0.0	727	100.0
Dibrugarh	19	16.4	93	80.2	112	96.6	1	0.9	3	2.6	116	100.0

Table 14.8: Number (#) & Relative Proportion (%) of head and neck cancer patients according to Type of Treatment given (1999-2000)

Type of	Mur	nbai	Bang	alore	Che	nnai	Thi'p	uram	Dibr	ugarh
Treatment	#	%	#	%	#	%	#	%	#	%
Total patients	5667	100.0	2227	100.0	1828	100.0	4766	100.0	832	100.0
Specific Treatments										
Surgery(S)	1635	28.9	349	15.7	235	12.9	164	3.4	49	5.9
Radiotherapy(R)	877	15.5	820	36.8	714	39.1	2012	42.2	635	76.3
Chemotherapy(C)	1200	21.2	396	17.8	389	21.3	1035	21.7	69	8.3
S + R	788	13.9	264	11.9	174	9.5	218	4.6	37	4.4
S + C	230	4.1	88	4.0	59	3.2	64	1.3	16	1.9
R + C	695	12.3	242	10.9	166	9.1	790	16.6	20	2.4
S + R + C	142	2.5	48	2.2	34	1.9	54	1.1	3	0.4
Others	100	1.8	20	0.9	57	3.1	429	9.0	3	0.4
Modality of therapy*										
Single	3712	65.5	1565	70.3	1338	73.2	3211	67.4	753	90.5
Combination	1855	32.7	642	28.8	433	23.7	1126	23.6	76	9.1
Type of Any Treatment*										
Any Surgery	2795	49.3	749	33.6	502	27.5	500	10.5	105	12.6
Any R	2502	44.2	1374	61.7	1088	59.5	3074	64.5	695	83.5
Any C	2267	40.0	774	34.8	648	35.4	1943	40.8	108	13.0

Type of	Mur	nbai	Bang	alore	Che	nnai	Thi'p	ouram	Dibr	ugarh
Treatment	#	%	#	%	#	%	#	%	#	%
Total patients	4470	100.0	3334	100.0	2616	100.0	3325	100.0	430	100.0
Specific Treatments										
Surgery(S)	1140	25.5	294	8.8	109	4.2	143	4.3	47	10.9
Radiotherapy(R)	1046	23.4	1506	45.2	1302	49.8	1247	37.5	254	59.1
Chemotherapy(C)	531	11.9	364	10.9	223	8.5	659	19.8	39	9.1
S + R	377	8.4	367	11.0	152	5.8	208	6.3	44	10.2
S + C	309	6.9	166	5.0	56	2.1	158	4.8	39	9.1
R + C	235	5.3	336	10.1	151	5.8	363	10.9	5	1.2
S + R + C	240	5.4	157	4.7	24	0.9	144	4.3	1	0.2
Others	592	13.2	144	4.3	599	22.9	403	12.1	1	0.2
Modality of therapy*										
Single	2717	60.8	2164	64.9	1634	62.5	2049	61.6	340	79.1
Combination	1161	26.0	1026	30.8	383	14.6	873	26.3	89	20.7
Type of Any Treatment*										
Any Surgery	2066	46.2	984	29.5	341	13.0	653	19.6	131	30.5
Any R	1898	42.5	2366	71.0	1629	62.3	1962	59.0	304	70.7
Any C	1315	29.4	1023	30.7	454	17.4	1324	39.8	84	19.5

# HISTOLOGIC TYPES OF SELECTED SITES OF CANCER

The number and relative proportion of the specific histologic types of cancer (for Microscopically Diagnosed Cases) as appropriate for the selected anatomical sites of cancer is given below.

## **TONGUE (ICD-10: C01-C02)**

Table 15.1: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologic	Mun	nbai	Ban	galore	Che	ennai	Thi'p	uram	Dibrugarh	
Туре	#	%	#	%	#	%	#	%	#	%
MALES										
Neoplasm Malignant	1	0.1	7	2.1	12	4.1	1	0.2	0	0.0
Carcinomas	5	0.4	30	9.2	10	3.4	7	1.5	4	6.1
Verrucous Carcinoma	4	0.3	3	0.9	1	0.3	1	0.2	0	0.0
Squamous Cell Carcinoma	1142	98.9	285	87.2	265	91.4	443	97.4	60	90.9
Adeno Carcinoma	3	0.3	1	0.3	2	0.7	2	0.4	0	0.0
Others	0	0.0	1	0.3	0	0.0	1	0.2	2	3.0
All Histologic Types	1155	100.0	327	100.0	290	100.0	455	100.0	66	100.0
FEMALES										
Neoplasm Malignant	0	0.0	3	3.7	3	3.5	1	0.5	0	0.0
Carcinomas	2	0.6	5	6.1	1	1.2	4	1.8	0	0.0
Verrucous Carcinoma	3	0.9	0	0.0	0	0.0	4	1.8	0	0.0
Squamous Cell Carcinoma	341	97.7	74	90.2	79	91.9	207	94.5	19	100.0
Adeno Carcinoma	1	0.3	0	0.0	3	3.5	3	1.4	0	0.0
Others	2	0.6	0	0.0	0	0.0	0	0.0	0	0.0
All Histologic Types	349	100.0	82	100.0	86	100.0	219	100.0	19	100.0

## MOUTH (ICD-10: C03-C06)

Table 15.2: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologic	Mun	nbai	Bang	galore	Che	nnai	Thi'p	uram	Dibrugarh	
Туре	#	%	#	%	#	%	#	%	#	%
MALES										
Neoplasm Malignant	3	0.2	5	1.4	12	3.8	1	0.1	0	0.0
Carcinomas	9	0.5	19	5.4	6	1.9	5	0.7	2	2.3
Verrucous Carcinoma	22	1.2	9	2.6	5	1.6	15	2.2	1	1.2
Squamous Cell Carcinoma	1828	97.4	313	89.2	290	91.8	649	95.0	81	94.2
Adeno Carcinoma	7	0.4	2	0.6	2	0.6	5	0.7	0	0.0
Others	8	0.4	3	0.9	1	0.3	8	1.2	2	2.3
All Histologic Types	1877	100.0	351	100.0	316	100.0	683	100.0	86	100.0
FEMALES										
Neoplasm Malignant	3	0.5	25	3.1	6	2.2	2	0.6	0	0.0
Carcinomas	5	8.0	24	3.0	5	1.9	2	0.6	1	2.7
Verrucous Carcinoma	10	1.6	35	4.3	3	1.1	10	2.8	1	2.7
Squamous Cell Carcinoma	595	93.8	713	88.1	244	90.7	328	92.9	35	94.6
Adeno Carcinoma	11	1.7	6	0.7	9	3.3	5	1.4	0	0.0
Others	10	1.6	6	0.7	2	0.7	6	1.7	0	0.0
All Histologic Types	634	100.0	809	100.0	269	100.0	353	100.0	37	100.0

### PHARYNX (ICD-10: C09-C10 and C12-C14)

Table 15.3: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologic	Mun	nbai	Bang	galore	Che	nnai	Thi'p	uram	Dibrugarh	
Туре	#	%	#	%	#	%	#	%	#	%
MALES										
Neoplasm Malignant	12	0.9	11	1.3	21	4.6	1	0.2	0	0.0
Carcinomas	20	1.4	62	7.5	16	3.5	26	5.4	13	5.3
Squamous Cell Carcinoma	1372	97.5	749	91.0	414	91.6	447	93.3	234	94.7
Others	3	0.2	1	0.1	1	0.2	5	1.0	0	0.0
All Histologic Types	1407	100.0	823	100.0	452	100.0	479	100.0	247	100.0
FEMALES										
Neoplasm Malignant	0	0.0	3	1.7	6	3.7	0	0.0	0	0.0
Carcinomas	5	2.2	12	6.9	7	4.3	1	1.9	2	5.1
Squamous Cell Carcinoma	222	97.8	156	90.2	148	91.9	50	96.2	37	94.9
Others	0	0.0	2	1.2	0	0.0	1	1.9	0	0.0
All Histologic Types	227	100.0	173	100.0	161	100.0	52	100.0	39	100.0

## **OESOPHAGUS (ICD-10: C15)**

Table 15.4: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologic	Mu	mbai	Bang	galore	Che	nnai	Thi'p	uram	Dib	rugarh
Туре	#	%	#	%	#	%	#	%	#	%
MALES										
Neoplasm Malignant	2	0.2	25	4.4	11	2.8	2	0.5	0	0.0
Carcinomas	34	3.7	47	8.3	25	6.5	18	4.6	1	8.0
Squamous Cell Carcinoma	765	84.0	449	79.5	306	79.1	304	78.4	127	95.5
Adeno Carcinoma	102	11.2	41	7.3	36	9.3	47	12.1	5	3.8
Others	8	0.9	3	0.5	9	2.3	17	4.4	0	0.0
All Histologic Types	911	100.0	565	100.0	387	100.0	388	100.0	133	100.0
FEMALES										
Neoplasm Malignant	1	0.2	11	2.4	3	1.3	0	0.0	0	0.0
Carcinomas	11	2.3	46	10.1	12	5.4	2	1.9	2	3.4
Squamous Cell Carcinoma	421	89.8	386	85.0	187	83.9	93	90.3	55	93.2
Adeno Carcinoma	31	6.6	9	2.0	21	9.4	6	5.8	1	1.7
Others	5	1.1	2	0.4	0	0.0	2	1.9	1	1.7
All Histologic Types	469	100.0	454	100.0	223	100.0	103	100.0	59	100.0

## STOMACH (ICD-10: C16)

Table 15.5: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologic	M	umbai	Bang	galore	Che	nnai	Thi'p	uram	Dibrugarh	
Туре	#	%	#	%	#	%	#	%	#	%
MALES										
Neoplasm Malignant	7	1.6	19	5.0	20	5.1	5	1.6	0	0.0
Carcinomas	19	4.3	51	13.4	34	8.7	46	15.1	4	12.5
Adeno Carcinomas	337	76.9	264	69.5	304	77.7	189	62.0	25	78.1
Papillary Adeno Carcinoma	0	0.0	6	1.6	1	0.3	4	1.3	0	0.0
Mucinous Adeno Carcinoma	10	2.3	18	4.7	25	6.4	35	11.5	3	9.4
Sarcomas	3	0.7	1	0.3	0	0.0	2	0.7	0	0.0
Others	62	14.2	21	5.5	7	1.8	24	7.9	0	0.0
All Histologic Types	438	100.0	380	100.0	391	100.0	305	100.0	32	100.0
FEMALES										
Neoplasm Malignant	0	0.0	8	5.3	13	8.1	1	1.2	0	0.0
Carcinomas	12	6.6	17	11.3	14	8.7	8	9.9	0	0.0
Adeno Carcinomas	124	68.5	105	69.5	107	66.5	48	59.3	10	62.5
Papillary Adeno Carcinoma	0	0.0	1	0.7	0	0.0	1	1.2	1	6.3
Mucinous Adeno Carcinoma	6	3.3	6	4.0	13	8.1	8	9.9	4	25.0
Sarcomas	2	1.1	1	0.7	0	0.0	0	0.0	0	0.0
Others	37	20.4	13	8.6	14	8.7	15	18.5	1	6.3
All Histologic Types	181	100.0	151	100.0	161	100.0	81	100.0	16	100.0

# LUNG (ICD-10: C33-C34)

Table 15.6: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologic	Mun	nbai	Bang	alore	Che	nnai	Thi'p	uram	Dibru	ıgarh
Туре	#	%	#	%	#	%	#	%	#	%
MALES										
Neoplasm Malignant	58	5.1	22	5.7	19	7.5	37	4.3	0	0.0
Large Cell Carcinoma	39	3.4	2	0.5	2	0.8	13	1.5	0	0.0
Undiff/Anaplastic Carcinoma	6	0.5	1	0.3	3	1.2	16	1.9	0	0.0
Small Cell Carcinoma	127	11.1	59	15.3	29	11.5	111	13.0	4	9.8
Squamous Cell Carcinoma	369	32.3	35	9.1	81	32.0	221	25.8	17	41.5
Other Carcinomas	111	9.7	67	17.4	57	22.5	184	21.5	1	2.4
Papillary AdenoCarcinoma	6	0.5	1	0.3	4	1.6	16	1.9	0	0.0
Adeno Squamous Carcinoma	12	1.1	0	0.0	0	0.0	9	1.1	0	0.0
Adeno Carcinoma NOS	390	34.2	74	19.2	54	21.3	226	26.4	10	24.4
Others	23	2.0	124	32.2	4	1.6	22	2.6	9	22.0
All Histologic Types	1141	100.0	385	100.0	253	100.0	855	100.0	41	100.0
FEMALES										
Neoplasm Malignant	10	3.7	6	8.1	14	21.5	3	2.4	0	0.0
Large Cell Carcinoma	7	2.6	2	2.7	2	3.1	0	0.0	0	0.0
Undiff/Anaplastic Carcinoma	1	0.4	1	1.4	2	3.1	2	1.6	0	0.0
Small Cell Carcinoma	15	5.5	7	9.5	3	4.6	5	4.1	0	0.0
Squamous Cell Carcinoma	44	16.2	8	10.8	4	6.2	18	14.6	4	57.1
Other Carcinomas	28	10.3	16	21.6	14	21.5	29	23.6	0	0.0
Papillary AdenoCarcinoma	1	0.4	1	1.4	1	1.5	5	4.1	0	0.0
Adeno Squamous Carcinoma	6	2.2	0	0.0	0	0.0	0	0.0	0	0.0
Adeno Carcinoma NOS	143	52.6	17	23.0	23	35.4	53	43.1	1	14.3
Others	17	6.3	16	21.6	2	3.1	8	6.5	2	28.6
All Histologic Types	272	100.0	74	100.0	65	100.0	123	100.0	7	100.0

## BONE (ICD-10: C40-C41)

Table 15.7: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologic	Mun	nbai	Ban	galore	Che	nnai	Thi'p	uram	Dib	rugarh
Туре	#	%	#	%	#	%	#	%	#	%
MALES										
Neoplasm Malignant	3	1.0	4	4.0	8	6.6	1	1.0	0	0.0
Sarcomas	9	3.0	2	2.0	3	2.5	9	9.0	2	12.5
Osteosarcomas	187	62.5	42	42.0	57	46.7	59	59.0	6	37.5
Chondrosarcomas	32	10.7	15	15.0	13	10.7	8	8.0	3	18.8
Giant Cell Tumour	1	0.3	0	0.0	5	4.1	1	1.0	0	0.0
Ewing's Sarcoma	52	17.4	19	19.0	28	23.0	16	16.0	0	0.0
Chondroma	1	0.3	0	0.0	0	0.0	1	1.0	0	0.0
Others	14	4.7	18	18.0	8	6.6	5	5.0	5	31.3
All Histologic Types	299	100.0	100	100.0	122	100.0	100	100.0	16	100.0
FEMALES										
Neoplasm Malignant	1	0.9	3	5.0	8	12.1	0	0.0	1	12.5
Sarcomas	7	6.6	4	6.7	4	6.1	1	1.6	0	0.0
Osteosarcomas	70	66.0	19	31.7	28	42.4	33	54.1	1	12.5
Chondrosarcomas	11	10.4	10	16.7	5	7.6	5	8.2	0	0.0
Giant Cell Tumour	1	0.9	3	5.0	4	6.1	0	0.0	0	0.0
Ewing's Sarcoma	15	14.2	13	21.7	13	19.7	15	24.6	1	12.5
Chondroma	0	0.0	1	1.7	0	0.0	1	1.6	0	0.0
Others	1	0.9	7	11.7	4	6.1	6	9.8	5	62.5
All Histologic Types	106	100.0	60	100.0	66	100.0	61	100.0	8	100.0

# **SOFT TISSUE (ICD-10: C47 &C49)**

Table 15.8: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologic	Mur	nbai	Bang	galore	Che	nnai	Thi'p	uram	Dib	rugarh
Туре	#	%	#	%	#	%	#	%	#	%
MALES										
Neoplasm Malignant	0	0.0	0	0.0	9	7.0	5	4.7	0	0.0
Sarcoma NOS	0	0.0	8	12.5	23	17.8	4	3.8	0	0.0
Spindle Cell Sarcoma	0	0.0	19	29.7	31	24.0	20	18.9	1	16.7
Pleomorphic Cell Sarcoma	0	0.0	7	10.9	9	7.0	7	6.6	0	0.0
Fibrous Histiocytoma	0	0.0	3	4.7	16	12.4	8	7.5	0	0.0
Liposarcoma	0	0.0	5	7.8	3	2.3	6	5.7	0	0.0
Leiomyosarcoma	0	0.0	1	1.6	3	2.3	2	1.9	1	16.7
Rhabdomyosarcoma	0	0.0	1	1.6	14	10.9	14	13.2	1	16.7
Synovial Sarcoma	0	0.0	10	15.6	9	7.0	15	14.2	1	16.7
Neurofibrosarcoma	3	5.4	1	1.6	1	0.8	4	3.8	1	16.7
Neurilemmoma	0	0.0	3	4.7	1	0.8	1	0.9	0	0.0
Others	53	94.6	6	9.4	10	7.8	20	18.9	1	16.7
All Histologic Types	56	100.0	64	100.0	129	100.0	106	100.0	6	100.0
FEMALES										
Neoplasm Malignant	0	0.0	2	4.3	3	4.1	4	5.0	0	0.0
Sarcoma NOS	0	0.0	2	4.3	15	20.3	5	6.3	0	0.0
Spindle Cell Sarcoma	0	0.0	16	34.8	20	27.0	22	27.5	0	0.0
Pleomorphic Cell Sarcoma	0	0.0	7	15.2	2	2.7	6	7.5	0	0.0
Fibrous Histiocytoma	0	0.0	1	2.2	5	6.8	8	10.0	0	0.0
Liposarcoma	0	0.0	1	2.2	3	4.1	8	10.0	0	0.0
Leiomyosarcoma	0	0.0	3	6.5	0	0.0	0	0.0	0	0.0
Rhabdomyosarcoma	0	0.0	3	6.5	6	8.1	5	6.3	2	100.0
Synovial Sarcoma	0	0.0	4	8.7	4	5.4	7	8.8	0	0.0
Neurofibrosarcoma	1	3.7	0	0.0	2	2.7	3	3.8	0	0.0
Neurilemmoma	0	0.0	1	2.2	1	1.4	1	1.3	0	0.0
Others	26	96.3	6	13.0	13	17.6	11	13.8	0	0.0
All Histologic Types	27	100.0	46	100.0	74	100.0	80	100.0	2	100.0

## FEMALE BREAST (ICD-10: C50)

Table 15.9: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologic	Mur	nbai	Bang	galore	Che	nnai	Thi'p	uram	Dibr	ugarh
Туре	#	%	#	%	#	%	#	%	#	%
Neoplasm Malignant	21	0.7	48	5.1	19	1.5	46	2.3	0	0.0
Carcinomas	71	2.2	52	5.5	15	1.2	143	7.3	2	3.1
Papillary Carcinoma	13	0.4	1	0.1	5	0.4	18	0.9	0	0.0
Squamous Cell Carcinoma	9	0.3	3	0.3	0	0.0	4	0.2	0	0.0
Adeno Carcinoma NOS	37	1.2	4	0.4	4	0.3	11	0.6	0	0.0
Mucinous Adeno Carcinoma	23	0.7	16	1.7	8	0.6	20	1.0	2	3.1
Infil. Duct Carcinoma	2815	88.7	761	80.6	1180	91.3	1638	83.1	54	84.4
Medullary Carcinoma	15	0.5	11	1.2	5	0.4	16	0.8	2	3.1
Lobular Carcinoma	90	2.8	19	2.0	22	1.7	44	2.2	1	1.6
Paget's Disease	13	0.4	2	0.2	2	0.2	2	0.1	0	0.0
Cystosarc. Phyllodes	14	0.4	14	1.5	8	0.6	10	0.5	1	1.6
Others	54	1.7	13	1.4	25	1.9	18	0.9	2	3.1
All Histologic Types	3175	100.0	944	100.0	1293	100.0	1970	100.0	64	100.0

**CERVIX (ICD-10: C53)** 

Table 15.10: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologic	Mur	nbai	Bang	galore	Che	ennai	Thi'ı	ouram	Dibru	ıgarh
Туре	#	%	#	%	#	%	#	%	#	%
Neoplasm Malignant	0	0.0	71	3.0	48	2.2	3	0.3	0	0.0
Carcinomas	31	1.3	59	2.5	50	2.3	17	1.9	2	2.5
Non-Kerat Large Cell	20	0.8	1047	43.8	1085	50.0	351	39.6	45	56.3
Non-Kerat Small Cell	2	0.1	4	0.2	6	0.3	8	0.9	4	5.0
Kerat Squa Cell Carcinoma NOS	12	0.5	531	22.2	191	8.8	200	22.6	6	7.5
Squa Cell Carcinoma NOS	2278	92.0	538	22.5	588	27.1	229	25.8	17	21.3
Other Squa Cell Carcinoma	3	0.1	11	0.5	5	0.2	3	0.3	0	0.0
Adeno Carcinoma	87	3.5	68	2.8	70	3.2	43	4.9	4	5.0
Adeno Squa Carcinoma	20	0.8	40	1.7	120	5.5	12	1.4	0	0.0
Others	24	1.0	20	0.8	6	0.3	20	2.3	2	2.5
All Histologic Types	2477	100.0	2389	100.0	2169	100.0	886	100.0	80	100.0

# **OVARY (ICD-10: C56)**

Table 15.11: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologic	Mur	nbai	Bang	galore	Che	nnai	Thi'p	uram	Dib	rugarh
Туре	#	%	#	%	#	%	#	%	#	%
Neoplasm Malignant	6	0.9	14	4.4	18	8.3	10	1.8	0	0.0
Carcinomas	24	3.6	33	10.4	14	6.4	14	2.6	0	0.0
Other Carcinomas	2	0.3	2	0.6	0	0.0	1	0.2	0	0.0
Papillary Carcinoma	2	0.3	2	0.6	1	0.5	3	0.5	1	3.6
Squamous Cell Carcinoma	1	0.1	7	2.2	0	0.0	2	0.4	0	0.0
Adeno Carcinoma	263	39.1	56	17.6	95	43.6	92	16.8	16	57.1
Papillary Adeno Carcinoma	36	5.3	38	11.9	31	14.2	45	8.2	5	17.9
Clear Cell Adeno Carcinoma	11	1.6	3	0.9	0	0.0	12	2.2	0	0.0
Endometroid Carcinoma	40	5.9	6	1.9	3	1.4	44	8.1	0	0.0
Papi/Serous Cystadeno	149	22.1	86	27.0	20	9.2	142	26.0	2	7.1
Muc Adeno/Cystadeno	34	5.1	21	6.6	12	5.5	95	17.4	1	3.6
Granulosa Cell Tumour	4	0.6	10	3.1	4	1.8	4	0.7	0	0.0
Sarcomas	1	0.1	3	0.9	0	0.0	0	0.0	0	0.0
Stromal Tumours	3	0.4	2	0.6	1	0.5	3	0.5	0	0.0
Dysgerminoma	32	4.8	15	4.7	4	1.8	32	5.9	0	0.0
Endodermal Sinus Tumour	18	2.7	5	1.6	2	0.9	9	1.6	0	0.0
Teratomas	16	2.4	5	1.6	2	0.9	10	1.8	0	0.0
Others	31	4.6	10	3.1	11	5.0	28	5.1	3	10.7
All Histologic Types	673	100.0	318	100.0	218	100.0	546	100.0	28	100.0

# **KIDNEY (ICD-10: C64)**

Table 15.12: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologic	Mur	nbai	Ban	galore	Che	nnai	Thi'p	uram	Dib	rugarh
Туре	#	%	#	%	#	%	#	%	#	%
MALES										
Neoplasm Malignant	5	3.0	4	7.4	0	0.0	0	0.0	0	0.0
Carcinoma NOS	6	3.6	2	3.7	2	6.5	3	4.4	0	0.0
Transitional Cell Carcinoma	4	2.4	1	1.9	2	6.5	1	1.5	0	0.0
Adenocarcinoma	3	1.8	1	1.9	2	6.5	4	5.9	0	0.0
Clear Cell AdenoCarcinoma	6	3.6	0	0.0	0	0.0	3	4.4	0	0.0
Renal Cell Carcinoma	106	64.2	33	61.1	20	64.5	43	63.2	0	0.0
Nephroblastoma	26	15.8	10	18.5	4	12.9	11	16.2	1	100.0
Others	9	5.5	3	5.6	1	3.2	3	4.4	0	0.0
All Histologic Types	165	100.0	54	100.0	31	100.0	68	100.0	1	100.0
FEMALES										
Neoplasm Malignant	0	0.0	0	0.0	1	4.2	0	0.0	0	0.0
Carcinoma NOS	5	7.0	0	0.0	0	0.0	1	2.7	0	0.0
Transitional Cell Carcinoma	1	1.4	1	2.6	1	4.2	1	2.7	0	0.0
Adenocarcinoma	0	0.0	0	0.0	3	12.5	1	2.7	0	0.0
Clear Cell Adeno Carcinoma	3	4.2	0	0.0	1	4.2	1	2.7	0	0.0
Renal Cell Carcinoma	44	62.0	23	60.5	15	62.5	13	35.1	0	0.0
Nephroblastoma	13	18.3	11	28.9	3	12.5	17	45.9	1	100.0
Others	5	7.0	3	7.9	0	0.0	3	8.1	0	0.0
All Histologic Types	71	100.0	38	100.0	24	100.0	37	100.0	1	100.0

# **BRAIN (ICD-10: C70-C72)**

Table 15.13: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologic	Mur	nbai	Ban	galore	Che	nnai	Thi'p	uram	Dib	rugarh
Туре	#	%	#	%	#	%	#	%	#	%
MALES										
Neoplasm Malignant	0	0.0	12	4.9	0	0.0	1	0.4	0	0.0
Gliomas	17	5.3	26	10.6	4	9.8	58	25.7	0	0.0
Ependymoma	14	4.3	3	1.2	1	2.4	2	0.9	2	25.0
Astrocytoma	198	61.5	133	54.3	20	48.8	97	42.9	2	25.0
Glioblastoma	26	8.1	19	7.8	5	12.2	30	13.3	0	0.0
Oligodendroglioma	14	4.3	10	4.1	1	2.4	7	3.1	0	0.0
Medulloblastoma	40	12.4	30	12.2	6	14.6	16	7.1	1	12.5
Others	13	4.0	12	4.9	4	9.8	15	6.6	3	37.5
All Histologic Types	322	100.0	245	100.0	41	100.0	226	100.0	8	100.0
FEMALES										
Neoplasm Malignant	1	0.5	7	6.4	0	0.0	3	2.2	0	0.0
Gliomas	12	6.4	3	2.7	2	11.1	29	21.2	0	0.0
Ependymoma	9	4.8	2	1.8	0	0.0	4	2.9	0	0.0
Astrocytoma	119	63.6	59	53.6	10	55.6	58	42.3	2	66.7
Glioblastoma	8	4.3	11	10.0	2	11.1	11	8.0	1	33.3
Oligodendroglioma	10	5.3	6	5.5	2	11.1	4	2.9	0	0.0
Medulloblastoma	23	12.3	11	10.0	1	5.6	18	13.1	0	0.0
Others	5	2.7	11	10.0	1	5.6	10	7.3	0	0.0
All Histologic Types	187	100.0	110	100.0	18	100.0	137	100.0	3	100.0

### **THYROID GLAND (ICD-10: C73)**

Table 15.14: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologic	Mui	mbai	Bang	alore	Che	nnai	Thi'p	uram	Dibr	ugarh
Туре	#	%	#	%	#	%	#	%	#	%
MALES										
Neoplasm Malignant	3	1.6	3	3.2	1	1.1	0	0.0	0	0.0
Other Carcinomas	7	3.8	9	9.7	7	8.0	4	2.0	0	0.0
Undifferentiated Carcinoma	6	3.3	1	1.1	4	4.6	9	4.4	2	40.0
Papillary CarcinomaNOS	94	51.4	55	59.1	55	63.2	139	68.1	0	0.0
Papillary Adeno Carcinoma	0	0.0	1	1.1	8	9.2	1	0.5	0	0.0
Follicular Carcinoma	28	15.3	13	14.0	6	6.9	16	7.8	2	40.0
Mixed Papi & Folli Carcinoma	9	4.9	6	6.5	1	1.1	25	12.3	0	0.0
Medullary Carcinoma	32	17.5	4	4.3	2	2.3	7	3.4	0	0.0
Others	4	2.2	1	1.1	3	3.4	3	1.5	1	20.0
All Histologic Types	183	100.0	93	100.0	87	100.0	204	100.0	5	100.0
FEMALES										
Neoplasm Malignant	2	0.9	9	4.3	1	0.8	2	0.3	0	0.0
Other Carcinomas	10	4.3	12	5.7	14	10.7	4	0.6	1	20.0
Undifferentiated Carcinoma	7	3.0	6	2.9	7	5.3	12	1.9	1	20.0
Papillary CarcinomaNOS	128	55.7	132	62.9	75	57.3	434	70.0	0	0.0
Papillary AdenoCarcinoma	1	0.4	0	0.0	8	6.1	1	0.2	0	0.0
Follicular Carcinoma	40	17.4	21	10.0	16	12.2	70	11.3	3	60.0
Mixed Papi & Folli Carcinoma	30	13.0	18	8.6	2	1.5	78	12.6	0	0.0
Medullary Carcinoma	10	4.3	5	2.4	3	2.3	14	2.3	0	0.0
Others	2	0.9	7	3.3	5	3.8	5	0.8	0	0.0
All Histologic Types	230	100.0	210	100.0	131	100.0	620	100.0	5	100.0

# TUMOURS OF LYMPHOID AND HAEMATOPOIETIC SYSTEM (LHM) (ICD-10: C81-C85 and C90-C96)

Table 15.15: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

LUM Tons	Mun	nbai	Ban	galore	Che	nnai	Thi'p	uram	Dib	rugarh
LHM Type	#	%	#	%	#	%	#	%	#	%
MALES										
NHL	363	11.9	121	14.6	77	10.3	75	6.5	1	5.0
HD	950	31.1	250	30.2	269	35.8	408	35.4	10	50.0
MM	181	5.9	46	5.5	43	5.7	154	13.4	0	0.0
Leukaemias	1560	51.1	412	49.7	362	48.2	514	44.7	9	45.0
All Types	3054	100.0	829	100.0	751	100.0	1151	100.0	20	100.0
FEMALES										
NHL	98	8.6	34	7.2	29	8.1	25	3.9	0	0.0
HD	359	31.6	127	26.8	96	27.0	200	31.2	1	11.1
MM	67	5.9	15	3.2	20	5.6	75	11.7	1	11.1
Leukaemias	611	53.8	298	62.9	211	59.3	341	53.2	7	77.8
All Types	1135	100.0	474	100.0	356	100.0	641	100.0	9	100.0

### **HODGKIN'S DISEASE (ICD-10: C81)**

Table 15.16: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologic	Mun	nbai	Ban	galore	Che	nnai	Thi'p	uram	Dib	rugarh
Туре	#	%	#	%	#	%	#	%	#	%
MALES										
Hodgkin's Disease NOS	61	17.9	27	22.3	32	41.6	13	17.3	1	100.0
HDLP	16	4.7	2	1.7	6	7.8	3	4.0	0	0.0
HDMC	149	43.8	45	37.2	23	29.9	36	48.0	0	0.0
HDLD	1	0.3	3	2.5	6	7.8	1	1.3	0	0.0
HDNS	113	33.2	44	36.4	10	13.0	22	29.3	0	0.0
All Histologic Types	340	100.0	121	100.0	77	100.0	75	100.0	1	100.0
FEMALES										
Hodgkin's Disease NOS	14	14.7	9	26.5	16	55.2	3	12.0	0	0.0
HD LP	5	5.3	1	2.9	2	6.9	1	4.0	0	0.0
HDMC	49	51.6	9	26.5	5	17.2	2	8.0	0	0.0
HD LD	0	0.0	1	2.9	0	0.0	0	0.0	0	0.0
HDNS	27	28.4	14	41.2	6	20.7	19	76.0	0	0.0
All Histologic Types	95	100.0	34	100.0	29	100.0	25	100.0	0	0.0

### LEUKAEMIAS (ICD-10: C91-C95)

Table 15.17: Number(#) and Relative Proportion(%) of different histologic types (1999-2000)

Histologia	NA	alaa!	Dom	a a la va	Oha		Th://		Dile	a.a.ula
Histologic -	iviun	nbai	Ban	galore	Cne	nnai	ını′p	uram	מוט	rugarh
Туре	#	%	#	%	#	%	#	%	#	%
MALES										
Leukaemia NOS	2	0.1	0	0.0	7	1.9	0	0.0	0	0.0
Acute Leukaemia NOS	101	6.9	35	8.5	30	8.3	6	1.2	0	0.0
Acute Lymphoid Leuk	468	32.1	94	22.8	99	27.3	250	48.7	2	22.2
Chronic Lymphoid Leuk	82	5.6	23	5.6	20	5.5	17	3.3	0	0.0
Acute Myeloid Leuk	349	23.9	100	24.3	102	28.2	150	29.2	3	33.3
Chronic Myeloid Leuk	436	29.9	81	19.7	103	28.5	73	14.2	4	44.4
Others	21	1.4	79	19.2	1	0.3	17	3.3	0	0.0
All Histologic Types	1459	100.0	412	100.0	362	100.0	513	100.0	9	100.0
FEMALES										
Leukaemia NOS	0	0.0	0	0.0	3	1.4	0	0.0	0	0.0
Acute Leukaemia NOS	39	6.7	25	8.4	34	16.1	9	2.6	0	0.0
Acute Lymphoid Leuk	177	30.6	60	20.1	46	21.8	144	42.2	0	0.0
Chronic Lymphoid Leuk	27	4.7	6	2.0	4	1.9	9	2.6	0	0.0
Acute Myeloid Leuk	167	28.8	92	30.9	60	28.4	141	41.3	5	71.4
Chronic Myeloid Leuk	161	27.8	74	24.8	61	28.9	30	8.8	1	14.3
Others	8	1.4	41	13.8	3	1.4	8	2.3	1	14.3
All Histologic Types	579	100.0	298	100.0	211	100.0	341	100.0	7	100.0

# Chapter 16

# EDUCATIONAL AND MARITAL STATUS; RELIGION AND LANGUAGE SPOKEN

The tables below provide the number and relative proportion of cancers (all sites) according to the educational level attained, marital status, pursuit of a specific religion and language spoken.

Table 16.1: Number(#) and Relative Proportion(%) by Educational Status (All Sites of Cancer) (1999-2000)

	Mun	nbai	Banç	galore	Chei	nnai	Thi'p	uram	Dibru	garh
Educational Status	#	%	#	%	#	%	#	%	#	%
MALES										
Illiterate	2921	16.6	3014	49.4	1296	20.9	666	8.5	365	36.6
Literate	239	1.4	488	8.0	268	4.3	62	0.8	384	38.5
Primary	3991	22.6	370	6.1	1549	25.0	2595	33.0	65	6.5
Middle	52	0.3	855	14.0	989	16.0	1440	18.3	37	3.7
Secondary	1551	8.8	745	12.2	1403	22.6	1622	20.6	76	7.6
Technical	391	2.2	82	1.3	90	1.5	134	1.7	0	0.0
College	2116	12.0	372	6.1	523	8.4	708	9.0	28	2.8
Below 5 years	383	2.2	124	2.0	77	1.2	157	2.0	15	1.5
Oth. & Unk.	5993	34.0	56	0.9	0	0.0	475	6.0	27	2.7
Total	17637	100.0	6106	100.0	6195	100.0	7859	100.0	997	100.0
FEMALES										
Illiterate	4984	36.4	5516	73.1	3756	52.6	1065	14.7	323	60.3
Literate	184	1.3	410	5.4	182	2.5	53	0.7	106	19.8
Primary	2622	19.2	254	3.4	1168	16.4	1923	26.5	46	8.6
Middle	13	0.1	539	7.1	762	10.7	1068	14.7	28	5.2
Secondary	890	6.5	477	6.3	876	12.3	1547	21.3	23	4.3
Technical	117	0.9	36	0.5	9	0.1	106	1.5	0	0.0
College	1138	8.3	159	2.1	329	4.6	882	12.2	3	0.6
Below 5 years	191	1.4	83	1.1	57	0.8	123	1.7	3	0.6
Oth. & Unk.	3540	25.9	69	0.9	0	0.0	480	6.6	4	0.7
Total	13679	100.0	7543	100.0	7139	100.0	7247	100.0	536	100.0

Table 16.2: Number(#) and Relative Proportion(%) by Marital Status (All Sites of Cancer) (1999-2000)

Marital Status	Mumbai		Bangalore		Chennai		Thi'puram		Dibrugarh	
	#	%	#	%	#	%	#	%	#	%
MALES										
Unmarried	2505	14.2	795	13.0	683	11.0	938	11.9	63	6.3
Married	14405	81.7	5195	85.1	5246	84.7	6616	84.2	840	84.3
Widowed	660	3.7	84	1.4	255	4.1	286	3.6	61	6.1
Divorced	16	0.1	3	0.0	2	0.0	18	0.2	1	0.1
Separated	12	0.1	2	0.0	9	0.1	1	0.0	1	0.1
Others & Unk.	39	0.2	27	0.4	0	0.0	0	0.0	31	3.1
Total	17637	100.0	6106	100.0	6195	100.0	7859	100.0	997	100.0
FEMALES										
Unmarried	1044	7.6	396	5.2	295	4.1	726	10.0	26	4.9
Married	10263	75.0	5786	76.7	5194	72.8	4868	67.2	452	84.3
Widowed	2133	15.6	1317	17.5	1559	21.8	1547	21.3	53	9.9
Divorced	28	0.2	7	0.1	5	0.1	106	1.5	0	0.0
Separated	14	0.1	34	0.5	86	1.2	0	0.0	0	0.0
Others & Unk.	197	1.4	3	0.0	0	0.0	0	0.0	5	0.9
Total	13679	100.0	7543	100.0	7139	100.0	7247	100.0	536	100.0

Table 16.3: Number(#) and Relative Proportion(%) of Cancer patients by Religion (1999-2000)

Religion	Mumbai		Bangalore		Chennai		Thi'puram		Dibrugarh	
	#	%	#	%	#	%	#	%	#	%
MALES										
Hindu	14709	83.4	5314	87.0	5441	87.8	4732	60.2	870	87.3
Muslim	2183	12.4	633	10.4	503	8.1	1398	17.8	104	10.4
Christian	440	2.5	144	2.4	237	3.8	1722	21.9	17	1.7
Sikh	73	0.4	1	0.0	0	0.0	0	0.0	2	0.2
Jain	99	0.6	7	0.1	12	0.2	0	0.0	0	0.0
Neo-Buddhist	1	0.0	1	0.0	2	0.0	0	0.0	1	0.1
Parsi	34	0.2	0	0.0	0	0.0	0	0.0	0	0.0
Others	10	0.1	2	0.0	0	0.0	0	0.0	3	0.3
Unknown	88	0.5	4	0.1	0	0.0	7	0.1	0	0.0
Total	17637	100.0	6106	100.0	6195	100.0	7859	100.0	997	100.0
FEMALES										
Hindu	11451	83.7	6707	88.9	6351	89.0	4479	61.8	465	86.8
Muslim	1399	10.2	656	8.7	443	6.2	1064	14.7	57	10.6
Christian	465	3.4	166	2.2	325	4.6	1695	23.4	8	1.5
Sikh	83	0.6	2	0.0	0	0.0	0	0.0	1	0.2
Jain	104	0.8	10	0.1	19	0.3	0	0.0	0	0.0
Neo-Buddhist	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0
Parsi	56	0.4	0	0.0	0	0.0	0	0.0	0	0.0
Others	15	0.1	0	0.0	0	0.0	0	0.0	5	0.9
Unknown	106	0.8	2	0.0	0	0.0	9	0.1	0	0.0
Total	13679	100.0	7543	100.0	7139	100.0	7247	100.0	536	100.0

Table 16.4: Number(#) and Relative Proportion(%) by Language Spoken (All Sites of Cancer) (1999-2000)

Language	Mumbai		Bangalore		Chennai		Thi'puram		Dibrugarh	
Spoken	#	%	#	%	#	%	#	%	#	%
MALES										
Assamese	342	1.9	1	0.0	193	3.1	2	0.0	681	68.3
Bengali	1724	9.8	6	0.1	38	0.6	0	0.0	93	9.3
Gujarati	1041	5.9	3	0.0	13	0.2	1	0.0	0	0.0
Hindi	6290	35.7	48	0.8	96	1.5	0	0.0	70	7.0
Kannada	224	1.3	3417	56.0	18	0.3	3	0.0	0	0.0
Kashmiri	22	0.1	0	0.0	2	0.0	0	0.0	0	0.0
Malayalam	241	1.4	77	1.3	271	4.4	7222	91.9	0	0.0
Marathi	5072	28.8	74	1.2	9	0.1	0	0.0	0	0.0
Oriya	355	2.0	5	0.1	9	0.1	0	0.0	66	6.6
Punjabi	177	1.0	1	0.0	1	0.0	2	0.0	4	0.4
Sanskrit	4	0.0	1	0.0	0	0.0	0	0.0	1	0.1
Sindhi	180	1.0	3	0.0	2	0.0	0	0.0	0	0.0
Tamil	134	0.8	539	8.8	3553	57.4	577	7.3	0	0.0
Telugu	281	1.6	1192	19.5	1796	29.0	0	0.0	1	0.1
Urdu	840	4.8	607	9.9	159	2.6	0	0.0	28	2.8
English	99	0.6	5	0.1	9	0.1	0	0.0	0	0.0
Others	598	3.4	106	1.7	26	0.4	52	0.7	50	5.0
Unknown	13	0.1	21	0.3	0	0.0	0	0.0	3	0.3
Total	17637	100.0	6106	100.0	6195	100.0	7859	100.0	997	100.0
FEMALES										
Assamese	161	1.2	2	0.0	48	0.7	2	0.0	345	64.4
Bengali	1147	8.4	2	0.0	20	0.3	0	0.0	36	6.7
Gujarati	769	5.6	10	0.1	11	0.2	0	0.0	0	0.0
Hindi	4195	30.7	56	0.7	73	1.0	0	0.0	31	5.8
Kannada	163	1.2	3957	52.5	33	0.5	1	0.0	0	0.0
Kashmiri	18	0.1	0	0.0	0	0.0	0	0.0	0	0.0
Malayalam	189	1.4	72	1.0	234	3.3	6618	91.3	0	0.0
Marathi	4894	35.8	94	1.2	15	0.2	1	0.0	0	0.0
Oriya	189	1.4	1	0.0	7	0.1	0	0.0	62	11.6
Punjabi	169	1.2	4	0.1	1	0.0	0	0.0	1	0.2
Sanskrit	1	0.0	1	0.0	0	0.0	0	0.0	2	0.4
Sindhi	205	1.5	2	0.0	1	0.0	1	0.0	0	0.0
Tamil	198	1.4	803	10.6	4097	57.4	561	7.7	2	0.4
Telugu	224	1.6	1788	23.7	2394	33.5	0	0.0	0	0.0
Urdu	546	4.0	612	8.1	174	2.4	0	0.0	24	4.5
English	98	0.7	6	0.1	5	0.1	0	0.0	0	0.0
Others	508	3.7	109	1.4	26	0.4	63	0.9	32	6.0
	_	0.0	0.4	0.0	_	0.0	0	0.0	4	0.0
Unknown <b>Total</b>	5 <b>13679</b>	0.0 <b>100.0</b>	24 <b>7543</b>	0.3 <b>100.0</b>	7 <b>139</b>	0.0 <b>100.0</b>	7 <b>247</b>	0.0 <b>100.0</b>	536	0.2 <b>100.0</b>

#### References

Maclennan R, Muir CS, Steinitz R and Winkler A. - Cancer Registration and its Techniques, IARC Scientific Pub. No 21, Lyon, 1978.

IARC Monographs - Supplement 7 Overall evauations of carcinogenicity: An updating of IARC monographs Volume 1-42: IARC monographs on the evaluation of the carcinogenic risks to humans. IARC Lyon, 1987, 357-61.

Parkin, D.M., Stiller, C.A., Draper, G.J., Bieber, C.A., Terracini, B. and Young J.L. International Incidence of Childhood Cancer, IARC Scientific Publications, No. 87, Lyon, 1988.

NCRP Code Manual for Hospital Based Cancer Registry, Indian Council of Medical Research, New Delhi, 1987.

Young, JL - The Hospital Based Cancer Registry, Ch. in Cancer Registration: Principals and Methods - Editors: Jensen OM, Parkin DM, Maclennan R, Muir CS and Skeet RG. IARC Scientific Pub. No 195, Lyon 1991

Parkin, D.M., Chen, V.W., Ferlay, J., Galceran, J., Storm, H.H. and Whelan, S.L. Comparability and Quality Control in Cancer Registration. IARC Technical Report No. 19, Lyon, 1994.

WHO International Classification of Diseases for Oncology, Third Edition, World Health Organization, Geneva, 2000.

#### Other Publications of NCRP

- 1. Annual Report 1982: National Cancer Registry, Indian Council of Medical Research, New Delhi, 1985
- 2. Annual Report 1983: National Cancer Registry, Indian Council of Medical Research, New Delhi, 1986
- 3. Annual Report 1984: National Cancer Registry, Indian Council of Medical Research, New Delhi, 1987
- 4. Annual Report 1985: National Cancer Registry, Indian Council of Medical Research, New Delhi, 1988
- 5. Annual Report 1986: National Cancer Registry, Indian Council of Medical Research, New Delhi, 1989
- 6. Annual Report 1987: National Cancer Registry Programme, Indian Council of Medical Research, New Delhi, 1989
- 7. Biennial Report 1988-1989: National Cancer Registry Programme, Indian Council of Medical Research, New Delhi, 1992
- 8. Consolidated Report of the Population Based Cancer Registries 1990-1996: National Cancer Registry Programme(ICMR), Bangalore, 2001
- 9. Consolidated Report of the Population Based Cancer Registries 1990-1996 Supplement: Year-wise Tabulation of Incident Cancers and Rates by Site and Gender: National Cancer Registry Programme (ICMR), Bangalore, 2001
- 10. Ten Year Consolidated Report of the Hospital Based Cancer Registries 1984-93 : National Cancer Registry Programme(ICMR), Bangalore, 2001
- 11. NCRP An Overview 1981-2001: National Cancer Registry Programme (ICMR), Bangalore, 2001
- 12. Two-Year Report of the Population Based Cancer Registries 1997-1998: National Cancer Registry Programme (ICMR), Bangalore, 2002
- 13. Five Year Consolidated Report on Hospital Based Cancer Registries 1994-1998: National Cancer Registry Programme(ICMR), Bangalore, 2002
- 14. Development of an atlas of cancer in India. First All India Report 2001-2002 vol. I and II. [www.canceratlasindia.org] : National Cancer Registry Programme(ICMR), Bangalore, 2004
- 15. An Overview Development of an atlas of cancer in India. First All India Report 2001-2002 vol. I and II. [www.canceratlasindia.org]: National Cancer Registry Programme(ICMR), Bangalore, 2004
- 16. Two-Year Report of the Population Based Cancer Registries 1999-2000: National Cancer Registry Programme (ICMR), Bangalore, 2005